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Abstract	  
The biological correlates of protection against HIV infection remain poorly characterized, 
hindering the development of an effective prevention strategy. Studies of individuals who 
resist HIV infection or progress more slowly after being infected are important for the 
conception of appropriate approaches for mimicking the effective responses against HIV 
infection or progression. The role of immune activation and chronic inflammation in the 
modulation of HIV acquisition risk and/or rate of HIV disease progression has been proposed 
as one of the most important mechanisms determining risk and pathogenesis but is not fully 
understood. A state of immune quiescence has been associated with protection against HIV 
infection and slower disease progression. To explore potential risk factors associated with 
HIV transmission and HIV disease progression, this dissertation investigates the relationship 
between clinical and biological biomarkers and resistance to HIV infection or disease 
progression (including viral load, CD4 counts, cellular activation, soluble inflammatory and 
regulatory cytokines, and HIV co-receptor expression) in stable long-term HIV 
seroconcordant and serodiscordant couples. 
Chapter 2 shows that HIV+ seroconcordant individuals (with HIV+ partners) had 0.5 log10 
higher plasma viral loads than HIV+ serodiscordant ones (p<0.0001), although this did not 
predict worse disease outcome (measured by absolute blood CD4 counts at later time points). 
Plasma viral loads were determined to account for 35% of the variability in CD4 counts in 
HIV+ individuals in this study, confirming previous findings that plasma viral load is not a 
reliable predictor of rate of CD4 loss during HIV infection. However, CD4 T-cell counts at 
enrolment into this study were found to be a stronger predictor of subsequent variability in 
CD4 counts, accounting for 77% of the fluctuation in CD4 counts.  
Chapter 3 shows that HIV+ seroconcordant individuals had greater frequencies of 
susceptible, activated T-cells (CD38+CCR5+) in blood compared to their HIV+ 
serodiscordant counterparts. Manifestation of a higher plasma viral load resulted in 
significantly higher frequency of CD4+CCR5+ (p=0.007), CD8+CD38+ (p=0.01) and 
CD8+HLA-DR+CD38+ (p=0.01) T-cells compared to individuals with lower HIV plasma load 
(<1500 cps/ml). HIV+ seroconcordant individuals also had significantly higher plasma 
concentrations of the pro-inflammatory cytokines IL-1β and TNF-α than HIV+ 
serodiscordant individuals. Multivariate regression analysis identified CD4+HLA-DR+CD38+ 
xvii 
 
T-cell frequencies and concentrations of TNF-α in plasma as the most influential factors 
determining plasma viral loads, independently of CD4 counts. Modeling to determine the 
variation in CD4% revealed that inclusion of systemic immune activation markers 
substantially improved predictive capacity by 16% from the univariate model with plasma 
viremia as predictor. 
In Chapter 4, HIV+ seroconcordant women also had significantly higher viral loads in their 
genital compartments compared to HIV+ serodiscordant women (p=0.001), with plasma viral 
loads being significantly associated with genital tract viral loads (Rho=0.65; p<0.0001). 
Despite HIV+ seroconcordant women having higher genital tract viral loads compared to 
HIV+ serodiscordant women, genital tract cytokine concentrations were similar between the 
two groups although women shedding HIV in their genital tracts had significantly higher 
mucosal inflammatory, regulatory and chemotactic cytokine concentrations (IP-10, p=0.002; 
IL-1α, P=0.007; IL-1β, p=0.004; IL-6, p=0.005; IL-8, p=0.008; MCP-1, p=0.03; MIP-1β, 
p=0.01; IL-10, p=0.01; G-CSF, p=0.002) compared to non-shedders. Mathematical modeling 
identified genital IL-1β and plasma HIV levels as being predictors of genital HIV shedding. 
Chapter 5 evaluates cellular activation markers in blood and plasma cytokine concentrations 
in HIV-exposed but uninfected individuals (HIV- serodiscordant with HIV+ partners) 
compared to HIV- unexposed controls (HIV- seroconcordant with HIV- partners). HIV- 
serodiscordant individuals had lower frequencies of activated CD8+ T-cell in blood (p<0.01) 
but also significantly lower expression levels of CCR5 than HIV- seroconcordant individuals 
(p<0.05 for CD4+ and p<0.05 for CD8+). 
Chapter 6 compares soluble cytokine biomarkers of HIV risk in matched plasma and genital 
tract secretions from HIV- serodiscordant and HIV- seroconcordant women. HIV- 
serodiscordant women had significantly elevated genital tract concentrations of IL-1α 
compared to HIV- seroconcordant women (p=0.001), which could suggest HIV exposure. 
However, no other differences were noted between HIV- serodiscordant and seroconcordant 
individuals in any of the other 13 cytokines measured in genital fluid, suggesting that no 
broad inflammatory signatures of risk were evident between groups. Concentration of 3/14 
cytokines (IL-1β, IL-6, IL-10) were evaluated in matching plasma and genital secretions, and 
data from this analysis suggest that the female genital tract and blood are immunologically 
separate compartments. 
xviii 
 
In conclusion, this dissertation suggests that HIV+ individuals who have not transmitted to 
their partners (in HIV+ serodiscordant relationships) and HIV- individuals who have not 
become infected despite being exposed (HIV- serodiscordant relationships) share an immune 
quiescent phenotype in that they both exhibit reduced frequencies of activated CCR5-
expressing T-cells than their seroconcordant counterparts. Studies of immune activation, 
inflammation, HIV-specific immune responses and immunoregulatory mechanisms both in 
blood and at the genital mucosal level in serodiscordant couples are important to characterise 
some of the determinants of transmissibility and protective mechanisms against HIV 
transmission. CCR5 expression on the surface of T-cells, especially the activated ones, is 
central to the perpetuation of HIV replicative cycle and confirms CCR5 agonists as 
appropriate targets in the design of an anti-HIV strategy. 
 
 
 
CHAPTER	  1	  Literature	  Review	  
1 
 
1.1 The status of the HIV/AIDS pandemic 
1.1.1 The global perspective 
It is estimated that 2.5 million people were newly infected with the human immunodeficiency 
virus (HIV) worldwide in 2011 (Figure 1.1; UNAIDS, 2012), bringing to 34 million the total 
number of people living with HIV infection (Figure 1.2; UNAIDS, 2012). For the first time 
since the start of the HIV pandemic, UNAIDS (2012) reported a 24% reduction in global 
acquired immunodeficiency syndrome (AIDS)-related deaths (comparing statistics for 2011 
to 2005). Despite these gains, HIV and AIDS remain a major global priority, with 1.7 million 
AIDS-related deaths in 2011 (Figure 1.1; UNAIDS, 2012). 
 
Figure 1. 1 New HIV infections and AIDS-related deaths worldwide, 1990-2011. Twenty five countries have 
seen a 50% or greater drop in new HIV infections since 2001. Sub-Saharan Africa remains the epicentre of the 
pandemic contributing 72% to the global pool of newly HIV infected individuals and accounting for 71% of 
global AIDS-related deaths in 2011. Source: UNAIDS Report on the Global AIDS Epidemic, 2012.
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Figure 1. 2 People living with HIV worldwide, 1990-2011. Sub-Saharan Africa accounted for 69% of HIV 
prevalence globally in 2011. It remains the most affected region with nearly 1 in every 20 adults living with 
HIV. Source: UNAIDS Report on the Global AIDS Epidemic, 2012. 
The scaling up of antiretroviral therapy (ART) in low- and middle-income countries has led 
to a substantial downturn in recent years in AIDS-related morbidity and mortality (a decline 
of 24% from 2005 to 2011; Figure 1.1 and Figure 1.3). As a result, HIV prevalence 
worldwide has reached a plateau, with the absolute number of people living with HIV 
remaining fairly stable over the past 5 years, having increased steeply for more than 10 years 
(from less than 10 million infections in 1990 to over 30 million in 2002; Figure 1.2). Despite 
rollout of ART globally, uneven progress has been made in different regions with 
significantly lower access to ART in regions like Eastern Europe and Central Asia and 
Middle-East and North Africa compared to the Caribbean and Sub-Saharan Africa (Figure 
1.3). These regional differences in ART rollout translated into increases in AIDS-related 
death in areas of low access to ART (21% increase in Eastern Europe and Central Asia and 
17% increase in Middle-East and North Africa), compared to decreases in the Caribbean 
(48%) and Sub-Saharan Africa (33%) over the period 2005 to 2011 (UNAIDS, 2012). 
m
ill
io
ns
People living with HIV
0
5
10
15
20
25
30
35
40
3 
 
 
Figure 1. 3 ART coverage between regions in adult populations, 2011. In 2011, more than 8 million people 
living with HIV had access to antiretroviral therapy, with the number increased by 63% from 2009 to 2011. 
However, there remain 7 million people eligible for HIV treatment who still do not have access, most notably 
children (72% globally). Source: UNAIDS Report on the Global AIDS Epidemic. 
 
1.1.2 The South African / Sub-Saharan African perspective 
Unlike other regions of the world, the majority of people living with HIV in Sub-Saharan 
Africa are women (58%; UNAIDS, 2012), leading some to say that the Sub-Saharan 
epidemic wears a ‘woman’s face’ (Annan, 2002). Of the countries making up Sub-Saharan 
Africa, Swaziland has the highest HIV prevalence rate at 26% (UNAIDS, 2012). Although 
South Africa only has the fourth highest HIV prevalence rate, it has the highest number of 
HIV-infected individuals of all countries in the region with 5.6 million infected people 
(UNAIDS, 2012). The HIV epidemic in South Africa is reflective of the Sub-Saharan region, 
whereby women represent 57% (UNAIDS, 2012) of infected individuals, with women aged 
20-24 being 4 times more at risk of having an HIV infection than men of the same age group 
(21.1% versus 5.2%; South African Global AIDS Response Report, 2012). In South Africa, 
30-34 year old women carry the highest burden of the HIV epidemic (HIV prevalence rate of 
42.6%) and 30.2% of pregnant women in South Africa aged 15-49 were living with HIV 
(South African Global AIDS Response Report, 2012). 
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The HIV epidemic in South Africa is mainly heterosexual, with mother-to-child transmission 
being the other main infection route. It has been suggested that the reproductive biology in 
the female genital tract makes women 2-8 times more vulnerable to HIV infection than men 
(Nicolosi et al., 1994, Padian et al., 1994). Male-to-female transmission could occur more 
efficiently relative to female-to-male, on the account of extended exposure to seminal fluid 
(Cummins and Dezutti, 2000; Hirbod and Broliden, 2007). 
 
1.1.3 HIV exposed seronegative individuals, HIV seroconcordance and serodiscordance 
Since the discovery of HIV in the early 1980s (Barré-Sinoussi et al., 1983), a number of 
studies from different parts of the world have reported on individuals who were repeatedly 
exposed to HIV but remain uninfected, sometimes called ‘HIV resistant’, HIV-exposed 
seronegative (HESN) or highly exposed persistently seronegative (HEPS; Kaul et al., 2000; 
Broliden et al., 2001; Iqbal et al., 2005; Liu et al., 1996). Because these individuals appear to 
be less susceptible to HIV infection, they have been the focus of intensive investigation to 
understand the genetic, immunologic, and environmental factors that may alter susceptibility 
to HIV (Horton et al., 2010). One of the best and clearest mechanisms of HIV resistance that 
has been documented is in individuals that are homozygous for the CCR5Δ32 deletion 
mutation, who lack a CCR5 co-receptor that HIV is able to use to gain entry into host cells 
(Liu et al., 1996). This homozygous genotype is rare (detected in ~1% of individuals 
globally) and has primarily been described in people of European descent (Gupta and Padh, 
2012). 
The best characterized cohorts of HESN have included individuals with high risk sexual 
behaviours such as commercial sex workers (Kaul et al., 2000; Broliden et al., 2001; Iqbal et 
al., 2005), men who have sex with men (MSM), injection drug users, infants exposed to 
vertical transmission and HIV serodiscordant couples (Ruzagira et al., 2011; Vernazza et al., 
2011; Abaasa et al., 2013). The HIV seronegative partner in a HIV discordant couple 
represents the ideal cohort for the identification of factors affecting susceptibility to HIV. It is 
however important to bear in mind that these different cohorts from which HESNs are 
recruited also have varying degrees of relative HIV risk; determined according to their 
respective frequency and type of sex acts, whether their partners have initiated ART, or their 
frequency of condom usage. It is generally very difficult to accurately and objectively 
quantify the risk profile of HESN individuals. Even though HIV infection risk may be lower 
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in these individuals, the identification of genuinely resistant subjects is challenging. 
However, HIV serodiscordant couples remain the most accessible and most representative 
population (with regard to global epidemic) for the identification of biological correlates of 
protection from a heterosexual transmission perspective. 
For the purposes of this dissertation, a couple is described as seroconcordant negative when 
both partners are HIV negative (HIV-) and seroconcordant positive when both are HIV 
positive (HIV+). A serodiscordant couple is one in which one partner is HIV+ and the other 
is HIV-. Guthrie and colleagues (2007) argued that the manner in which HIV serodiscordancy 
arises may differ in less mature compared to mature HIV epidemics. They suggest that most 
serodiscordant couples arise in early epidemics when HIV is introduced into a pre-existing 
relationship through sex outside of the relationship (such that both partners may be HIV- at 
the start of a relationship and one becomes infected from outside the relationship). A mature 
epidemic is characterised by a plateau in the incidence of HIV, accounted for by a balance in 
the number of new HIV infections and AIDS-related deaths. In more mature HIV epidemics, 
a greater proportion of HIV serodiscordant couples are formed with one partner already being 
HIV infected prior to a couple formation. Countries with hyperendemic, generalised and 
mature epidemics, like South Africa (Abdool Karim et al., 2011), are characterised by 
heterosexual transmission, HIV serodiscordant relationships are common and it has been 
estimated that transmission in stable serodiscordant couples accounts for >50% of new HIV 
infections in Africa (Curran et al., 2012; Eyawo et al., 2010). 
Because they represent a key HIV risk group, HIV serodiscordant individuals have been the 
focus of many important biomedical trials to prevent or reduce HIV transmission, including 
medical male circumcision (Gray et al., 2000; Wawer et al., 2009), ART for the HIV+ 
partner (CDC, 2009; Cohen et al., 2011), pre-exposure prophylaxis (Vernazza et al., 2011; 
Mastro et al., 2011), post-exposure prophylaxis (van der Straten et al., 2000), herpes simplex 
virus type 2 (HSV-2) suppression (Lingappa et al., 2009; Mujugira et al.,2011), microbicides 
(Abaasa et al., 2013), and HIV vaccines (Horton et al., 2010; Ruzagira et al., 2011). 
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1.2 The natural history of HIV infection 
1.2.1 Systemic HIV-specific immune responses, CD4+ T-cell depletion and HIV viral load  
HIV infects CD4+ T helper lymphocytes using the CD4 receptor (Rubbert et al., 2006) and 
CCR5 or CXCR4 co-receptor (Moore et al., 1997). HIV hijacks the cellular machinery of 
CD4+ host cells to replicate within them and eventually lyses the cells as newly formed 
virions are released extracellularly to infect other CD4+ host cells (Fauci et al., 2003). As a 
consequence, CD4+ T-cells are progressively depleted during the course of HIV infection 
(Meyaard et al., 1993). In parallel, the host immune system becomes progressively crippled 
because of CD4+ T-cell depletion, which are pivotal in directing and coordinating the 
functions of other adaptive immune cells (CD8+ T-lymphocytes, B-lymphocytes, monocytes 
and macrophages) (Zhu and Paul, 2008; Wan and Flavell, 2009). 
Fiebig and collaborators (2003) have demonstrated that HIV RNA is detectable in blood by 
PCR as early as 10-14 days post-infection. Within 4 weeks, there is an exponential increase 
in HIV plasma viremia coupled with the massive depletion of CD4+ T-lymphocytes (Figure 
1.4). The emergence of cytotoxic CD8+ T-cell responses and the production of antibodies by 
B-cells that bind to HIV coincide with lowering of HIV load in blood to a steady state, 
termed viral set-point. Viral set point is generally reached by 6 months post-infection. Along 
with this initial decline in plasma viremia comes a transient replenishment of CD4+ T-cell 
numbers, but to levels lower than before infection (Simon et al., 2006). In the absence of 
ART, infection with HIV leads to a prolonged and gradually progressive disease which 
eventually results in opportunistic infections and ultimately death. Depending on a number of 
host and viral characteristics (such as host immunity, host genetics, viral virulence), or when 
ARTs were initiated, the asymptomatic phase of HIV infection may last ten years or more. In 
the absence of ART, the functional capacity of the immune system is impaired with time and 
the clinical manifestations of AIDS become progressively apparent (Pantaleo and Fauci, 
1996). In HIV+ individuals, absolute CD4+ T-cell counts in blood predict the development of 
opportunistic infections and death due to AIDS (Gulick et al., 1997; Hammer et al., 1997; 
Cameron et al., 1998; Hulgan et al., 2006). 
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Figure 1. 4 Course of HIV-1 infection defined by the level of viral replication. Plasma viremia (top), and 
dynamic changes of the CD4+ T-lymphocyte compartments (bottom). Primary infection characterised by high 
plasma viremia (redline, top), low CD4 cells (green line, bottom), and absence of HIV-specific antibodies 
(orange line, bottom). Viremia drops as cytotoxic CD8+ T-lymphocytes (CTL) develop (blue line, bottom) and 
an individual viral-load set point is reached during chronic infection. Viral set points differ greatly among 
individuals (e.g., red dotted line, top) and predict disease progression. Viral diversity increases throughout the 
disease (closed circles, top). The risk of transmission is highest in the first weeks when viremia peaks (closed 
circles, top). GALT = gut-associated lymphoid tissues (Adapted from Simon et al., 2006). 
 
HIV-specific T-cells emerge at about 2 weeks following infection, generally persist 
throughout the course of disease, and systemic HIV-specific CD8+ T-cells are considered to 
be one of the best correlates of immune control (McMicheal and Rowland-Jones, 2001; Betts 
et al., 2005; Jiao et al., 2006). Gag-specific CD8+ T-cells are the best characterized and the 
magnitude and breadth of Gag-specific CD8+ T-cell IFN-γ responses are associated with 
lower viral loads, independently of human leukocyte antigen (HLA) (Edwards et al., 2002; 
Kaufmann et al., 2004; Kiepiela et al., 2004). Furthermore, flow cytometry based studies 
including multiple immune parameters simultaneously have suggested that polyfunctional 
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CD8+ T-cells, which have the capacity to secrete multiple cytokines, are associated with 
better control of HIV (Betts et al., 2006; Valor et al., 2008; Pantaleo and Koup, 2004). 
Several lines of evidence in humans and primates have suggested that HIV- and SIV-specific 
CTL responses are associated with protection during infection, including: (1) peak viremia 
declined rapidly during acute HIV infection in humans following the appearance of HIV-
specific CD8+ T-cells (Borrow et al., 1994; Koup et al., 1994); (2) plasma viral loads 
increased following depletion of CD8+ T-cells in SIV-infected macaques (Jin et al., 1999; 
Schmitz et al., 1999); (3) HIV+ individuals with low viral loads or slower disease 
progression generally have protective HLA alleles (O’Brien and Nelson, 2004; Fellay et al., 
2007); and (4) HIV and SIV clearly demonstrate the ability to mutate in CTL epitopes under 
CTL pressure (called CTL escape mutations; Leslie et al., 2004; Oxenius et al., 2004). 
In addition to CD8+ T-cells, the ability of HIV-specific CD4+ T-cells to secrete either IL-2 
alone, or both IL-2 and IFN-γ has also been shown to correlate with viral control during 
chronic HIV infection (Harari et al., 2004). Similarly, studies in vaccinated macaques have 
demonstrated that the presence of T-cells secreting both IFN-γ and IL-2 was associated with 
protection from infection following SHIV challenge (Sadagopal et al., 2005). In HIV+ 
individuals who are able to control their HIV plasma load and sustain a normal CD4 count in 
absence of ART (called long term non-progressors), Gag-specific IL-2 and IFN-γ secreting 
CD4+ T-cell responses best predicted control of viremia (Boaz et al., 2002). Both CD8+ and 
CD4+ T-cells produce a variety of cytokines during HIV infection and among the best 
described are IFN-γ, IL-2, TNF-α and MIP-1β (Brenchley et al., 2008; Ferrando-Martinez et 
al., 2012; Riou et al., 2013). 
Despite a generally robust HIV-specific T-cell response during infection, which has the 
ability to significantly reduce viremia during the chronic stages of infection, the human 
immune response to HIV is generally unable to completely eradicate or suppress HIV or halt 
CD4 decline over time. This indicates that other host and viral factors may facilitate 
incomplete suppression and ultimately loss of control. Immune activation of T-cells has been 
demonstrated to play an important role in ongoing CD4+ T-cell loss, even in individuals 
controlling their viral loads. 
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1.2.2 Antiretroviral therapy (ART) 
Morbidity and mortality associated with HIV / AIDS has been curbed with the advent of 
ARTs. The health benefits of ARTs is well documented, with different ART drug classes 
targeting various stages of the HIV life cycle, from binding and infection of target cells, to 
the budding of newly formed virions (Hogg et al., 2001; Kitahata et al., 2009; Zolopa et al., 
2009). The public health benefits of ART are not limited to HIV+ individuals. Studies have 
shown that the drastic decline in HIV genital shedding in HIV+ individuals on ART 
translated to a significant decreased risk of heterosexual HIV acquisition in their uninfected 
partners (Attia et al., 2009; Donnell et al., 2010; Cohen et al., 2012). The use of ART by 
HIV+ women during pregnancy and breast feeding has considerably diminished the incidence 
of paediatric HIV infection resulting through mother-to-child transmission (MTCT) (Tonwe-
Gold et al., 2007; Kumwenda et al., 2008). 
The World Health Organisation (WHO) has been supplying guidelines on various aspects of 
HIV diagnosis, treatment and care since 2002 and strongly recommends the administration of 
ART in HIV+ persons (Table 1.1). A classification system for staging of HIV disease and 
AIDS for HIV+ adults and adolescent that has been defined by the Centre for Disease Control 
and prevention (CDC) and adopted by the WHO. Both the ARV guidelines and AIDS staging 
rely on specific biomarkers or predictors of HIV disease (CD4 count and plasma viral load) 
outcome that are necessary for administration of the right treatment at the right time. 
Table 1. 1 Eligibility criteria for starting ART regimen for adults and adolescents. Guidelines 
recommended by WHO. Source: The South African Antiretroviral Treatment Guidelines, 2013. 
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1.3 Immune activation and HIV pathogenesis  
Recruitment of activated immune cells to control or eliminate an infection is a key feature of 
an efficient host immune response. During a T-cell response, priming through cytokine 
signalling or antigen recognition in association with HLA molecules leads to cellular 
functions such as cytotoxic, proliferative, secretory, differentiation, or regulatory being 
‘switched on’. During HIV infection, the molecular mechanisms causing immune activation 
are still incompletely understood but are likely to be a multifactorial. During an immune 
response to HIV infection, almost all components of innate and adaptive immune system 
become activated (including T cells, B cells, NK cells, macrophages and monocytes, Lane et 
al., 1983; Giorgi et al., 1999; Deeks et al., 2004; Fauci et al., 2005; Brenchley et al., 2006; 
Catalfamo et al., 2011; van Grevenynghe et al., 2012). 
Infection with HIV leads to significant changes in the level of activation of lymphocytes as 
measured by activation markers such as CD25, CD38, CD69, CD71, CD95 and HLA-DR 
(Imlach et al., 2001; Mueller et al., 2001; Li et al., 2012). The expression of CD38 and HLA-
DR on CD4+ and CD8+ T-cells has been shown to increase dramatically during chronic 
infection. Kestens et al. (1994) showed that changes in expression of HLA-DR and CD38 on 
CD4+ T-cells correlated with similar changes on CD8+ T-cells and as well as with the 
presence of HIV antigen in systemic circulation and disease stage. 
 
1.3.1  Immune activation in natural hosts challenges the ‘classical’ model of HIV 
pathogenesis 
There is compelling evidence from both human and macaque studies that markers of immune 
activation and T-cell proliferation are elevated in blood and gastrointestinal tract during HIV 
and SIV infections, and that these strongly predict with the rate of disease progression 
(d’Ettorre et al., 2011). Although the course of SIV infection in rhesus macaques is generally 
similar to the natural history of HIV infection in humans, macaques are not the natural 
primate hosts for SIV with Sooty mangabeys and African green monkeys recently being used 
a representative natural host primate models for SIV infection (Chahroudi et al., 2012). Sooty 
mangabeys and African green monkeys can be chronically infected with SIV without 
developing severe disease, have high viral loads throughout the course of infection but do not 
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experience persistent immune activation or CD4 decline (Silvestri et al., 2007). Primary SIV 
infection in these natural hosts was associated with a modest and transient decline of systemic 
blood CD4 count, which was accompanied by drastic depletion of CD4 cells in the gut 
associated lymphatic tissues (GALT) and lungs (Gordon et al., 2007; Pandrea et al., 2007). 
During chronic infection however, the level of immune activation was persistently low in 
spite of high SIV loads in blood (Figure 1.5). 
 
Figure 1. 5 Comparison of SIV infection in non-natural (left panel) and natural host (right panel). SIV 
infection in the non-natural host is characterised by high viral load, a progressive depletion of CD4+ T-cells in 
blood and mucosal compartments, microbial translocation from the GALT and chronic immune activation. In 
contrast, SIV infection of natural host is non-pathogenic associated with a stable CD4+ T-cell count and absence 
of immunodeficiency, chronic immune activation and bacterial translocation in spite of high viremia and 
depletion of mucosal CD4+ T-cells (taken from Silvestri, 2009). 
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The course of SIV infection of the natural primate hosts differs significantly to the clinical 
course of HIV infection in most humans, who almost invariably progress to AIDS if left 
untreated. A similar phenomenon of decreased or lack of pathogenicity in humans could be 
drawn from a rare group of HIV-infected individuals, termed long-term non-progressors 
(LTNPs), who typically maintain stable levels of systemic CD4+ T-cells. These LTNPs 
similarly also exhibit lower levels of immune activation and microbial translocation than 
individuals who progress normally during HIV infection (Silvestri et al., 2007). In contrast to 
high levels of viremia observed in SIV-infected natural hosts, LTNPs are typically able to 
control virus replication. Some studies have ascribed better control of viral replication in 
LTNPs to strong and broad immune responses to the HIV, while the natural hosts generally 
show only low levels of SIV-specific immune responses (Dunham et al., 2006). Whilst the 
absence of hyperimmune activation in LTNPs can be explained by lower viral loads 
(resulting in lower concentrations of antigen), the reason for only minimal immune activation 
in the highly viremic SIV-infected natural hosts is unclear. Table 1.2 summarizes the events 
unfolding during chronic HIV infection in “normal” human progressors, LTNPs, and SIV 
infection in natural hosts like SM and AGM. 
Table 1. 2 Similarities and differences between HIV-infected Progressors, 
LTNPs and natural SIV hosts 
  Progressors LNTPs 
Natural 
Hosts 
AIDS Yes No No 
CD4 Depletion in blood Yes No No 
CD4 Depletion in MALT Yes Yes Yes 
Viral load High Low High 
Microbial translocation High Low Low 
Immune activation High Low Low 
CCR5 on CD4+ T-cell High High Low 
 
1.3.2 Causes of systemic immune activation during HIV infection 
The establishment of chronic immune activation during HIV and SIV infection involves both 
direct and indirect mechanisms. Direct antigenic stimulation by the virus represents the most 
common cause of T-cell activation (Catalfamo et al., 2008). Approximately 20% of 
circulating CD8+ T-cell and ~3% of CD4+ T-cells recognize HIV antigens (Betts et al., 2001; 
Papagno et al., 2002). Although these T-cells are generally protective during disease course 
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(Section 1.2.2), they can conversely also be harmful to the host because these cells become 
chronically activated in the presence of chronic antigen stimulation during the course of HIV 
infection (Sauce and Appay, 2008). Another mechanism of direct HIV-mediated immune 
activation comes from interaction of HIV proteins (such as gp120 and Nef) with T-cells. 
Several studies have shown that the envelope glycoprotein gp120 can either directly activate 
cells or enhance their responsiveness to activation through binding to CD4 and/or CCR5 
(Merrill et al., 1989; Lee et al., 2003; Sailaja et al., 2007). HIV accessory protein Nef induces 
direct lymphocyte activation (Wang et al., 2000; Simmons et al., 2001) or through the 
infection of macrophages (Swingler et al., 1999). Expression of Nef in primary macrophages, 
in an adenovirus recombinant system, was enough to induce expression of macrophage 
inflammatory-1 alpha and beta (MIP-1α and MIP-1β). Schindler and collaborators (2006) 
reported that differences in Nef function within humans during HIV infection and in 
pathogenic SIV infections in macaques partly accounted for much higher level of T-cell 
activation during HIV and pathogenic SIV infection when compared to non-pathogenic SIV 
infections.  
Indirect antigenic stimulation from sources other than HIV, such as opportunistic infections 
with Epstein-Barr virus (EBV) and Cytomegalovirus (CMV), which may reactivate as a 
result of HIV-induced immunosuppression, may also induce immune activation. Reactivation 
of CMV is known to occur recurrently, even in healthy HIV-uninfected individuals (Dunn et 
al., 2002). Significant activation of both EBV- and CMV-specific CD8+ T-cells has been 
reported during HIV infection (Doisne et al., 2004; Papagno et al., 2004). Another indirect 
mechanism by which HIV can enhance immune activation is through the depletion of 
regulatory CD4+ T-cells during the course of chronic infection, as these regulatory cells are 
normally involved with suppression of T-cell activation and limiting inflammatory damage to 
tissues (Eggena et al., 2005). It has been postulated that the persistent activation of the innate 
arm of the immune system may give rise to unrestricted production of inflammatory 
cytokines, which in turn activate T-cells in a non-specific manner (Matsuyama et al., 1991). 
 
1.3.3 Consequences of systemic immune activation  
Irrespective of the causes of immune activation during HIV infection, it results in elevated T-
cell turnover that have increased expression of the nuclear antigen Ki67 (only expressed by 
cycling cells), the early activation marker CD38; and the late activation marker HLA-DR 
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(McCune et al., 2000; Hazenberg et al., 2000; Lempicki et al., 2000; Kovacs et al., 2001; Ho 
et al., 1993; Mahalingam et al., 1993; Kestens et al., 1994; Ausiello et al., 1996; Orendi et 
al., 1998; Savarino et al., 2000). Measuring CD38 expression by T-cells has been used 
widely to assess the extent of immune activation by T-cells, but the prognostic value of this 
marker is improved when it is measured together with HLA-DR (Benito et al., 2004). 
Although blood CD4+ T-cell counts and viral loads are considered to be the gold standard 
prognostic tool for predicting rate of HIV disease progression, several studies have shown 
that immune hyperactivation - measured by dual expression of CD38 and HLA-DR - allows 
better prediction of HIV pathogenesis than either of these markers alone (Fahey et al., 1998; 
Lawn et al., 2001; Karim et al., 2013). In support of this, Wilson et al. (2004) showed that 
CD8+CD38+ T-cells but not HIV load predict CD4+ T-cell depletion. Moreover, results from 
a study by Froebel and collaborators (2000) have shown that measurement of CD8+CD38+ T-
cell frequencies performed better than CD4 counts for predicting HIV clinical progression. In 
a study in HIV+ individuals from Uganda, the extent of CD8+ T-cell activation prior to 
initiation of ART predicted lower CD4 recovery rate following the first year of therapy, 
independently of CD4 counts at the time of initiating ART, demonstrating the predictive 
value of T-cell activation in relation to CD4 reconstitution after therapy initiation. This 
finding confirmed that factors other than the virus itself, contribute to the ongoing stimulation 
of the immune system (Hunt et al., 2011). 
Immune hyperactivation has been directly or indirectly linked to disruption of the immune 
system during HIV infection. One of the unresolved paradoxes of HIV pathogenesis is the 
dichotomy between the extent of activation of CD4+ and CD8+ T-cell subsets. Widespread 
activation of T-cells during HIV infection continually depletes both the naïve and resting 
memory CD4+ T-cell pools, disrupting T-cell homeostasis and subsequently resulting in 
CD4+ T-cell depletion (Hazenberg et al., 2003; Li et al., 2005; Mattapallil et al., 2005). In 
contrast, an expansion of the CD8+ T-cell subset occurs in HIV-infected humans 
(Suntharalingam et al., 2006) and in mouse-models of retroviral infection (Tesselaar et al., 
2003). Although the fact that HIV directly infects and replicates in CD4+ T-cells may explain 
this, these findings may suggest that CD4+ T-cell homeostasis is more susceptible to chronic 
generalised immune activation than that of CD8+ T-cells. 
Chronic immune activation of CD4+ T-cells also facilitates direct HIV infection by multiple 
mechanisms, hence fuelling further viral replication during chronic infection. Firstly, immune 
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activation promotes the expression of coreceptor CCR5 on HIV target cells, leading to the 
increased infectiousness of both T-cells and macrophages bearing this receptor (Bleul et al., 
1997; Wu et al., 1997). Elevated trafficking of T-cells to lymphoid tissues through 
upregulation of adhesion molecules and chemokine production also facilitates enhanced 
infectivity (Shattock et al., 1996). Secondly, T-cell activation causes an increase in 
intracellular nuclear factor κappa βeta (NFκβ) expression, which in turn results in enhanced 
transcription of integrated HIV, thus turning activated T-cells into viral ‘superproducers’, 
promoting expression of HIV from latently infected cells (Kawakami et al., 1988; Bellas et 
al., 1993; Wu et al., 1995). In spite of the massive depletion of CD4+CCR5+ T-cells during 
the acute phase of HIV infection, the aforementioned mechanisms lead to the continued 
recruitment of new activated T-cells to lymphoid compartments and maintenance of viral 
replication during the chronic phase of infection (Grossman et al., 2006). This gives rise to a 
vicious cycle of persistent viral replication causing continued T-cell activation which in turn 
promotes further CD4+ T-cell loss through both direct viral infection and apoptosis (Figure 
1.6). 
T-cell activation can also impair the regenerative potential of the immune system. Several 
studies have shown that continued immune activation causes progressive collagen deposition 
and destruction of lymph node architecture (Schacker et al., 2002, 2006; Estes et al., 2008; 
Estes, 2009). Since lymph node architecture is critical for supporting normal T-cell 
homeostasis via interactions with antigen presenting cells (APC), the gradual depletion of 
normal architecture implies the shortening of resting naïve and memory T-cell half life, 
limiting CD4+ T-cell recovery after initiation of ART (Schacker et al., 2005; Zeng et al., 
2012). 
 
1.3.4 Effect of ART on systemic immune activation 
Recently, several studies found that HIV+ individuals, who were successfully controlling 
viremia either as the result of ART or naturally, still experienced a persistent systemic 
inflammation and chronic immunodeficiency, which promoted continuing loss of CD4+ T-
cells and disease progression despite controlled viremia (Hazenberg et al., 2003; Appay et 
al., 2008). Even when ART was initiated during acute HIV infection, markers of immune 
activation (as measured by frequencies of CD8+CD38+HLA-DR+ T-cells in blood) remained 
substantially higher than seronegative controls (HIV+ individuals frequencies of 
16 
 
CD8+CD38+HLA-DR+ T-cells decrease from 72.6% to 15.6% by 96 weeks following ART 
initiation compared to 8.9% in HIV- women; Vinikoor et al., 2013). In the SMART study, a 
randomised trial comparing alternate ART strategies (El-Sadr et al., 2006), markers of 
inflammation such as interleukin-6 (IL-6) and D-dimer (involved in blood coagulation), were 
shown to independently predict mortality from non-HIV conditions such as cardiovascular 
disease in HIV+ individuals in whom viremia was controlled. 
In another report from the FRAM cohort, even HIV+ individuals with a CD4+ T-cell 
counts>350 cells/mm3 and doing clinically well had higher mortality rates than the uninfected 
controls (Modrich et al., 2010). The findings of Vinikoor et al. (2013) that HIV-infected 
individuals still have substantially greater levels of systemic activation compared to 
seronegative controls even long after initiating ART suggest that factors other than CD4 
counts alone (such as inflammation and systemic immune activation) may impact on HIV-
related morbidity and mortality. Although ART initiation substantially restores CD4+ T-cell 
numbers and reduces circulating viral loads to undetectable, ART has been shown to have 
less profound an impact on immune activation levels. This persistent immune activation takes 
a variety of forms and a better understanding of the causes and pathways involved in immune 
activation during HIV will be of value for the design of therapeutic strategies that could lead 
to a more quiescent immune system. 
The next section of this review looks at systemic inflammation in the context of HIV 
infection in more depth. 
 
1.3.5 Cytokines in HIV pathogenesis 
During chronic HIV infection, homeostasis to restore T-cell numbers and virally-induced 
inflammation differentially impact on CD4+ and CD8+ T-cell immune activation. This 
difference in T-cell subset activation is reflected in the ways that these subsets respond to the 
homeostatic and inflammatory environments. Cytokines are generally classed according to 
the primary function they fulfil in the immune system. Historically, CD4+ T-cells were 
classified as Thelper 1 (Th1) or Th2 type, depending on the specific classes of cytokines CD4 
T-cells produced (Mosmann and Coffman, 1986). Using this historical definition, Th1 cells 
tend to produce pro-inflammatory cytokines and stimulate cellular immunity responsible for 
the elimination of intracellular parasites and the perpetuation of autoimmune diseases. Th2, 
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on the other hand, tend to stimulate humoral immune responses, upregulating antibody 
production and balancing out Th1 responses through anti-inflammatory mechanisms. 
Overactivation of either Th pathway has been shown to cause disease, and both are able to 
down-regulate the activity of the other (Del Prete, 1998; Desmedt et al., 1998; Romagnani, 
1999; Kidd, 2003). These broad definitions have subsequently been shown to completely 
oversimplify a very complex network of cytokines, which includes much more diversity in 
helper responses than captured by these two classes alone (T regulatory cells produce IL-10, 
Th17 cells produce IL-17 and IL-22).  
Several cytokines have been shown to play important roles on HIV replication and the 
ensuing pathogenesis. Therefore, it is important to measure cytokines in the context of HIV 
infection and immune activation as an additional means to evaluate the host immune 
response. The following sections discuss a subset of these cytokines, considered to be most 
important to this dissertation and their effects on HIV pathogenesis and disease progression 
in more depth. Table 1.3 summarizes some of the cytokines important to this study. 
Inflammation is the immediate reaction of the immune system in response to infection and 
acute injury. It involves an intricate cascade of events which gives rise to migration and 
activation of various immune cells and release of soluble pro-inflammatory cytokines in 
recognition of a threat. Host genes involved in inflammatory pathways are generally switched 
on by cellular protein NFκβ, leading to newly activated macrophages to then start releasing 
pro-inflammatory cytokines such as interleukin (IL)-1β, IL-6 and tumour necrosis factor-
alpha (TNF-α). 
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    Table 1. 3 Overview of the characteristics of the cytokines important to this study 
Class Cytokine Cellular Source Main function Targets Reference 
Inflammatory IL-β Macrophages, 
monocytes, fibroblast, 
DC 
 
Enhances inflammation, activation, 
fever, synthesis of acute phase 
proteins 
Lymphocytes, 
endothelial cells, 
CNS, liver 
Dunn et al., 2001 
 IL-6 T-cells, macrophages, 
epithelial cells 
 
Involved in mediation of 
inflammation, activation, 
proliferation, apoptosis and 
differentiation 
 
B-cells, liver Shah et al., 2010 
 IL-12p70 Phagocytes, DC Induction of T-cells and NK cells 
cytotoxicity 
 
T-cells, NK cells Trinchieri, 2003 
 
  TNF-α Monocytes, 
macrophages, and NK 
cells 
Activation of NFκβ, T-cell apoptosis, 
fever, increases permeability and 
stimulates adhesion molecules 
Endothelial cells, 
neutrophils, liver 
Alfonso and Poli, 
2005 
Regulatory IL-10 T-cells, DC, 
macrophages 
Inhibition of pro-inflammatory 
responses 
Macrophages, DC Brockman et al., 2009 
Adaptive IL-2 T-cells Growth, differentiation and survival of 
antigen specific CD4+ and CD8+ T-
cells 
 
T-cells, NK cells, B-
cells 
Kinter et al., 2000 
  IFN-γ NK cells, T-cell Inhibition of viral replication T-cells, B-cells,  
macrophages 
Hematopoietic IL-7 DC, fibroblast, 
keratinocytes 
Homeostasis - survival, proliferation 
and repertoire diversity of T-cells 
 
CD4+ T-cells Fry and Mackall, 2005 
  GM-CSF T-cells, macrophages, 
endothelial cells, 
fibroblasts 
Monocyte differentiation into 
macrophages 
Monocytes Hercus et al., 1994 
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IL-1β 
Pro-inflammatory cytokines like IL-1β can activate NFκβ transcription factors in the 
cytoplasm of host cells, and these activated transcription factors then mediate NFκβ 
production (Crofford et al., 1997). The role of IL-1β in the enhancement of HIV replication 
through the direct activation of NFκβ has been shown (Osborn et al, 1989; Chene et al., 
1999). NFκβ is known to regulate viral transcription through two NFκβ sites in the long 
terminal repeat region of HIV (Nabel and Baltimore, 1987). During HIV infection, IL-1β 
plays an important role by increasing the expression of adhesion factors on endothelial cells 
which enable immune cell transmigration (Dinarello, 1994; Copeland, 2006). IL-1β has also 
been shown to synergise with IL-6 to enhance HIV expression of latently infected human 
promonocytic cell line U1 via distinct molecular pathways, independently of NFκβ (Poli et 
al., 1994).  
HIV gp120 has also been shown to have the ability to induce production of IL-1β directly and 
in a CCR5-dependent manner (Cheung et al., 2008). Exogenous IL-1β has also been shown 
to enhance AIDS-related Kaposi’s sarcoma cell growth (Louie et al., 1995) and potentially 
contributes to other complications in chronic HIV infection including neurological and 
haematological disorders (Maury et al., 1990; Weiss et al., 1992). In addition to its ability to 
directly enhance HIV replication, IL-1β is regarded as a stimulatory haematopoetic factor, 
acting as an agent that induces both differentiation and maturation for a variety of cells (Neta 
et al., 1986; Moore et al., 1987). 
 
IL-6 
IL-6 has been shown to have a direct effect on immune cells, inducing their activation, 
proliferation, apoptosis and differentiation (especially B-cells and Kupffer cells; Nakajima et 
al., 1989; Breen et al., 1990). A number of studies have reported an increase in the 
expression of IL-6 in plasma during HIV infection (Breen et al., 1990; Ullum et al., 1996; 
Bastard et al., 2012). IL-6, either alone or in synergy with TNF-α, has been shown to induce 
HIV expression in infected monocytic cells (Poli et al., 1990; Spear et al., 2008). Two 
mechanisms have been proposed for this synergy. Firstly, IL-6 may enhance levels of viral 
transcription and increase steady state RNA levels. Secondly, IL-6 may increase expression 
of HIV proteins and reverse transcriptase activity from a post-transcriptional perspective. IL-
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6 and its soluble receptor, IL-6R, have also been shown to play a role in the induction of 
monocytes chemoattractant protein-1 (MCP-1) and recruiting neutrophils, monocytes and 
lymphocyte (Romano et al., 1997).  
 
TNF-α 
TNF-α is one of the best characterized pro-inflammatory cytokines, which is thought to be 
crucial in the pathogenesis in infections like HIV, as it initiates an inflammatory cascade 
(Bahia and Silakari, 2010). TNF-α production by monocytes, macrophages and natural killer 
cells is thought to be triggered by host viral enhancing immune-regulatory responses (Alfano 
and Poli, 2005). Other pro-inflammatory cytokines, such as IL-6 and IL-8, can be induced by 
TNF-α, aiding in the upregulation of viral replication (Fernandez-Ortega et al., 2004). TNF-α 
is regulated by a negative feedback loop, where its own expression stimulates the production 
of anti-inflammatory cytokine IL-10, which in turn dampens inflammation by inhibiting 
TNF-α production and activity (Leghmari et al., 2008). The main pathogenic role of TNF-α 
during HIV infection is via its activation of NFκβ, which stimulates T-cell apoptosis and 
initiates a cascade of inflammatory responses (Duh et al., 1989; Folks et al., 1989). 
 
IL-12 
IL-12 is the main cytokine controlling the switch of uncommitted naïve CD4 T-cells towards 
Th1 cells and in the activation of natural killer cells (Villinger and Ansari, 2010). IL-12 is 
known to directly induce T-cell and natural killer cells cytotoxicity, and also promote 
macrophage ability to produce IFN-γ (Trinchieri, 2003; Egilmez et al., 2011). Yang and 
colleagues (2010) have highlighted the protective role of IL-12 against various microbial 
infections, and a decrease in IL-12 concentrations has been associated with increased risk for 
developing opportunistic infections during HIV infection, and with a concurrent increase in 
IL-10 concentrations (Taoufik et al., 1997; Mirani et al., 2002). Finally, addition of IL-12 
was shown to enhance antigen-specific CD4 and CD8 T-cell responses ex vivo (Villinger and 
Ansari, 2010). 
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IL-10 
The regulatory cytokine IL-10 plays a role in both innate and adaptive immunity, and is 
produced by T-cells, dendritic cells and macrophages (Brockman et al., 2009; Hedrich and 
Bream, 2010). IL-10 suppresses many genes that are up-regulated via toll-like receptors in 
both macrophages and dendritic cells, and inhibits the production and action of pro-
inflammatory cytokines such as IL-1β, IL-6, IL-12, and TNF-α by limiting the major 
histocompatibility complex (MHC) class II and CD80/86 expression on monocytes and 
macrophages (Wang et al., 2005; Kwon et al., 2012). IL-10 also promotes proliferation of 
cytotoxic T-cells (Rowbottom et al., 1999) and activation of B-cells (Trincheri, 2007). IL-10 
has been suggested to have differing roles at different stages of HIV disease. During acute 
HIV infection, IL-10 may promote viral replication through the inhibition of effector immune 
response from both the innate and adaptive arms of the immune response (Naicker et al., 
2010). During the chronic phase of disease, however, IL-10 may have a more protective role, 
by reducing immune activation, and interfering with viral replication (Naicker et al., 2009). 
In support of this, IL-10 concentrations systemically have also been shown to correlate 
negatively with HIV viremia and positively with better CD4+ T-cell recovery during chronic 
HIV infection (Moore et al., 2001; Blackburn and Wherry, 2007). 
 
IL-2 
IL-2 is generally produced by T-cells in response to antigen binding to the T-cell receptor and 
this immune response also stimulates the expression of IL-2 receptors (IL-2R). This IL-2/IL-
2R interaction promotes the growth, differentiation and survival of antigen-specific CD4+ and 
CD8+ T-cells (Cantrell and Smith, 1984; Smith, 1988) and enhances the production of IFN-γ 
and TNF-α by these cells (Kinter et al., 2000). In a study comparing elite HIV controllers to 
chronically infected progressors, the highest levels of protection correlated most strongly 
with presence of IL-2 expressing CD8+ T-cells (Akinsiku et al., 2011). In another study, HIV 
viremia was associated with the inability to develop functional HIV-specific CD4+ T-cells 
capable of IL-2 production (Younes et al., 2003). However, when IL-2 was tested as a 
therapy for HIV in HIV-infected individuals, in vivo administration induced increased plasma 
viral loads in those that received IL-2 by stimulating HIV replication in T-cells (Davey et al., 
1997). Furthermore, when IL-2 was added ex vivo to PBMCs from HIV-infected individuals, 
it resulted in increased replication of HIV during cell culture (Chun et al., 1998; Al-Harthi et 
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al., 1998). Pertinently, this induction of viral replication was counterbalanced by the 
concurrent induction of CD8+ T-cell mediated HIV suppression (Kinter et al., 1995). 
 
IFN-γ 
During HIV infection, IFN-γ acts by inhibiting viral replication (Dhawan et al., 1995; 
Schroder et al., 2004; Pedroza-Martins et al., 2006). It induces an antiviral state through the 
initiation of Fas-mediated cell killing and heightened sensitivity to TNF-α (Tsujimoto et al., 
1986; Xu et al., 1998). In addition, IFN-γ acts on APCs to enhance their expression of HLA 
class II, hence enhancing their capacity to present antigens (Li et al., 2011). IFN-γ has also 
been positively associated with viral replication (Koyanagi et al., 1988; Vingerhoets et al., 
1998) and T-cell activation (Whitmire et al., 2005). It is also the most commonly assayed 
marker in antigen-specific T-cell responses by either flow cytometry or ELISPOT, and is the 
gold standard measure of efficacy for HIV-specific vaccine or therapeutic trials aimed at 
eliciting T-cell responses (Reece et al., 2004). Despite its wide use in clinical and vaccine 
trials, a strong IFN-γ response to vaccination is not a widely useful correlate of protection 
against HIV infection (Skinner et al., 2003; Elias et al., 2005). 
 
IL-7 
During HIV infection, production of the homeostatic cytokine IL-7 is closely linked with 
HIV-induced lymphopenia and CD4+ T-cell depletion (Llano et al., 2001; Napolitano et al., 
2001; Albuquerque et al., 2007). IL-7 plays a vital role in the homeostasis of naïve and 
memory T-cell by regulating survival, proliferation and repertoire diversity (Fry and Mackall, 
2005; Surh and Sprent, 2008). IL-7 has been linked to the upregulation of the expression of 
the death receptor Fas on naïve T-cells (Fluur et al., 2007; Rethi et al., 2008). The depletion 
of CD4+ and CD8+ T-cells caused by a combination of alterations in lymphoid tissue 
mediated homeostasis and IL-7 exposure can be partially reversed by initiation of ART (Zeng 
et al., 2012). Moreover, due to its potent effect on survival and expansion of T-cells, IL-7 is 
being targeted as a therapeutic agent for T-cell reconstitution (Snyder et al., 2006; Sportès et 
al., 2008). IL-7 therapeutic trials in humans have shown that it does facilitate better CD4 
reconstitution but also increases plasma viral loads substantially, with the result being that 
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individuals on IL-7 therapy did clinically worse than those not taking IL-7 (Vandergeeten et 
al., 2013). 
 
Granulocyte-macrophage colony stimulating factor (GM-CSF) 
GM-CSF has been shown to induce monocyte differentiation into macrophages, and 
enhancing the effector function of mature macrophages by increasing their phagocytic 
activity (Smith et al., 1990). GM-CSF directly enhances HIV replication through interacting 
with HIV long terminal repeat (LTR) (Watanabe et al., 2002; Osiecki et al., 2005), by down-
modulating the anti-viral properties of beta-chemokines (Si et al., 2002) and by inducing 
proliferation in monocytes and macrophages (Crowe and Lopez, 1997). Studies have 
demonstrated that GM-CSF, administration in tandem with ART, can be clinically beneficial 
(Krown et al., 1992). 
 
1.3.6 Causes of systemic cytokine production during HIV infection 
The acute stage of HIV infection is characterised by a systemic cytokine storm (Stacey et al., 
2009) in which cytokines like IFN-α, IL-15, TNF-α, MCP-1 and inducible protein-10 (IP-10) 
were shown to be upregulated. Even though the production of these cytokines coincided with 
peak viremia during acute HIV infection, studies have shown that cytokine concentrations do 
not return to pre-infection levels following reduction in viremia or during the chronic phase 
of infection, when viral setpoint has been reached (Stacey et al., 2009; McMicheal et al., 
2010). Pathogenic SIV infection in macaques, which are not the natural hosts for SIV, is 
similarly characterised by a cytokine storm identical to the one described in HIV infection 
(Katsikis et al., 2011). In contrast to studies in macaques, SIV infection in the natural primate 
hosts for SIV are characterised by either a complete absence or a much more attenuated 
cytokine storm and generally lower systemic levels of these cytokines (Kornfeld et al., 2005; 
Jacquelin et al., 2009; Campillo-Gimenez et al., 2010). 
Gordon and collaborators (2007) described the massive depletion of memory type CD4+ T-
cells lining the gastrointestinal mucosa of SIV-infected macaques and HIV-infected humans. 
They hypothesized that translocation of microbial products across the damaged GI mucosa 
was a major cause of increased systemic inflammation during HIV pathogenesis. They 
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proposed that the CD4+ T-cell depletion resulted in alterations in gut epithelial integrity, 
which then facilitates translocation of microbial products such as lipopolysaccharides (LPS), 
flagellin and CpG DNA across the leaky gastrointestinal mucosa into systemic circulation. 
Marchetti et al. (2013) further suggested that binding of microbial products to Toll-like 
receptors (TLR) on activated host cells induced the release of pro-inflammatory cytokines 
which results to further immune activation. Initiation of ART did not reverse the loss of 
memory CD4+ T-cells lining the gastrointestinal mucosa and ‘leaky gut’ has been postulated 
to remain a significant factor in ongoing activation and inflammation detected during chronic 
disease even in those individuals on ART (Mehandru et al., 2006). 
Several studies have shown that other viral and bacterial coinfections may contribute to 
systemic inflammation during HIV infection. A weakening immune system related to HIV 
infection can lead to loss of control of other pathogens in the body. For instance, many HIV+ 
individuals also harbour infections with other latent viruses such as herpes simplex virus 1 
and 2 (HSV-1 and HSV-2), varicella zoster and CMV (Lisco et al., 2009). Studies have 
suggested that hepatitis C virus (HCV) co-infection of HIV+ individuals may be an important 
contributor to high levels of systemic inflammation, potentially place these individuals at 
much higher risk for the development of subsequent liver disease (Bruno et al., 2008; Page et 
al., 2011; Kushner et al., 2013). Almost all HIV+ individuals are also infected with CMV 
(Shepp et al., 1996) and these co-infections with CMV and HIV have been implicated in 
enhanced systemic inflammation associated with premature ageing of the immune system and 
development of AIDS co-morbidities (Barrett et al., 2012). The South African TB/HIV 
coinfection rate is higher, with 55% of TB patients also testing positive for HIV, relative to 
the 33% prevalence globally (CDC, 2011). The immune reconstitution inflammatory 
syndrome (IRIS) after the initiation of ART for HIV is well documented (Elliot et al., 2009; 
Pawlowski et al., 2012). 
 
1.3.7 Consequences of systemic cytokine production during HIV infection 
The initiation of systemic inflammation and long term persistence of inflammation in blood 
during HIV infection has extensive and detrimental effects on health of HIV+ individuals. 
Systemic markers of inflammation have been linked with cardiovascular disease during HIV 
infection (Friis-Moller et al., 2003; Palella and Phair, 2011; Duprez et al., 2012). In addition, 
inflammation is thought to cause fibrosis of lymphatic tissue, damaging the architecture of 
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lymph nodes and disturbing homeostatic balance (Schacker et al., 2002). Pro-inflammatory 
cytokines have been shown to suppress thymic function, resulting in a decline in thymic 
output and atrophy of the thymus (Linton and Dorshkind, 2004). 
Inflammatory changes in brain tissue are common among HIV+ individuals, and these are 
associated with the development of a spectrum of motor, cognitive and psychological 
manifestations including HIV-related dementia (Harezlak et al., 2011). Inflammation and a 
suppressed immune system contribute to cancer development during HIV infection by 
causing oxidative stress and DNA damage. A number of large general population studies 
have linked a variety of cancers during HIV infection to elevated levels of inflammation 
markers (Borges et al., 2013). Finally, chronic inflammation in the event of HIV infection has 
been shown to have an effect on mortality itself (Kuller et al., 2008; Boulware et al., 2011). 
In summary, HIV infection is characterised by immunodeficiency, which occurs in a setting 
of chronic immune activation and inflammation, even in those individuals on ART. A decline 
occurs in the CD4+ T-cell pool while CD8+ T-cell population expands during the course of 
HIV infection. This general and persistent cellular activation and inflammation drive the 
cycle of HIV replication, serving as fuel to HIV pathogenesis (Figure 1.6). 
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Figure 1.6 Consequences of immune activation and inflammation during chronic HIV infection in vivo. 
The schematic highlights the broad consequences of immune activation on the biology of HIV and on T-cell and 
associated lymphoid tissues in vivo and their subsequent effect on HIV transmission, pathogenesis, and survival 
in HIV infected individual. 
 
1.4 Markers of HIV disease progression 
1.4.1  Classical markers of HIV disease progression: Absolute blood CD4+ T-cell counts 
and HIV viral load 
Because CD4+ T-helper cells are both the primary targets for HIV infection but also a central 
component of host immunity to most other infections, absolute blood CD4 counts have 
become a valuable indicator of the state of immune function in HIV-infected individuals. 
Together, measurement of absolute CD4 counts and HIV plasma loads in blood are 
invaluable in the staging and management of HIV infection and are the major criterion used 
in the WHO/CDC classification of HIV infection (Table 1.1). The WHO guidelines (2013) 
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now recommend that ART, consisting of a cocktail of three antiretrovirals used in 
combination, is prescribed for HIV-infected individuals with blood CD4 counts of <500 
cells/mm3 irrespective of symptoms and for any individuals with symptoms of AIDS or an 
AIDS defining illness. 
Several studies have compared the prognostic value of plasma HIV RNA level and/or blood 
CD4 counts as predictors of pathogenesis in individuals infected with HIV (Loveday et al., 
1995; Coombs et al., 1996; O’Brien et al., 1996; Welles et al., 1996; O’Brien et al., 1997; 
Chene et al., 2003; Bonnet et al., 2005; May et al., 2006). Changes in either or both of these 
markers, even after initiation of ART, have been shown to have predictive value in HIV+ 
individuals in both early phases of disease (Katzenstein et al., 1996; Langford et al., 2007) 
and during the advanced stages of disease (Tsoukas et al., 1994). Marschner and 
collaborators (1998) performed a meta-analysis on data available from seven AIDS Clinical 
Trials Group (ACTG) studies and reported that both absolute blood CD4 count and HIV 
plasma loads were important markers of HIV disease progression in individuals with 
advanced disease, with the combined use of the two markers yielding the strongest prediction 
power. They did report, however, that these two markers were independently prognostic. 
The standard of care to monitor HIV disease progression in most settings are clinical 
assessment, monitoring blood CD4+ T-cell counts (by flow cytometry) and plasma viral loads 
(by RNA PCR). Although clinical assessment remains the easiest and most cost effective 
approach (especially in developing countries), it lacks sensitivity in predicting disease stage, 
and rate of disease progression. 
 
1.4.2 Alternate markers of HIV disease progression 
In addition to the classic markers for HIV disease progression, many other novel biomarkers 
have been studied over the past decade, including those that use cellular, viral, 
immunological, human leukocyte antigen (HLA) and neural markers to predict HIV disease 
course. Rather than measurement of absolute CD4 T-cell counts, some studies have evaluated 
monitoring of specific subsets of CD4 T-cell frequencies as an alternate to absolute counts. 
Using cox proportional hazards regression model, the significant association between 
percentage CD4 and disease progression was highlighted in an observational study (Hulgan et 
al., 2007), while elevated regulatory T-cells were identified as a marker predicting worse 
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HIV disease prognosis (Nilsson et al., 2006). Three independent cross-sectional studies 
evaluated host HLA (Fernandes et al., 2003), serum C-reactive protein (CRP, Lau et al., 
2006) and soluble toll-like receptors (Heggelund et al., 2004) as alternative biomarkers for 
monitoring HIV disease progression. In the absence of ART, some studies have documented 
that more rapid progression from HIV infection to AIDS is strongly associated with certain 
detrimental HLA types while slower progression is associated with protective HLA types 
(Kuniholm et al., 2011; Fenandes et al., 2003). Lau et al. (2006) demonstrated that the 
associations between CRP were correlated inversely with CD4 lymphocyte counts and 
directly with HIV RNA levels. Heggelund and collaborators (2004) reported that individuals 
with AIDS have lower serum levels of soluble toll-like receptor 2 compared with healthy 
controls and individuals with less advanced disease. Neural markers such as sphingomyelin 
have also been shown to predict disease progression, suggested to predict encephalic 
involvement (Saktor et al, 2004). 
Over the past decade, CD8+ and CD4+ T-cell activation status has been shown to be better 
biomarkers for predicting progression to AIDS and for more general immunological 
dysregulation associated with HIV infection than either absolute CD4 counts or plasma HIV 
loads. Karim et al. (2013) reported that coexpression of activation markers CD38 and HLA-
DR were strongly predictive of worse HIV disease outcome. The percentage of CD8+ T-cells 
expressing CD38+ was shown to predict the development of AIDS, independently of the latest 
absolute CD4 counts and beta-2-microglobulin levels. Mocroft et al. (1997) reported that a 
10% increase in frequencies of activated CD8+ T-cells (expressing CD38+) was associated 
with a 37% increase in the risk of AIDS. Similarly, Liu et al. (1997) compared CD8+ T-cell 
activation with other markers (including CD4 counts, plasma level of neopterin, beta-2-
microglobulin, soluble IL-2 receptor, soluble CD8, and TNF-α) and found that elevated 
CD38 on CD8+ T-cells was the most predictive marker of those studied for development of a 
clinical AIDS diagnosis and death. Deeks et al. (2004) defined a immune activation “set 
point” as stable CD38 expression on both CD4+ and CD8+ T-cells during early HIV infection 
and suggested that this activation set point predicted subsequent CD4+ T-cell changes, 
independently of viral load. Sousa et al., (2002) showed a direct causal relationship between 
immune activation (HLA-DR and CD38) and CD4 depletion in HIV disease and only an 
indirect relationship of these parameters to the virus replication rate.  
Although several surrogate markers to monitor the rate of HIV disease progression have been 
proposed, validation of these markers has proven difficult for various reasons, with reasons 
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ranging from low detection limits of putative biomarkers in body fluids and wide variability 
in different cohorts. Evaluation of these alternative markers for HIV disease progression has 
enabled key insight into novel on the pathogenesis of HIV/AIDS (Moanna et al., 2005). In 
summary, these studies showed that: (1) HIV is a key but by no means the only factor 
predicting disease progression; (2) disruption to the immune system function can be largely 
attributed to a chronic state of generalised immune activation and associated increased T-cell 
turnover; and (3) HIV-induced chronic immune activation provides a new alley for the 
targeting of disease marker and subsequently personalised therapeutic intervention. 
 
1.5 The female genital tract 
While the mucosal surfaces of the gastrointestinal, reproductive and respiratory tracts serve 
as a barrier to the external environment, they are also constantly exposed to the external 
environment and represent a major portal of entry for numerous invading microbes, which 
leave them exposed to foreign antigens (Ganz, 2002; Mowat, 2003; Nagler-Anderson, 2006; 
Shacklett et al., 2009). Therefore, the mucosal immune system faces the delicate balance of 
safeguarding the body and combating invading pathogens through the secretion of various 
soluble factors of antimicrobial nature, cytokines, and the modulation of innate and adaptive 
immune responses involving phagocytic dendritic cells and T-cell responses (Pitman and 
Blumberg, 2000; Mowat, 2003; Montilla et al., 2004; Shacklett et al., 2009). At the same 
time, it needs to induce tolerance to the commensal microbes that make up the flora at the 
surface of these anatomic sites (Shin and Kaul, 2008). In short, the mucosal immunological 
compartments are unique and consist of both mechanical and cellular interactions which 
serve as the first line of defence against external elements. 
The gastrointestinal and respiratory tracts consist of organised mucosal-associated lymphoid 
tissue (MALT). At the gut mucosa, this is referred to as the gut associated lymphoid tissues 
(GALT) and this is where adaptive immune responses take place. In GALT, Peyer’s patches 
and the draining mesenteric lymph nodes provide a platform for the priming of T and B-cells 
found there, with antigens taken up and redirected from the epithelial lamina propria (Mowat 
and Viney, 1997; Mowat, 2003). While GALT and bronchus-associated lymphoid tissues 
(BALT) are characterised by the same form of organisation (with diffuse lymphoid tissues 
that fulfil the purpose of effector sites), the female genital tract lacks similar organisation, 
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with scattered populations of immune cells responsible for antigen uptake throughout the 
compartment (Neutra et al., 1996; Hladik et al., 2007; Haase, 2010). Given that sexual 
contacts account for the majority of HIV transmission worldwide, knowledge of the anatomy 
of the female genital tract is essential for the understanding events unfolding at this site prior, 
during and thereafter transmission (Gouws et al., 2006). 
 
1.5.1 Organisation of the cervicovaginal compartment 
The lower genital compartment of women consists of three distinct regions: (1) the vagina 
and its associated mucosa, (2) the ectocervix and (3) the endocervix (Figure 1.7; Hladik and 
McElrath, 2008; Kumamoto and Iwasaki, 2012). The endocervix is lined with a single layer 
of columnar epithelium, while the ectocervix and vagina comprises of a non-keratinised 
stratified squamous epithelium (Quayle, 2002; Coombs et al., 2003; Hirbod and Broliden, 
2007). The presence of a multilayered squamous epithelium in the vagina and ectocervix may 
confer a greater mechanical protection against invading pathogens compared to the single-
layered epithelium of the endocervix (Hladik and Hope, 2009). On the other hand, the larger 
surface area of the vaginal and ectocervical mucosa may allow greater access to pathogens 
(Hladik and McElrath, 2008). The transformation zone is an abrupt transition between the 
ectocervix and endocervix and is characterised by the presence of the largest number of 
lymphocytes, in particular CD4+ T-cells, in the lower genital compartment in women 
(Edward and Morris, 1985; Pudney et al., 2005; Hladik and McElrath, 2008). A thick mucus 
plug is also present in this squamocolumnar junction. A comparable amount of dendritic cells 
and Langerhans cells have been characterised in the endo- and ectocervix, as well as the 
vaginal opening regions (Pudney et al., 2005). A variety of other immune cells, such as 
macrophages and granulocytes, have also been identified in the cervicovaginal compartment 
(White et al., 1997; Nkwanyana et al., 2009). Because of its greater density of CD4+ T-cells 
and CD1a+ dendritic cells compared to the vagina, the ectocervical mucosa is considered 
more vulnerable to HIV transmission (Coombs et al., 2003). High frequencies of CD8+ T-
cells and APC in the ectocervix and transformation zone suggest the possibility that these 
sites are the predominant locations for the induction of effector CTL responses in the lower 
female genital tract (Pudney et al., 2005). 
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Figure 1. 7 Architecture of the lower female genital tract. The cervicovaginal compartment is made up of the 
vaginal mucosa, the ectocervix, the transformation zone and the endocervix. Each of these sites is defined by a 
specific cellular architecture and leukocytes distribution. (Adapted from Hladik and McElrath, 2008 and 
Kumamoto and Iwasaki, 2012). 
 
1.5.2 Factors affecting susceptibility to heterosexual HIV acquisition 
The vagina, ectocervix and endocervix have all been shown to be susceptible to HIV 
infection, with penetration of the virus having been demonstrated in all three sites (Hladik 
and Hope, 2009). An intact vaginal epithelium offers the best protection against HIV 
acquisition (≈99%; to date unmatched by any prophylactic strategies tested against 
transmission) (Royce et al., 1997), acting as a physical barrier to viral penetration (Shattock 
and Moore, 2003; Miller et al., 2005). In addition, cervical mucus has shown to be effective 
in trapping HIV-infected seminal cells and free virus (Maher et al., 2005; Miller et al., 2005). 
Despite these effective barriers, HIV still gains entry across the female genital mucosa via 
breaches in the barrier. 
Disruption in the physical integrity of the mucosal barrier (Haase, 2010), by mechanisms 
such as micro-trauma possibly during penetrative sex (Figure 1.7), may provide immediate 
access to sub-mucosal target cells - including T-cells, dendritic cells and Langerhans cells 
(Prakash et al., 2004; Li et al., 2009; Keele et al., 2011). Sexually transmitted infections 
(STIs), especially those that cause ulcers or other disruptions in the mucosal barrier, have also 
been shown to increase risk for HIV infection (Johnson et al., 2008; Kaushic, 2009; Ward 
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and Ronn, 2010; Petrova et al., 2013). The natural and recurrent sloughing of the 
multilayered stratified epithelium of the vagina and ectocervix has been suggested to provide 
some measure of protection, because this process would result in rapid healing of 
microabrasions in the female genital tract. This process is generally thought to prevent 
bacterial colonisation and/or viral access to intraepithelial target cells (Quayle, 2002). This 
has been confirmed in studies of vaginal transmission of SIV in primates where thicker 
genital epithelium in the genital compartment has been shown to be protective against 
infection by SIV (Kaizu et al., 2004; Smith et al., 2004). Use of progesterone-based 
contraceptives, such as Depo-Provera (DMPA), which results in thinning of the genital 
epithelium, has been suggested to increase susceptibility to HIV infection (Baeten et al., 
2005; Stringer and Antonsen, 2008; Mestecky et al., 2009). 
Plasma HIV load of the HIV+ individuals has been reported in multiple studies to be a 
significant predictor of HIV transmission to HIV- individuals, with plasma viral levels of 
>50 000 cps/ml being associated with transmission and viral loads <1500 cps/ml being 
associated with a lower risk of transmission (Quinn et al., 2000; Donnell et al., 2010). 
Furthermore, a number of studies have reported the positive association between plasma HIV 
load and HIV shedding in both the male and female genital secretions (Hart et al., 1999; 
Kovacs et al., 2001; Gumbi et al., 2008). 
Two main mechanisms have been suggested by which HIV establishes infection in vivo: (1) 
cell-free HIV infection of target cells resident at the genital mucosa including CD4+ T-cells, 
macrophages and DCs; and/or (2) cell-to-cell transfer of HIV from HIV-infected donor cells 
(Pope and Haase, 2003). During cell-to-cell infection, the transfer of HIV can take place 
either from one T-cell to another T-cell, from an infected macrophage to a DC or from an 
infected DC to T-cells (Pope and Haase, 2003; Groot et al., 2008). Resting and activated 
CD4+ T-cells were found to be the predominant targets for SIV and HIV infection in the 
genital tract (Zhang et al., 1999; Hladik et al., 2007). This was further evidenced by the large 
scale depletion of mucosal CD4+ T-cells during acute HIV infection and maintained 
systemically during the chronic phase of infection (Veazey et al., 2003; Brenchley et al., 
2004). Likewise, the earliest targets of HIV in cervical tissue culture were shown to be 
memory CD4+ T-cells (Gupta et al., 2002). Macrophages have, in contrast, been identified as 
the predominant target cells in the vaginal lamina propria (Greenhead et al., 2000). The 
highly phagocytic Largerhans cells are common residents of the genital epithelium and 
express both CD4 and CCR5 and may thus internalise R5 HIV strain and transfer virus to 
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CD4+ T-cells (Hladik et al., 2007). HIV can also be either endocytosed or transferred to CD4 
and CCR5 receptors on DCs, leading to viral-cell membrane fusion and infection. 
Endocytosed HIV may be degraded or transferred to CD4+ T-cells or macrophages 
(Geijtenbeek et al., 2000). 
 
1.5.3 Characterisation of HIV-specific immune responses in the genital tract 
Numerous studies have demonstrated the existence of mucosal T-cell responses in the female 
genital compartment and semen of HIV-infected individuals (Musey et al., 1997; Kaul et al., 
2000; Shacklett et al., 2000; Musey et al., 2003) and it has been suggested that these local T-
cell responses may be involved in local control of HIV infection. Activation of lymphocytes 
through antigen presentation or via cytokines produced by antigen-associated stimulation of 
the innate immune system induces a multitude of anti-viral responses by the adaptive arm of 
the immune system (Iwasaki, 2010). The existence of an inflammatory gradient and 
chemotactic signals call immune cells to migrate from lymph nodes to cervicovaginal effector 
tissue to exert an anti-viral response. Cervical HIV-specific CD8+ T-cells at the genital 
mucosa have been found to secrete IFN-γ, TNF-α and MIP-1β (Bere et al., 2013) and be 
capable of cytolytic effector function in response to HIV antigens in infected women. Studies 
in HEPS women have implicated HIV-reactive CTLs and genital HIV-specific neutralising 
antibodies in protection from HIV infection (Kaul et al., 2000; Kulkarni et al., 2003; 
Alimonti et al., 2006; Hirbod and Broliden, 2007). 
It is known that polyfunctional T-cells, capable of secreting multiple cytokines, having 
cytolytic activity and with high proliferative capacity, predict better HIV disease outcome as 
it became clear that IFN-γ production alone by CD8+ T-cells may not be sufficient for HIV 
control (Harari et al., 2004, Pantaleo and Koup, 2004). The role for genital tract anti-HIV 
CTLs in controlling HIV locally therefore needs further investigation. Though detectable in 
acutely SIV-infected macaques, CTL responses only arise after the peak in viremia had 
occurred and after a productive infection was established in blood (Reynolds et al., 2005). 
The majority of HIV-infected individuals, except for ECs and LTNPs, would inevitably 
progress to AIDS even in the presence of anti-HIV CTLs in the absence of ART. Even if 
CTLs play an important role in the control of HIV, there are other factors associated with the 
virus itself that may drive HIV pathogenesis, rendering the immune system overwhelmed. 
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1.5.4 Inflammation and HIV shedding at the female genital mucosa 
Many studies have attempted to investigate biological factors that may influence 
susceptibility to HIV infection. Many of these studies have shown that plasma HIV load is 
one of the most important predictors of HIV shedding in the genital tract, even among HIV-
infected women on ART (Quinn et al., 2000; Sheth et al., 2004; Rebbapragada et al., 2007). 
Independently of plasma viral load, inflammation in the genital tract has been identified as a 
central factor influencing both susceptibility to infection and the amount of HIV shed in 
genital secretions (Spear et al., 2008). 
Production of pro-inflammatory cytokines are thought to increase the risk for HIV infection 
(in HIV- individuals) and transmission (from HIV+ individuals) in the mucosal compartment 
because these cytokines are involved in immune cell recruitment, activation and 
differentiation (Wira et al., 2005; Gabay et al., 2006; Dinarello et al., 2009; Nkwanyana et 
al., 2009). Unlike DCs and Langerhans cells, whose maturation is accompanied by down-
regulation of CCR5, monocyte differentiation to macrophages, which is induced by pro-
inflammatory cytokines, is accompanied by up-regulation of the HIV co-receptor, CCR5 
(Hariharan et al., 1999; Kaufmann et al., 2001; Cunningham et al., 2008). Pro-inflammatory 
cytokines such as IL-1α, IL-1β, IL-6 and TNF-α induce the expression of transcription factor 
NFκβ (Poli et al., 1990; Niu et al., 2004). In addition to enhancing the expression of various 
host cell proteins involved in inflammation (cytokines, growth factors, adhesion molecules 
and acute phase proteins), NK-κB also binds to HIV LTR and directly up-regulates HIV 
replication (Poli et al., 1990; Niu et al., 2004). IL-8 and GM-CSF stimulate HIV replication 
in macrophages (Lane et al., 2001) while IL-8 and IL-2 induce HIV replication in T-cells 
(Chun et al., 1998; Lane et al., 2001). Additionally, pro-inflammatory cytokines such as 
TNF-α may facilitate HIV infection by disrupting tight junctions between genital tract 
epithelial cells, reducing the integrity of this barrier (Nazli et al., 2010). Pro-inflammatory 
cytokine production and associated recruitment of CD4+ T-cell targets for infection have been 
shown to be important prerequisites for establishment of a productive systemic SIV infection 
following vaginal infection (Li et al., 2009; Haase, 2011). Furthermore, inhibition of 
inflammatory responses using a topically-applied anti-inflammatory agent (glycerol-
monolaurate) was found to prevent SIV infection (Li et al., 2009). 
Many potential inducers of inflammation exist in the female genital tract. Among the most 
significant and well characterised are infections with STIs (including HSV-2, syphilis, 
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gonorrhoea, trichomoniasis and chlamydia) and perturbations in the vaginal microflora 
involved in bacterial vaginosis, all of which have been associated with upregulation of pro-
inflammatory cytokines in the genital compartment (Agrawal et al., 2007; Rebbapragada et 
al., 2007; Libby et al., 2008). Changes in oestrogen and progestin concentrations associated 
with the use of hormonal contraceptive have also been shown to influence inflammation in 
the genital tract (Hunt et al., 1997; Prakash et al., 2001). Physiological concentrations of 
oestrogen been shown to stimulate IL-1β production by endometrial cells, which in turn 
induces MCP-1 expression (Akoum et al., 2000). Cytological alterations of the cervix occur 
as a result of hormone changes and are associated with higher cervicovaginal IL-1β and IL-6 
concentrations (Zara et al., 2008). Progesterone-based injectable hormone contraceptives 
have been associated with increased numbers of inflammatory cells in cervicovaginal fluid, 
while oral contraceptive use is associated with increased CCR5 expression on CD4+ T-cells 
(Ghanem et al., 2005; Prakash et al., 2001). 
Studies of serodiscordant couples have suggested that genital tract inflammation, due to 
current or prior STIs, is an important contributing risk factor for HIV transmission to the 
uninfected partner (Quinn et al., 2000; Gray et al., 2001; Freeman et al., 2006; Ward & 
Ronn, 2010). However, a definitive causal relationship between genital tract inflammation 
and the frequency of activated targets for HIV replication has yet to be described at the 
female genital tract as well as the consequences to susceptibility to infection and local HIV 
pathogenesis. Our current understanding of the relationship between inflammation, immune 
activation and HIV risk in the genital mucosa largely comes from epidemiological studies 
where cause and effect are difficult to define, and from non-human primate studies which 
may imperfectly mirror vaginal transmission in the human female genital tract. 
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1.6 Study aims and objectives 
The overall aims of this study were to investigate the impact of partner HIV status on HIV 
susceptibility and disease progression in HIV serodiscordant heterosexual couples by 
measuring systemic immune activation and inflammation, genital tract inflammation and HIV 
shedding in South African women with HIV seroconcordant or serodiscordant male partners. 
Study rationale 
Several studies have described biological and behavioural differences that exist between 
HIV-infected individuals in HIV seroconcordant and discordant relationships, focusing on 
plasma HIV load, blood CD4 counts and sociobehavioural factors (Freeman et al., 2004; 
Malamba et al., 2005; Rogers et al., 2005; Kumarasamy et al., 2010). HIV serodiscordant 
couples account for close to 44% of HIV seroprevalence in Sub-Saharan Africa (Were et al., 
2006) and heterosexual transmission of HIV is considered to be the leading cause of new 
HIV infection in adults from Africa. This study in HIV seroconcordant and serodiscordant 
couples aims to investigate whether systemic immune activation and inflammation, which are 
important determinants of HIV pathogenesis, have an impact on disease progression in HIV-
infected individuals or protection against HIV acquisition in HIV negative individuals. One 
of the many biological factors determining HIV transmission efficiency that may play a role 
in differential spread and disease patterns is genital tract inflammation (Spear et al., 2008). 
This study aims to further investigate whether differences in HIV status impacts on genital 
tract inflammation or release of HIV into genital secretions in women with stable HIV 
seroconcordant or serodiscordant male partners. 
 
Specific Objective 1 
To investigate the impact of sexual partner HIV status on classical markers of HIV disease 
progression (blood CD4 counts and plasma HIV load) in HIV+ individuals in seroconcordant 
and serodiscordant relationships. 
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Specific Objective 2 
To investigate the impact of partner HIV status on systemic T-cell activation and 
inflammation in HIV+ individuals in serodiscordant versus seroconcordant relationships; and 
the value of these alternative markers in predicting rates of HIV disease progression. 
 
Specific Objective 3 
To investigate the role of inflammatory and homeostatic cytokines in the female genital tract 
on HIV shedding in HIV+ women in serodiscordant versus seroconcordant relationships. 
 
Specific Objective 4 
To investigate how biological markers of HIV risks (including genital and systemic 
inflammation and immune activation) differ in HIV negative women at risk of HIV infection 
(with HIV+ serodiscordant partners) compared to women with HIV- seroconcordant partners. 
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2.1 Introduction 
Sub-Saharan Africa remains the epicentre of the HIV/AIDS epidemics, accounting for 69% 
of the global HIV prevalence and 68% of new cases in 2011 (UNAIDS, 2012). A 
considerable fraction of HIV infections are transmitted between stable couples, especially in 
countries with mature epidemics (Guthrie et al., 2007; Lingappa et al., 2008). With an 
estimate of only 62% of HIV-infected individuals in sub-Saharan Africa having access to 
ART and the yearly 1.8 million new HIV infections in this region, it is likely that a greater 
number of HIV-infected individuals will be in relationships with serodiscordant partners 
(UNAIDS, 2012). By the end of 2008, of the 22.4 million HIV positive people living in sub-
Saharan Africa (UNAIDS, 2009), approximately 44% of couples were estimated to be HIV 
serodiscordant (Were et al., 2006). 
Studies in HIV serodiscordant couples have provided useful insight into the dynamics of 
factors that influence risk of HIV acquisition, allowing measurement of HIV incidence per 
person year, rate of acquisition from one gender to another and per coital act HIV 
transmission risk (Quinn et al., 2000; Gray et al., 2001; Hollingsworth et al., 2010). Many 
studies have focused on the biological and behavioural differences that exist between HIV+ 
individuals in HIV seroconcordant and serodiscordant relationships (Freeman et al., 2004; 
Malamba et al., 2005; Rogers et al., 2005; Kumurasamy et al., 2010). Studies in HIV 
seroconcordant and serodiscordant couples can lead to the development of couples-focused 
HIV prevention interventions that target risky sexual behaviours and control the biological 
correlates of HIV transmission. Moreover, HIV serodiscordant couples are increasingly seen 
as a critical target for the evaluation of HIV vaccines and other prevention strategies. 
Transmission of HIV at an individual level is dependent on two important factors: (1) the 
infectiousness of the ‘HIV donor’; and (2) the susceptibility of the uninfected ‘recipient’ (Fox 
and Fidler, 2010). This depends on the amount of virus within the secretions of the ‘donor’, 
the frequency and nature of exposure, and finally the concomitant existence of co-factors that 
have been documented to enhance the efficiency of HIV transmission such as STIs (Nusbaum 
et al., 2004; Johnson et al., 2008; Ward et al., 2010). The risk of HIV acquisition is estimated 
to be quite low following a single sexual exposure (Royce et al., 1997; Quinn et al., 2000) 
and one of the main determinants of this is the level of HIV in the inoculum deposited during 
sex (Chakraborty et al., 2001; Coombs et al., 2003). It is well documented that HIV loads in 
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blood significantly predict the amount of virus being shed in genital secretions, although 
other local factors are likely also important (Hart et al., 1999; Garcia-Bujalance et al., 2004; 
Vettore et al., 2006; Chan et al., 2008; Cu-Uvin et al., 2010). 
Immunosuppression after HIV infection leads to the lysis and depletion of CD4+ T-
lymphocytes, making CD4 count in blood a reliable indicator of immune function (McCune 
et al., 2001). Blood CD4 counts have hence been used as a major criterion on which the 
Centres for Disease Control and Prevention/World Health Organisation (CDC/WHO) 
classification of HIV infection and AIDS staging for clinical management is based (WHO, 
2012). In addition to absolute CD4+ T-cell counts, the prognostic significance of HIV RNA 
loads in plasma as a predictor of clinical progression in infected subjects is well documented 
(Mellors et al., 1996; Phillips et al., 2001; Badri et al., 2008; Ding et al., 2009). Mellors et al. 
(1997) described the relationship between higher plasma HIV loads and more rapid clinical 
progression, which lead to plasma HIV load being linked to increased risk of rapid 
progression, and thus became a widely used indicator for initiation of ART. 
While direct cellular killing of infected target cells is an important correlate of protection 
during HIV-infection, CTLs also secrete a number of different soluble factors (mainly 
cytokines and chemokines; Cocchi et al., 2000), which have also been implicated either 
directly or indirectly in protection. It is now known that virus-specific CD8+ T-cells with a 
"polyfunctional" profile, defined by the capacity to secrete multiple cytokines or chemokines, 
are most competent in controlling viral replication in chronic HIV infection. Some studies 
have evaluated CD4+ and CD8+ T-cell HIV-specific polyfunctional responses on exposure to 
specific HIV immunogen (Lichterfeld et al., 2004; Precopio et al., 2007). These studies 
showed that long-term enhancement of HIV-specific CD4+ T-cells and polyfunctional CD8+ 
T-cell responses are associated with immune control. 
Blood HIV-specific CTLs have been shown to secrete the antiviral cytokine IFN-γ and 
display cytolytic function in response to various HIV epitopes in HIV+ individuals (Fan et 
al., 1993; McMicheal et al., 2001). Harari et al. (2004) described a correlation between IL-2 
production by CD4+ T-cells and HIV load. The primary function of IL-2 is to trigger T-cell 
division and also acts as a co-stimulator for resting naïve CD8+ T-cells and enhances 
activation and proliferation of CD8+ T-cell, B-cells and natural killer cells (Goldsby et al., 
2000; Li et al., 2007). β-chemokines RANTES, MIP-1α and MIP-1β have been associated 
with better control of HIV and slower disease progression in LTNP (Zagury et al., 1998; 
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Ullum et al., 1998; Xiang et al., 2004). These chemokines have also been shown to suppress 
HIV activity through competition for the HIV coreceptor CCR5 (Cocchi et al., 2000). 
A number of studies have reported that partner status impacts on plasma viral loads in HIV+ 
individuals (Malamba et al., 2004; Rogers et al., 2005; Kumarasamy et al., 2010), although 
the consequence of these differences on clinical disease course in individuals has not been 
thoroughly investigated. This chapter aims to investigate the impact of partner HIV status on 
(1) the rate of HIV clinical disease progression (measured by plasma viral loads and absolute 
blood CD4 counts) and (2) systemic HIV-specific T-cell responses in HIV-infected 
individuals. 
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2.2 Materials and Methods 
2.2.1 Description of study participants 
One hundred and ninety five (195) HIV-infected individuals in stable HIV seroconcordant 
relationships and 142 HIV-infected individuals in HIV serodiscordant relationships were 
included for this part of the study. These couples in stable long-term relationship with their 
partners were recruited from the Empilisweni Clinic in Gugulethu, Cape Town. They 
generally attended the clinic as couples, although interviews regarding demography and 
sexual behaviours were conducted individually with each participant. A history of 
symptomatic STIs, genital discharge, ulceration and genital warts was obtained during 
clinical examination. Absolute blood CD4 cell counts and HIV viral loads were measured for 
each HIV+ individual at enrolment into the study (baseline), and then at months 12 and 24. 
All HIV+ individuals were naïve to ART. All aspects of the study were approved by the 
Research Ethics Committee of the University of Cape Town (UCT REC# 258/2006) and 
informed written consent was obtained from all individuals before initiation of the study. 
 
2.2.2 Peripheral blood mononuclear cells (PBMCs) collection and processing 
Blood (16ml) was collected from each study participant by standard venipuncture into sterile 
ACD anti-coagulated vacutainer tubes (BD Biosciences, Plymouth, UK) and processed 
within 4 hours of collection. PBMCs were isolated using Ficoll-Hypaque (Sigma-Aldrich, St 
Louis, MO, USA) density gradient centrifugation using Leucosep® tubes. Ficoll, wash buffer 
and medium used during PBMC isolation were warmed to room temperature prior to use. 
Three millilitres of Ficoll-Hypaque density gradient was poured into a 15ml Leucosep® tube 
fitted with filter disc at its 3ml mark and centrifuged at 2500rpm (1215 x g) for one minute in 
a bench top centrifuge (Megafuge 1.0, Heraeus Instrument) to allow the Ficoll to move below 
the disc. Whole anti-coagulated blood was gently poured onto the Leucosep gradient and 
centrifuged at 2500rpm for 15 minutes. Plasma was aspirated using a disposable Pasteur 
pipette to within 0.5–1 cm from the PBMCs “disc” or “buffy” layer and was transferred to 1.8 
ml cryovials (Greiner Bio-one, Frickenhausen, Germany) and stored at -80°C. The buffy 
layer enriched with PBMCs was removed using a disposable Pasteur pipette and transferred 
to a 15ml Sterilin tube. The PBMCs were washed twice in 15ml of 1% FCS PBS (phosphate 
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buffered saline (PBS, Sigma-Aldrich, St Louis, MO, USA) supplemented with 1% fetal calf 
serum (FCS, Life Technologies Corporation, Carlsbad, CA, USA)), with centrifugation at 
1200rpm (280 x g) for 10 minutes. After the second wash, PBMCs were resuspended in 10ml 
RPMI1640 (Life Technologies Corporation, Carlsbad, CA, USA) medium supplemented with 
5mM glutamine, 100 units/ml penicillin, 100 µg/ml streptomycin, 10 mg/ml fungin and 10% 
FCS. Cells were counted using an automated Guava cell counter. 
 
2.2.3 Counting of PBMCs using the automated Guava cell counter 
Ten microlitres of the resuspended PBMCs was added to 190µl Guava Viacount reagent 
(Guava Technologies, Hayward, CA, USA) and mixed thoroughly using a vortex mixer. Cells 
were incubated at room temperature for 8 minutes, acquired using the automated Guava cell 
counter and analysed using the Cytosoft® software. 
 
2.2.4 Ex-vivo stimulation, intracellular cytokine staining and flow cytometry 
Fresh PBMCs were used for this part of the study. Peripheral blood mononuclear cells (2 x 
106 cells/ml) were investigated for their functional capacity to produce either of IFN-γ, IL-2 
or MIP-1β following antigenic stimulation with (i) a single pool of 121 HIV-1 subtype C 
(Du422) Gag overlapping peptides (final concentration of 1 µg/ml; peptides kindly provided 
by the NIH AIDS Reagent Repository), (ii) PMA/ionomycin (final concentration 10 µg/ml 
each; Sigma-Aldrich, St Louis, MO, USA), or (iii) left untreated for 6 hours at 37ºC and 5% 
CO2. Brefaldin A (10 µg/ml; Sigma-Aldrich, St Louis, MO, USA) was added after the first 
hour of stimulation. After stimulation, the cells were washed once in 2ml of 10% FCS PBS 
containing 0.01% NaN3 for 5 minutes at 1500rpm (437 x g) at room temperature. The pelleted 
cells were resuspended in the dead volume and stained with APC-labelled anti-CD3 (Becton-
Dickinson, San Jose, CA, USA) and PE-Cy5-labelled anti-CD8 (Becton-Dickinson, San Jose, 
CA, USA) for 30 minutes on ice. Cells were then washed in 2ml of 10% FCS PBS containing 
0.01% NaN3 for 5 minutes at 1500rpm (437 x g) at room temperature followed by fixation 
and permeabilisation with 0.5ml of BD Cytofix/Cytoperm (Becton-Dickinson, San Jose, CA, 
USA) for 20 minutes at room temperature. Cells were washed in 2ml of BD Perm/Wash 
buffer (Becton-Dickinson, San Jose, CA, USA) by centrifugation at 1500rpm at room 
temperature for 5 minutes. The supernatant was discarded, the cell pellet resuspended and 
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stained with Phycoerythrin (PE) labelled anti-IFN-γ and Fluorescein Isothiocyanate (FITC) 
labelled anti-IL-2 or FITC labelled anti-MIP-1β for 30 minutes on ice. Finally, cells were 
washed in 2ml of Perm/Wash buffer and fixed with BD Cell Fix (Becton-Dickinson, San 
Jose, CA, USA). Cell fluorescence was assessed using a FACSCalibur flow cytometer (BD 
Immunocytometry Systems, San Jose, CA, USA). Compensation and analysis of data were 
done using FlowJo software (Tree Star, Ashland, OR, USA). 
 
2.2.5 Determination of HIV viral load in blood plasma 
HIV viral loads were measured in blood plasma using Nuclisens Easyq HIV Version 1.2 
(National Health Laboratory Services Diagnostic Virology Laboratory, Groote Schuur 
Hospital, Cape Town, South Africa). The detection limit of the assay was 50 HIV RNA 
copies/ml. Participants with blood plasma ≤50 HIV RNA copies/ml were considered to be 
aviremic. 
 
2.2.6 Statistical analysis 
Shapiro-Wilk test for normality was performed to determine the distribution of variables 
within the dataset. Comparison of unpaired non-parametric data was done using the Mann-
Whitney U test. The Spearman’s rank test was applied to test for correlation between non-
parametric data. Statistical inferences on binary sets of data were performed using the 
Fisher’s exact test and odds ratios calculated. Statistical analyses were performed using 
GraphPad Prism version 5.0 for Windows (GraphPad Software, San Diego, California, USA). 
All tests were two-tailed and p-values of ≤0.05 were considered significant. 
 
 
 
 
 
45 
 
2.3 Results 
2.3.1 Clinical and socio-behavioural characteristics 
One hundred and ninety-five individuals in chronic HIV seroconcordant relationship and 142 
chronically HIV-infected individuals in HIV serodiscordant relationship were included for 
this study. All individuals were naїve to anti-retroviral therapy at the time of study. The 
baseline socio-demographic and clinical characteristics of participants included in this 
Chapter are reported in Table 2.1. In this cohort, women were more likely to be the HIV+ 
partner in a serodiscordant couple than men, with 77% of HIV+ serodiscordant individuals 
being women compared to 23% men (p<0.0001 compared to almost equal men:women 
distribution in HIV seroconcordant couples). The median age of the HIV+ individuals in 
seroconcordant relationships was 33 years (IQR 28-40) while those in serodiscordant 
relationships had a median age of 34 (IQR 28-40). There was no significant difference in the 
ages when comparing individuals in those two groups. There was no difference between HIV 
seroconcordant and serodiscordant participants in sociodemographic and sexual behavioural 
parameters like cohabitation, lifetime sexual exposure duration and monthly frequency of sex 
act. However, HIV+ serodiscordant individuals reported a significantly higher condom usage 
over the last month than did HIV seroconcordant individuals (75% versus 62%; p=0.01). 
Clinical manifestations of genital disease as defined by the presence of ulceration and/or 
discharge over the past 6 months were not different when comparing HIV seroconcordant 
individuals to serodiscordant individuals. All men in the study were circumcised. 
Table 2. 1 Clinical and socio-behavioural characteristics of participants included in the study 
 
Characteristics n Concordant n Discordant P-value 
n 
 
195 
 
142 
 Male [%] † 
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23 P<0.0001 
Age [yr; median (IQR)] * 195 33 (28-40) 139 34 (28-40) 1.0 
Living together with partner [%] † 194 70 140 62 0.2 
Sexual exposure [median years of sex (IQR)] 
* 194 16 (11-22.) 139 16 (11-24) 0.9 
Sex acts in the last month [median (IQR)] * 190 4 (2-10) 131 4 (2-8) 0.4 
Condom usage [%] † 191 62 137 75 0.01 
Genital ulceration in the last 6 months [%] † 100 13 107 12 0.7 
Vaginal discharge in the last 6 months [%] † 100 30 107 29 1.0 
† p-value calculated using Fischer's exact test 
     * p-value calculated using Mann-Whitney U-test 
     IQR: Interquartile range 
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2.3.2 Impact of partner HIV status on individual plasma viral loads 
The level of HIV in plasma was compared in HIV-infected individuals in seroconcordant and 
serodiscordant relationships (Figure 2.1). HIV seroconcordant participants had 0.5 Log 
higher plasma viral load than HIV serodiscordant participants, with a median Log 4.4 (IQR 
3.7-5.0) for seroconcordant individuals versus Log 3.9 (IQR 3.3-4.5) for serodiscordant 
individuals. This 0.5 Log difference was equivalent to a difference of 14700 HIV RNA 
copies/ml in individuals in seroconcordant versus serodiscordant relationships. The difference 
in viremia observed between seroconcordant and serodiscordant participants persisted over 
time (month12 and month24; Table 2.2). 
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Figure 2. 1 Comparison between plasma HIV viral load in seroconcordant versus serodiscordant HIV+ 
individuals. Each data point represents an individual’s plasma viral load. The red line indicates the median viral 
load and associated IQR for each group. Mann-Whitney U test was used to compare the plasma viral load 
between HIV seroconcordant and HIV serodiscordant individuals. 
Table 2. 2 Longitudinal plasma HIV load in seroconcordant and serodiscordant individuals 
 
Median (IQR) HIV Plasma Viral Load cps/ml 
Time 
point  n       Concordant             Discordant 
Baseline 195, 142 23000 (5600-92000) 8300 (2125-35250) 
12month 76, 65 21500 (5000-100000) 7900 (2200-35500) 
24month  29, 34 25100 (2500-112200) 11200 (1200-27000) 
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Gender did not impact on this difference in viral load between HIV seroconcordant and 
serodiscordant individuals, with HIV+ women and men in seroconcordant relationships 
having similar plasma viral loads, and those in serodiscordant relationships having similar 
viral loads (Figure 2.2A and B, respectively).  
 
Figure 2. 2 Comparison between plasma HIV viral load in women versus men, in seroconcordant (A) and 
serodiscordant (B) relationship. Each data point represents an individual’s plasma viral load. The red line 
indicates the median viral load and associated IQR for each group. Mann-Whitney U test was used to compare 
the plasma viral load between men and women in HIV seroconcordant or HIV serodiscordant individuals. 
To test whether there was evidence for sharing of viruses with similar characteristics (HIV 
set-point similarities) within HIV+ seroconcordant couples, the relationship between male 
and female partners’ viral loads was investigated (Figure 2.3). No relationship was found 
between partners’ plasma HIV load, possibly suggesting that either properties of virus were 
not influencing viral loads in each partner in a couple (ie, host genetics may have been 
confounding this analysis) or that the phenotype of the virus was not similar between 
individuals in a couple. 
Concordant
Female Male
1
2
3
4
5
6
7
Pl
as
m
a 
H
IV
 v
ir
al
 lo
ad
 (l
og
10
 co
pi
es
/m
l)
Discordant
Female Male
1
2
3
4
5
6
7
Pl
as
m
a 
H
IV
 v
ir
al
 lo
ad
 (l
og
10
 co
pi
es
/m
l)
A B
48 
 
1 2 3 4 5 6 7
1
2
3
4
5
6
7
Spearman r=-0.06
p=0.6
Women Plasma HIV viral load (log10 copies/ml)
M
en
 P
la
sm
a 
H
IV
 v
ir
al
 lo
ad
 (l
og
10
 co
pi
es
/m
l)
 
Figure 2. 3 Correlation between seroconcordant male partner HIV plasma viral load and matching 
female partner HIV plasma viral load. Matching HIV plasma viral loads of partners within HIV 
seroconcordant couples were correlated using Spearman rank test. 
2.3.3 Relationship between HIV plasma viral load and absolute blood CD4 count 
In these individuals, plasma viral loads correlated significantly with absolute CD4 counts 
(Figure 2.4; HIV seroconcordant individuals (Rho=-0.44, p<0.0001) and serodiscordant 
individuals (Rho=-0.47, p<0.0001). 
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Figure 2. 4 Correlation between HIV plasma viral load and absolute blood CD4 count. Matching HIV 
plasma viral load and absolute blood CD4 count of HIV seroconcordant and HIV serodiscordant individuals 
combined were correlated using Spearman rank test. 
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2.3.4 Impact of partner HIV status on absolute blood CD4 counts during HIV infection 
The impact of differences in plasma viral loads in HIV seroconcordant and serodiscordant 
individuals was investigated on whether there were stellar differences between the absolute 
CD4 count in the two groups (Figure 2.5). Despite a 0.5 Log difference in viral loads between 
serodiscordant versus seroconcordant couples (Figure 2.1) and a significant correlation 
between CD4 counts and plasma viral loads in both groups (Figure 2.4), HIV+ individuals in 
seroconcordant relationship had a very moderate reduction in median absolute CD4 count 
compared to their serodiscordant counterparts [354 CD4 cells/ml (IQR 217-561) in 
seroconcordant versus 387 cells/ml (IQR 250-526) in serodiscordant, Δ 23 CD4 cells/ml; 
p=0.3]. This trend in absolute CD4 counts was maintained over 2 years of study (month12 
and month24; Table 2.3). Previous studies in serodiscordant couples have shown variable 
outcomes with relation to impact of partner status on absolute CD4 count as a clinical marker 
of disease status. While some have reported no significant difference in absolute CD4 count 
when comparing participants according to couple status (Malamba et al., 2005; Kumarasamy 
et al., 2010), others reported lower CD4 counts in concert with higher plasma viral loads in 
seroconcordant versus serodiscordant couples (Chatterjee Rogers et al., 2005; Kumarasamy 
et al., 2010). 
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Figure 2. 5 Comparison between absolute CD4 count in seroconcordant versus serodiscordant HIV+ 
individuals. Each data point represents an individual’s absolute CD4 count. The red line indicates the median 
absolute CD4 count and associated IQR for each group. Mann-Whitney U test was used to compare the absolute 
CD4 count between HIV seroconcordant and HIV serodiscordant individuals. 
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Table 2. 3 Longitudinal absolute blood CD4 count in seroconcordant and serodiscordant individuals 
 
        Median (IQR) CD4+ T-cell counts (cell/µl) 
Time 
point  n       Concordant             Discordant 
Baseline 192, 136 354 (217-561) 387 (250-526) 
12month 64, 60 352 (238-489) 379 (242-493) 
24month  27, 26 275 (208-429) 296 (181-440) 
 
2.3.5 Relationship between changes in HIV plasma load and blood CD4 count 
In light of the finding that HIV seroconcordant and serodiscordant individuals have similar 
absolute blood CD4 counts despite a 0.5 log10 difference in plasma HIV load, the 
relationship between changes in these two markers and their respective level at baseline were 
determined. HIV+ individuals were classified according to whether they experienced an 
increase or a decrease in absolute blood CD4 count or plasma HIV load from baseline visit to 
month 12 (Table 2.4). 
Only 83 individuals had matching data available for these two time points, of which 53 
experienced a decrease in CD4 count from baseline to month 12. This decrease in CD4 count 
was associated with a corresponding increase in HIV plasma burden for the same period. This 
increase in plasma HIV load accounted for 35% of the CD4+ T-cell depletion in blood and 
was statistically significant in univariate analysis. A high CD4 absolute count in this group of 
53 individuals at baseline was highly predictive of the eventual decrease over the one year 
period (R2 = 0.77, p<0.0001). The same trends were observed when separating the 53 
individuals according to their partner’s HIV status. None of the other three groups (increased 
CD4 count, increased HIV plasma load, decreased HIV plasma load) showed any association 
with either of the two markers. Exploratory analyses by gender, sexual practices, clinical 
manifestations (ulceration and genital discharge) and stratifying HIV plasma load or CD4 
absolute count did not reveal any characteristic resulting in a greater predictive ability to 
determine fluctuations in either of the two disease markers in peripheral blood. This analysis 
suggest that HIV+ individuals who experienced the greater CD4 decline over the first year of 
study were those that started with the highest CD4 counts at baseline; and that viral load was 
a major contributor to this decline. This analysis also suggests that a possible contributor to 
the apparent discrepancy between (1) correlation between VL and CD4 counts generally; (2) 
higher VL in seroconcordant versus serodiscordant individuals; but (3) no difference in CD4+ 
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T-cells counts at the same time point or longitudinally may be the fact that individuals 
enrolled in this study already had relatively low CD4 counts at baseline (354 cells/ml for 
seroconcordant vs 387 cells/ml for serodiscordant at baseline, Table 2.3). 
Table 2. 4 Longitudinal analysis of changes in blood CD4 count and HIV load 
 
          
 
            Spearman rank correlation coefficient 
    n ΔCD4 ΔHIV load m0 CD4 m0 HIV load 
Decreased CD4† 53 - -0.34* 0.77*** -0.19 
Increased CD4‡ 30 - 0 0.12 0.06 
Decreased HIV load† 38 -0.09 - -0.08 -0.20 
Increased HIV load‡ 45 0.14 - -0.03 -0.35* 
 
m0: baseline; m12: month12; ΔCD4: change in CD4 count from m0 to m12; ΔHIV load: change in 
HIV load from m0 to m12 
†: decrease in parameter from m0 to m12; ‡: increase in parameter from m0 to m12 
P-values<0.05 are denoted by *, <0.001 by *** 
 
2.3.6 Impact of partner status on magnitude of HIV-specific T-cell responses 
The magnitude of ex vivo HIV Gag-specific cytokine producing T-cell responses in the blood 
of HIV+ individuals in seroconcordant and serodiscordant relationships was investigated. 
Representative plots of the gating strategy used and cytokine (IFN-γ, IL-2, MIP-1β) 
production by CD4+ and CD8+ T-cells isolated from blood are shown in Figure 2.6. 
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Figure 2. 6 Representative plots showing gating strategy for ex vivo intracellular cytokine production by 
peripheral blood monuclear cells (PBMCs) in absence of, or response to stimulation with 
PMA/ionomycin. A. PBMCs were stained with fluorochromes-labelled monoclonal antibodies to define CD3 
(APC), CD8 (PE-Cy5), IFN-γ (PE) and IL-2 or MIP-1β (FITC) interchangeably. CD3+ T-cell populations were 
distinguished into CD8- and CD8+ T-cell populations. B. Cells were either left unstimulated (top panels) or 
stimulated ex vivo with PMA/ionomycin for 6 hours (bottom panels). Cell fluorescence was measured using an 
LSRII flow cytometer, gates set according to fluorescence minus-one (FMO) staining, while compensation and 
analysis was performed using FlowJo software. 
 
Overall, more HIV+ seroconcordant individuals had HIV-specific immune responses (IFN-γ 
and MIP-1β) and at higher frequencies than HIV+ serodiscordant individuals. Of the 195 
HIV+ seroconcordant individuals, 30/195 had PBMC available and were included in this part 
of the study. Of these, 21/30 (70%) had IFN-γ responses above background for the CD8- T-
cell subset. Of the 142 HIV+ serodiscordant individuals, 27/142 were studied and 11/27 
(41%) had IFN-γ responses above background (Fisher’s exact test revealed a significant 
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difference, p=0.04). As for the CD8+ T-cell subset, of the 30 HIV seroconcordant individuals, 
25/30 (83%) had IFN-γ responses above background while only 14/27 (52%) serodiscordant 
individuals showed IFN-γ responses above background (Fisher’s exact test revealed a 
significant difference, p=0.02). Similarly, a higher number of HIV+ seroconcordant 
individuals had Gag-specific IFN-γ responses above background than serodiscordant 
individuals for CD8- T-cells 23/30 [(77%) compared to 6/27 (23%), respectively, p=0.02]. A 
similar pattern was observed for CD8+ T-cells, although this was not significant. In 
comparison to IFN-γ and MIP-1β responses, IL-2 response frequencies were generally lower 
following Gag-stimulation and no difference in IL-2 responsiveness was observed between 
serodiscordant or seroconcordant individuals by either CD8- or CD8+ T-cells. 
Figure 2.7 shows the net Gag responses between HIV+ seroconcordant and serodiscordant 
individuals, showing CD8- and CD8+ T-cell subsets separately. The frequencies of Gag-
specific IFN-γ producing T-cells were elevated in HIV+ seroconcordant compared to 
serodiscordant individuals in both T-cell subsets. Similarly, frequencies of MIP-1β producing 
cells were elevated in HIV+ seroconcordant compared to serodiscordant individuals, 
significantly so for CD8- T-cells (p=0.006 for CD8- and p=0.06 for CD8+). However, no 
difference was found when comparing the frequencies of IL-2 production by T-cells between 
the two groups. The lack of difference in response to PMA stimulation when comparing 
cytokine production of CD8- and CD8+ T-cells of seroconcordant individuals to 
serodiscordant ones suggest that there was no different on the potential functionality of the T-
cell subsets between the two groups. 
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Figure 2. 7 Comparison between ex vivo cytokine production by PBMCs from HIV seroconcordant and 
HIV serodiscordant individuals. Top panel. Frequencies of IFN-γ+CD3+, IL-2+CD3+ and MIP-1β+CD3+ for the 
CD8- and CD8+ T-cells were assessed in response to Gag-stimulation. Background frequencies (measured as 
unstimulated PBMCs) of these subsets were subtracted from the Gag stimulated specimen. Bottom panel. 
Frequencies of IFN-γ+CD3+, IL-2+CD3+ and MIP-1β+CD3+ for the CD8- and CD8+ T-cells were assessed in 
response to PMA-stimulation. Background frequencies (measured as unstimulated PBMCs) of these subsets 
were subtracted from the PMA stimulated specimen. 
 
Others have suggested that polyfunctional CD8+ T-cell responses are associated with immune 
control (Chakrabarti, 2010). When looking at dual production of cytokines (IFN-γ+IL-2+& 
IFN-γ+MIP-1β+) no difference was found between concordant and discordant individuals 
(Figure 2.8). 
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Figure 2. 8 Comparison between ex vivo cytokine production by PBMCs from HIV seroconcordant and 
HIV serodiscordant individuals. Top panel. Frequencies of IFN-γ+IL-2+CD3+ and IFN-γ+MIP-1β+CD3+ for the 
CD8- and CD8+ T-cells were assessed in response to Gag-stimulation. Background frequencies (measured as 
unstimulated PBMCs) of these subsets were subtracted from the Gag stimulated specimen. Bottom panel. 
Frequencies of IFN-γ+IL-2+CD3+ and IFN-γ+MIP-1β+CD3+ for the CD8- and CD8+ T cells were assessed in 
response to PMA-stimulation. Background frequencies (measured as unstimulated PBMCs) of these subsets 
were subtracted from the PMA stimulated specimen. 
 
The relationship between the function of HIV-specific CD8+ T-cell responses and viral load 
has been defined previously. While certain studies have shown that the relationship between 
CD8+ T-cell response and viral load is not universally consistent throughout the chronic 
phase of infection (Addo et al., 2003; Cao et al., 2003; Jiao et al., 2006; Kiepiela et al., 
2007), analysis of HIV-specific CD8+ T-cell responses in other studies were shown to 
positively correlate with HIV viral load (Ogg et al., 1998; Betts et al., 2001; Edwards et al., 
2002). A significant association was observed between the HIV-specific IFN-γ responses by 
CD8+ T-cell and HIV plasma load in 32 individuals for which both measurements were 
characterised (Figure 2.9; R=0.51, p=0.007). The association remained strong and significant 
when performed for HIV seroconcordant individuals alone (n=17; R=0.51, p=0.04). Though a 
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positive correlation was observed between IFN-γ specific responses in CD8+ T-cells of 
serodiscordant individuals and their plasma HIV load, this association was not significant 
(n=15; R=0.4, p=0.14). No association was observed between any of the levels of the three 
cytokines assayed and CD4%.  
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Figure 2. 9 Correlation between HIV plasma viral load and HIV-specific IFN-γ Response by CD8+ T-cells. 
Matching HIV plasma viral load and HIV-specific IFN-γ Response by CD8+ T-cells of 17 HIV seroconcordant 
and 15 HIV serodiscordant individuals combined were correlated using Spearman rank test. 
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2.4 Discussion 
This chapter explores potential risks associated with being an HIV+ individual in a 
relationship with a stable partner who is either HIV seroconcordant or serodiscordant, using 
objective biomarkers of HIV disease progression, such as plasma HIV load and absolute 
blood CD4 count. HIV seroconcordant individuals in this study had a 0.5 log10 higher 
plasma HIV load than their serodiscordant counterparts, which was equivalent to a difference 
in viral load of 14700 copies viral RNA/ml. Even though HIV loads in plasma were found to 
be negatively associated with absolute CD4 counts, this 0.5 log10 difference in viremia 
between groups did not predict a worse clinical outcome as indicated by lower absolute CD4 
counts at future visits over a 2 year period of follow-up. 
There have been several studies in couples which have yielded conflicting findings about the 
relationship between viral load and CD4 counts in HIV seroconcordant and serodiscordant 
couples (Malamba et al., 2005; Chatterjee Rogers et al., 2005; Kumarasamy et al., 2010). 
Malamba et al. (2005) reported that HIV+ seroconcordant individuals had an average of 0.34 
Log10 higher plasma viral load than those in HIV serodiscordant relationships. In their study, 
a 0.34 Log10 difference in viral load translated to a difference of 71 422 RNA copies/ml, and 
this was associated with greater CD4 decline in the seroconcordant than the serodiscordant 
individuals. It could be that the 5-fold greater difference in plasma viral load in the Malamba 
et al. (2005) study compared to the current study accounted for the difference in clinical 
outcome and that a 71 422 RNA copies/ml difference was sufficient to drive greater absolute 
blood CD4 decline between their two groups. Interestingly, the median CD4 count reported 
in seroconcordant participants in the Malamba study was much lower than the baseline 
median CD4 count in the seroconcordant individuals in this current study (250 cells/ml 
versus 354 cells/ml) while an opposite trend was found between median CD4 count of 
serodiscordant individuals in the Malamba study (467 cells/µl) and the same marker in the 
current study (387 cells/µl). As longitudinal analysis in this study revealed that a higher CD4 
count at previous visit was associated with a greater CD4 decline as measured at the 
following visit, it could be that the individuals included in this study had already reached set-
point in their chronic stage of HIV infection, characterised only by slight changes in both 
blood CD4 count and viral load over time. Similarly, Chatterjee Rogers et al. (2005) reported 
that HIV-infected men in seroconcordant relationship had significantly lower CD4 counts and 
higher viral load than men in serodiscordant relationship. However, the very low CD4 count 
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(97 in seroconcordant men and 222 in serodiscordant men) and higher median plasma viral 
load (360 000 cps/ml for seroconcordant men and 291 000 cps/ml for serodiscordant men) in 
their study could be indicative of these participants being in AIDS stages. No mention is 
made of the length of time for which those participants have been infected. The participants 
included in the present study are all in the chronic phase of infection. Moreover, the 
consistent level of viremia maintained in both seroconcordant and serodiscordant individuals 
from baseline through month 12 and up to month 24 reflects the fact that these individuals 
have probably reached viral set-point already. 
The finding in this Chapter that a higher plasma HIV load in HIV+ seroconcordant 
individuals compared to individuals in serodiscordant relationships did not predict lower 
absolute blood CD4 counts in seroconcordant individuals is unexpected. It may be that the 
difference in plasma viral load between HIV+ individuals in seroconcordant versus 
serodiscordant relationships is central to whether these individuals experience worse HIV 
clinical course based on CD4 decline. For instance, if the difference in plasma viral load is 
high in seroconcordant versus serodiscordant individuals, then the impact of CD4 decline will 
be more evident. Similarly, if the cohort is chronic and average CD4 counts are relatively low 
at baseline, then decline in CD4 counts will be more difficult to quantify because the study is 
starting off an already low base. 
Many factors have been shown to affect blood CD4 count and HIV load during infection. It is 
essential that all these factors are controlled for if one is to dissect the intricacies governing 
over the differences in CD4 count and plasma HIV load. As an example, in a cross-sectional 
analysis of married couples in seroconcordant and serodiscordant heterosexual relationships, 
Kumarasamy et al. (2010) reported completely contrasting findings to our studies. They 
reported seroconcordant individuals having a significantly higher CD4 count (205 cells/µl) 
and lower viral load (89 000 cps/ml) than serodiscordant individuals (139 cells/µl and 
100 000 cps/ml respectively). However, it is also important to point out that more 
seroconcordant individuals were on ART compared to serodiscordant individuals (14.1% 
versus 8.5%; p=0.004), which would influence both plasma viral loads and CD4 counts. In 
the present study, ART was controlled for by only enrolling participants naïve to therapy. 
Moreover, in the study conducted by Malamba et al. (2005), they reported that women in 
HIV seroconcordant relationship were 6.5-fold more likely to have reported an STI in the 6 
months prior to enrolment than those in serodiscordant relationship. In contrast, HIV+ 
individuals in the study presented in this Chapter reported an equal manifestation of STDs 
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across the two groups, which suggests that concomitant STIs did not impact on differences 
seen in plasma viral load in this cohort. Of note, Malamba et al. (2005) also suggested that 
circumcision status of male partners impacted on viral load differences in the context of 
couples, with a significantly of higher report of circumcision in serodiscordant males (24%) 
compared to seroconcordant males (6%). There is strong epidemiological evidence that 
uncircumcised men are at an increased risk of HIV transmission than circumcised men 
(Moses et al., 1998; Bailey et al., 1999; Quinn et al., 2000; Gray et al., 2007). Since all of the 
men in this study were circumcized, this potential factor would not be considered a 
confounder. While Chatterjee Rogers et al. (2005) documented a lower CD4 count associated 
with the elevated viremia in seroconcordant participants compared to serodiscordant 
participants, the couples enrolled in their study were recruited from men having sex with 
HIV+ commercial sex workers. Since the individuals in this current study were in stable 
long-term heterosexual relationships, the nature of the partnership when interpreting results 
from seroconcordant versus serodiscordant individuals is important to consider. 
There is broad consensus about the prognostic value of CD4 counts in predicting rate of 
disease progression (Lepri et al., 1998; Williams et al., 2006) and that clinical HIV disease 
progression is preceded in all untreated individuals by an increase in HIV RNA in plasma 
(Henrard et al., 1995). However, there is substantial debate about the utility of using CD4 
absolute cell counts alone as a valid surrogate for virological outcome in plasma, and whether 
variability in CD4 cell counts adequately reflect variability in viral load (Badri et al., 2008). 
While some studies have shown that this may have limited predictive value (Grabar et al., 
2000; Florence et al., 2003; Jevtovic et al., 2005), others suggest that these parameters are 
predictive of one another, where in one such study, it was determined that an average of 1 
Log10 increase in viral load was associated with a 55 cell/µl decrease in CD4 count (Lima et 
al., 2009). Rodriguez et al. (2006) reported that even though elevated plasma HIV loads were 
associated with greater rates of CD4 decline overall, viral burden had minimal value for 
predicting the rate of CD4 cell decline in individual patients, with only 4-6% of the 
variability in CD4 numbers being explained by changes in plasma VL. Mellors et al. (2007) 
subsequently confirmed the poor association between these two markers. In a selected group 
of participants for whom CD4 count and plasma HIV load were available for two consecutive 
time points in this present study, 35% of the variability in CD4 depletion in blood was 
attributable to changes in HIV plasma load. Collectively, all these studies suggest a limited 
capacity of CD4 cell counts alone to explain variability in viral load measurement at an 
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individual level in untreated patients. CD4 T-cell counts can be influenced by sex, age, race, 
concomitant infections, and even geography (Maini et al., 1996). However, all of these 
factors have been controlled for in our study. If differences in plasma viral loads only 
partially account for changes in absolute blood CD4 level, a key question to address is what 
are the other determinants accounting for this residual variability in CD4 cell decay? 
Improvements in the treatment of HIV infection and AIDS may result from an improved 
understanding of this 65% of CD4 cell decline that remains enigmatic. 
One of the most important questions raised by the finding in this Chapter that HIV+ 
seroconcordant individuals sustain a higher plasma viral load over time than serodiscordant 
individuals is about the potential influence of each of the seroconcordant partner’s HIV load 
and viral characteristics on properties of viremia in their similarly HIV+ partners. Several 
studies have shown that qualitative aspects of the virus can be additional risk factors 
associated with HIV progression and transmission (Baeten et al., 2007; Kiwanuka et al., 
2008; Alizon et al., 2010; Shirreff et al., 2011). HIV is characteristically highly genetically 
diverse (Hoelscher et al., 2002; Kiwanuka et al., 2008). Previous studies have reported that 
HIV infection with multiple types simultaneously is an important factor that might influence 
subsequent viral load setpoint and HIV disease progression, with those individuals infected 
with >1 type having higher setpoints (Kanki et al., 1999; Grobler et al., 2004; Campbell et 
al., 2009; Redd et al., 2011). In this Chapter, it was impossible to determine who had donated 
the virus compared to who received the virus in HIV+ seroconcordant couples, whether these 
couples in fact infected each other or came into the relationship already infected. No 
association was observed between plasma viral loads within a couple, suggesting that either 
properties of virus were not influencing viral loads in each partner in a couple (ie, host 
genetics may have been confounding this analysis) or that the phenotype of the virus was not 
similar between individuals in a couple. Since one of the hypotheses of this study was that 
HIV+ seroconcordant couples would share HIV that was phenotypically similar, this finding 
was unexpected and suggested that other non-viral factors were possibly influencing viral set-
point. Recently, the genomic determinants of susceptibility to HIV infection, control of viral 
replication and pathogenesis have been investigated in depth (Telenti, 2006). Telenti (2006) 
argued that there was a great deal of inter-individual variability in HIV viral setpoint after 
seroconversion, part of which is known to be due to genetic differences among infected 
individuals. Rotger and collaborators (2010) have shown a significant contribution of variable 
host gene expression in the control of HIV, related to host DNA polymorphisms. In their 
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genome-wide search, they observed two distinct profiles with 260 genes differentially 
expressed depending on HIV viral load. While it has been shown that host variants identified 
in multiple genome-wide analyses (Dalmasso et al., 2008; Limou et al., 2009; Fellay et al., 
2009) explain only 13% of the variation in viral setpoint, the remaining 87% of variation 
unaccounted for, indicating that other biological determinants of control are yet to be 
identified. 
Despite this finding, ongoing HIV superinfection resulting from intracouple transmission 
could be occuring (Piantadosi et al., 2007; Redd et al., 2011) and could be a molecular 
mechanism influencing viral load within seroconcordant couples. Hecht et al. (2010) recently 
observed a strong correlation between HIV RNA levels within HIV transmission pairs that 
they followed up from the time of transmission through to the chronic stage of infection and 
concluded that virus characteristics are an important determinant of viral load in early HIV 
infection. The cohort studied in this dissertation consisted of infected individuals who have 
reached set-point and are already in the chronic phase of infection. Although not measured in 
this study, the lack of association in viremia between partners could be driven by host 
immune factors such as HLA genotype. Moreover, strong CTL responses have been reported 
to select for escape mutations in HIV, particularly those in Gag, which could substantially 
impact on fitness and therefore viral loads (Friedrich et al., 2004; Martinez-Picado et al., 
2006). These mutations can persist after transmission and influence viral load in recipients 
after transmission and during early HIV infection (Chopera et al., 2008; Goepfert et al., 
2008). 
Possibly linked to higher plasma HIV load in HIV+ seroconcordant compared to 
serodiscordant individuals, HIV+ seroconcordant individuals also had substantially higher 
frequencies of IFN-γ producing CD8- and CD8+ T-cells. The observation of a strong positive 
correlation between Gag-specific IFN-γ responses by CD8+ T-cells and plasma HIV load 
confirms that a higher antigenic exposure in immune compartments can immunologically 
translate into elevated HIV-specific antiviral responses. IFN-γ has been shown to be an 
important antiviral cytokine, commonly produced in response to HIV infection (Fan et al., 
1993; McMicheal et al., 2001). It is a useful predictive tool for how effectively the host 
immune system is fighting the infection and has been shown to inhibit viral replication in 
infected cells (Dhawan et al., 1994; Guidotti et al., 1999). IFN-γ has also been shown to 
promote protective T helper type 1 (Th1) immune responses (Mosmann et al., 1989) which 
include both cell-mediated immunity and antibody mediated immunity. 
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In addition to IFN-γ production as a means of identifying HIV-specific T-cell responses, IL-2 
and MIP-1β were also assayed in this study to get a broader measurement of HIV-specific 
effector function. While no difference was observed between seroconcordant and 
serodiscordant individuals for IL-2 expression in CD8+ and CD8- T-cells, it was evident that 
higher frequencies of T-cells from HIV+ seroconcordant individuals produced MIP-1β than 
serodiscordant individuals. MIP-1β was interesting to include in this study because it is a 
chemokine that directly binds to and can therefore potentially modulate expression of the 
HIV co-receptor CCR5 (Trumpfheller et al., 1998). MIP-1β has also been shown to be 
associated with asymptomatic HIV infections (Cocchi et al., 2000) and with a decreased risk 
of HIV disease progression (Ullum et al., 1997), because it acts as antagonists to HIV cell 
entry. Collectively, these findings suggest that antiviral immunity might be afforded through 
the release of HIV-suppressive chemokines from activated CD8+ T-cells, and as these 
chemokines down-regulate CCR5 expression on cell surface, it leads to a lower proportion of 
CD4+ T-cell being infected and targeted for killing. This higher production of MIP-1β could 
be indirectly driving the similitude in CD4 count in seroconcordant and serodiscordant 
individuals. 
This first chapter provides evidence that differences exist between HIV+ individuals in 
seroconcordant and serodiscordant relationships. A difference of 0.5 Log10 or 14 700 
copies/ml was observed in plasma HIV load between HIV+ seroconcordant versus 
serodiscordant individuals. It appears that 0.5 Log10 difference in plasma HIV load (14 700 
copies/ml) between HIV seroconcordant and serodiscordant individuals did not significantly 
influence subsequent rates of disease progression in this cohort since CD4 counts remained 
comparable over the 24 months of follow-up. If this 0.5 Log10 difference in plasma HIV load 
(14 700 copies/ml) was not great enough to impact on pathogenesis as measured by absolute 
CD4 count, what could be the implication of this difference during the course of chronic HIV 
infection? Pedraza et al. (1999) have shown that a 15 000 copies/ml difference in plasma 
viral load was enough to differentiate successful heterosexual HIV transmission from non-
transmission. We can therefore hypothesise that a higher HIV load could increase the risk of 
HIV acquisition in uninfected partners and possibly also the risk of superinfection within 
seroconcordant couples. While it seems intuitive that plasma HIV RNA levels are an 
important determinant in therapeutic decision making, and recommended as one of the 
elements on which timing of initiation of ART is based (BHIVA, 2005; DHHS, 2006; 
Hammer et al., 2006), the clinical impact of the relatively modest difference from this study 
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on long term CD4 loss was not evident. Chapter 3 explores the role of systemic immune 
activation and inflammation as potential mediator driving differences observed in plasma 
viral load between HIV+ individuals in HIV seroconcordant and serodiscordant relationships. 
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3.1 Introduction 
In response to pathogen challenge, humans generally experience persistent, low-grade, 
periodic immune activation and inflammation, which reflects that anti-microbial immunity 
has been mounted and should be beneficial (Deeks and Walker, 2004). In contrast, our non-
human primates ancestors do not experience similar persistent immune activation (Silvestri, 
2008). During HIV-infection, however, studies have demonstrated that the level of systemic 
T-cell activation predicted worse disease course for those infected (Liu et al., 1998; Giorgi et 
al., 1999; Hazenberg et al., 2003; Deeks et al., 2004; Wilson et al., 2004). Immune activation 
in the context of HIV infection is a term that refers to a wide range of biological processes, 
such as cell activation, proliferation and apoptosis, and their associated consequences (Appay 
et al., 2008). Although these immune processes are generally considered to be protective to 
the host during most other infections, this paradoxically also exacerbates pathogenesis during 
HIV infections by resulting in a constant supply of activated HIV target cells (Lawn et al., 
2001). 
Zhang and colleagues (1998) showed that CD4+CCR5+ T-cells are the target cells 
preferentially infected by HIV. The infection and depletion of CD4+ T-cells characterize the 
most influential event in the pathogenesis of HIV infection, with the main cellular target 
during the established infection being activated CCR5+CD4+ T-cells. Low density of the HIV 
co-receptor CCR5 expressed on T-cells was found to be a determining factor in resistance to 
HIV infection (Reynes et al., 2003). Hazenberg et al. (2003) reported that these persistently 
elevated levels of systemic immune activation represent the main driver of disease 
progression in HIV pathogenesis and plays a bigger role than the actual CD4+ T-cell 
depletion in determining disease course. Studies of SIV disease course in macaques, which 
are not considered to be the natural hosts for SIV and experience similarly high viral loads as 
humans, have shown that systemic CD4+ T-cell loss and persistent but low levels of immune 
activation point to immune activation being the most important driver of disease progression 
(Milush et al., 2007). 
A network of pro-inflammatory, regulatory and haematopoetic cytokines has been shown to 
affect virtually every step of the life cycle of HIV, from entry into new cells to budding of 
new progeny (Catalfamo et al., 2012). These systemic cytokines are also thought to be 
responsible for localised and systemic inflammatory responses, including the recruitment of 
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potential HIV target cells at point of infection. IL-1β, IL-6, and TNF-α, either alone or 
synergistically, have been shown to act on HIV-infected cells to up-regulate HIV replication 
(Fauci et al., 1996; Poli et al., 1999). Initiation of systemic inflammation during HIV 
infection and chronic establishment of this state, driven by the replication of HIV in blood 
and mucosal compartments, have detrimental and far-reaching consequences to human health 
during chronic infection. 
The aim of this Chapter was to evaluate the impact of stable sexual partner status on the 
extent of systemic immune activation and inflammatory cytokine production in HIV+ 
individuals during the chronic stages of HIV infection. A statistical model of HIV 
pathogenesis is proposed, which incorporates the four important factors possibly impacting 
on higher plasma viral loads in HIV+ seroconcordant compared to serodiscordant individuals 
and rate of disease progression depending on partner status. These include the role of (1) 
CD4+ T-cell frequencies, (2) immune activation of systemic T-cells, (3) production of 
inflammatory and regulatory cytokines in plasma, and (4) plasma viral load. Use is made of 
differences, both biological and behavioural, between HIV+ individuals in stable 
relationships with either HIV+ seroconcordant or HIV- serodiscordant partners, and to try 
understand mechanisms predicting the establishment and exacerbation of HIV 
immunodeficiency. 
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3.2 Materials and Methods 
3.2.1 Description of study participants 
A total of 262 HIV+ individuals were included for this part of the study, of which 144/262 
were in HIV seroconcordant relationship and 118/262 were in serodiscordant relationship. 
Chapter 2 (Section 2.2.1) provides a full description of these individuals. HIV+ individuals 
were followed longitudinally during chronic infection, with immune activation and 
inflammatory cytokine production in blood being measured at 6, 18 or 30 months into the 
study. Although HIV plasma loads were available for all 262 individuals at enrolment into 
the study (month 0), viral loads were only available for 77/262 participants at the subsequent 
longitudinal time points included in this Chapter. 
 
3.2.2 PBMCs collection and processing 
Blood (16ml) was collected from all study participants using standard venipuncture into 
sterile ACD anti-coagulated vacutainer tubes (BD Biosciences, Plymouth, UK). Blood was 
processed within 4 hours of collection; PBMCs were isolated using Ficoll-Hypaque (Sigma-
Aldrich, St Louis, MO, USA) density gradient centrifugation as described in Chapter 2 
(Section 2.2.2). 
 
3.2.3 Cryopreservation of PBMCs 
All PBMCs used in this study were cryo-preserved and subsequently stored in liquid 
nitrogen. Briefly, fresh freezing solution (20% DMSO in FCS) was prepared prior to cryo-
preservation of cells and reduced to 0oC on ice prior to addition to reduce its cellular toxicity. 
PBMCs were pelleted by centrifugation at 1200rpm (280 x g) for 10 minutes and re-
suspended in cold 100% FCS at 2 x 107 cells/ml. PBMCs were then aliquoted into pre-cooled 
2ml cryovials at 500 µl (1 x 107 cells) per cryovial. To each cryovial, 500 µl of the pre-cooled 
20% DMSO FCS freezing solution was added dropwise, with constant swirling, to bring the 
final concentration of cells to 1 x 107 cells/ml per cryovial and the final concentration of 
DMSO to 10%. The sealed cryovials were transferred immediately to a pre-cooled “Mr. 
Frosty” (Nalgene) freezing container which facilitated slow controlled cooling at -
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1°C/minute. The “Mr. Frosty” container was transferred immediately to -80°C for 24 hours 
after which the cells were transferred to liquid nitrogen for long term storage. 
 
3.2.4 Thawing of cryo-preserved PBMCs 
Frozen PBMCs were thawed rapidly in a 37ºC water bath until a small piece of the ice crystal 
was still visible in the thawed cryovial. Pre-warmed (37ºC) R1 (RPMI1640 [Life 
Technologies Corporation, Carlsbad, CA, USA] medium supplemented with 5mM glutamine, 
100 units/ml penicillin, 100 µg/ml streptomycin, 10 mg/ml fungin and 1% FCS) was added 
dropwise, with continuous gentle shaking. Once the thawed cryovial was filled with R1, the 
content of the vial was transferred to a 50 ml Sterilin tube which was then topped up to the 25 
ml mark with R1. This cell suspension was carefully mixed by inverting the tube 3 times and 
centrifuged at 1500rpm (437 x g) for 10 minutes. The resulting supernatant was decanted, the 
cell pellet resuspended and the wash step repeated. After the second wash, the supernatant 
was decanted and cell pellet resuspended in 10 ml of R20 (RPMI1640 (Life Technologies 
Corporation, Carlsbad, CA, USA) medium supplemented with 5mM glutamine,100 units/ml 
penicillin, 100 µg/ml streptomycin, 10 mg/ml fungin and 20% FCS) and rested overnight at 
37ºC and 5% CO2. The cell concentration and viability of the thawed PBMCs was measured 
using the Guava cell counter and viacount reagent as previously described (Section 2.3.3). 
 
3.2.5 Counting of PBMCs using the automated Guava cell counter 
Thawed PBMCs were diluted 20-fold in Guava Viacount reagent and counted using a Guava 
Automated cell counter as previously described in Chapter 2 (Section 2.2.3). 
 
3.2.6 Staining for markers of T-cell activation by flow cytometry 
PBMCs were stained in BD Falcon Round-Bottom tubes (BD Biosciences, San Jose, CA, 
USA) and 1 million PBMCs were used per staining reaction per participant. Prior to staining 
with antibodies, PBMCs were incubated with LIVE/DEAD® Fixable Violet Dead Cell Stain 
for 20 minutes at room temperature and then washed with 1% FCS PBS. The pelleted cells 
were resuspended in a dead volume and stained for 30 minutes at room temperature with 
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phenotypic marker Peridin Chlorophyll Protein-Cyanine 5.5 (PerCP-Cy5.5) labeled anti-CD4 
(BD Pharmingen, San Jose, CA, USA), QDot605 labelled anti-CD8 (Invitrogen, Carlsbad, 
CA, USA), Allophycocyanin (APC) labelled anti-CD195/CCR5 (BD Biosciences, San Jose, 
CA, USA), Phycoerythrin Cyanine 7 (PE-Cy7) labelled anti-CD38 (BD-Biosciences, San 
Jose, CA, USA), Phycoerythrin (PE) labelled anti-HLA-DR (BD Biosciences, San Jose, CA, 
USA), and finally Pacific Blue (Pac Blue) labelled anti-CD14 (BD Pharmingen, San Jose, 
CA, USA) and anti-CD19 (Invitrogen, Carlsbad, San Jose, CA, USA). Anti-CD14 and anti-
CD19 antibodies were included as dump markers to exclude monocytes and B-cells from 
analysis, respectively. Cells were then washed twice with 1% FCS PBS, centrifuged for 5 
minutes at 1500rpm at room temperature, fixed and permeabilised with BD 
CytoPerm/CytoFix (BD Biosciences, San Jose, CA, USA) for 20 minutes at room 
temperature. Cells were then washed with Perm/Wash buffer (BD Biosciences, San Jose, CA, 
USA) for 5 minutes at 1500rpm, room temperature. The intracellular staining then ensued, 
with Allophycocyanin-Hilite (APC-H7) labelled anti-CD3 (BD Biosciences, San Jose, CA, 
USA) and Fluorescein Isothiocyanate (FITC) labelled anti-Ki67 (BD Biosciences, San Jose, 
CA, USA). Cells were washed in 2ml of BD Perm/Wash buffer by centrifugation at 1500rpm 
at room temperature for 5 minutes and fixed with BD Cell Fix (Becton-Dickinson, San Jose, 
CA, USA). Cell fluorescence was assessed using a BD LSR Fortessa flow cytometer (BD 
Immunocytometry Systems, San Jose, CA, USA). Fluorescence minus one (FMO) was used 
to distinguish continuous population. Compensation and analysis of data were done using 
FlowJo software (Tree Star, Ashland, OR, USA). 
 
3.2.7 Measurement of cytokine concentrations in blood plasma 
The concentrations of IL-1β, IL-6, IL-12p70, TNF-α, IL-10, IL-2, IFN-γ, IL-7, and GM-CSF 
were measured in blood plasma using High Sensitivity Human Cytokine LINCOplex 
Premixed kits (LINCO Research, MO, USA). The sensitivity of the kits ranged between 0.01 
and 0.48 pg/ml for each of the 9 cytokines measured. Data was collected using a Bio-Plex 
Suspension Array Reader (Bio-Rad Laboratories Inc) and a 5 PL regression formula was used 
to calculate cytokine concentrations from the standard curves. Data was analysed using BIO-
plex manager software (version 4; Bio-Rad Laboratories Inc). Cytokine concentrations that 
were below the detection limit of the assay were reported as the mid-point between the lowest 
concentration measured for each cytokine and zero. 
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3.2.8 Determination of HIV viral load in blood plasma 
HIV viral load in plasma was assayed using the NuclisensEasyq HIV Version 1.2 by the 
NHLS Diagnostic Virology Laboratory (Groote Schuur Hospital, Cape Town, South Africa). 
The detection limit of the assay was 50 HIV RNA copies/ml. 
 
3.2.9 Statistical analysis 
Shapiro-Wilk test for normality was performed to determine the distribution of variables 
within the dataset. Comparison of unpaired non-parametric data was done using the Mann-
Whitney U test. Statistical inferences on binary sets of data were performed using the 
Fisher’s exact test and odds ratios calculated. Non-parametric assessments of variation 
between groups was carried out through the Kruskal-Wallis Analysis of Variance (ANOVA), 
with Dunn’s post-test being applied to test for the effect of multiple comparisons. Quantile 
regression analyses were used to estimate the median value of the independent (response) 
variable for given levels of the dependent (predictor) variables. Adjustment for multiple 
comparisons was performed using a false discovery rate step-down approach. Statistical 
analyses were performed using GraphPad Prism version 5.00 for Windows (GraphPad 
Software, San Diego, CA, USA) and STATA 11 (College Station, TX, USA). All tests were 
two-tailed and p-values of ≤0.05 were considered significant. 
 
 
 
 
 
 
 
 
68 
 
3.3 Results 
3.3.1 Characteristics of HIV seroconcordant and serodiscordant participants 
Two hundred and sixty two black South African HIV+ individuals, from 194 heterosexual 
couples, were included to study the role of sexual partner status on systemic immune 
activation and inflammation, as potential drivers of HIV disease progression (Table 3.1). The 
participants were classified into HIV seroconcordant or serodiscordant relationships, based 
on the HIV status of their current stable partners. Of the 194 couples, 76/194 (39%) were 
HIV seroconcordant (both partners HIV+), and 118/131 (61%) were HIV serodiscordant (one 
partner HIV+ and the other HIV-). In this cohort, women were more likely to be the HIV 
seropositive partners in HIV serodiscordant couples than men (80/118 couples, 68%). No 
difference in age, age at sexual debut or whether couples cohabited was observed when 
comparing HIV+ individuals in serodiscordant and seroconcordant relationships (Table 3.1). 
All HIV+ individuals were naïve to HAART and all men were circumcised. 
 
Although absolute CD4 counts were performed at enrolment into this study (considered to be 
month 0; Chapter 2), they were not performed at subsequent time points studied in this 
Chapter. As a result, CD4 percentages (of CD3+ T-cells) were used in this study as a marker 
for absolute CD4+ T-cell counts. Hulgan et al. (2007) and Pirzada et al. (2006) have reported 
that CD4 percentages are a reliable biomarker for absolute CD4. In this Chapter, CD4 
percentages were similar in HIV+ individuals in seroconcordant or serodiscordant 
relationships (Table 3.1). 
The median plasma HIV load in HIV+ individuals was 22000 copies/ml (IQR: 50-100000). A 
higher proportion of individuals in HIV seroconcordant relationships had plasma viral loads 
of >1500 cps/ml than those in HIV serodiscordant relationships (89% versus 58%, p=0.003), 
suggesting that HIV seroconcordance is associated with higher viral loads. Possibly as a 
result of perceived risk of transmitting to their HIV- partners, a higher frequency of condom 
use was self reported by HIV+ individuals in serodiscordant relationship when compared to 
their seroconcordant counterparts (p=0.009). Despite this, 42% of participants in 
serodiscordant relationship who reported condom usage also reported recent genital 
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ulceration or/and vaginal discharge. This suggests that self-reported condom use in this 
cohort may be over-reported. 
Table 3. 1 Clinical and socio-behavioural characteristics of HIV+ individuals	  
	  	  
  
              HIV Positive P-value 
Characteristics n Concordant Discordant   
N 
 
144 118 
 Male [%] † 
 
53 32 0.004 
Age [yr; median (IQR)] * 141, 116 37 (32-42) 38 (32-45) 0.4 
Living together with partner [%] † 142, 117 70 66 0.5 
Age at first sex [median (IQR)] * 141, 117 17 (16-18) 16 (16-18) 0.9 
Sexual exposure [median years of sex (IQR)] * 140, 116 21 (15-25) 20 (14-29) 0.5 
Blood CD4% [median (IQR)] * 40, 36 45 (24-65) 38 (21-64) 0.5 
Plasma HIV load >1500 cps/ml [%] † # 38, 39 89 58 0.003 
Sex acts in the last month [median (IQR)] * 137, 116 3 (1.5-6) 3 (1.25-5) 0.3 
Condom usage [%] † 123, 112 58 74 0.009 
Genital ulceration in the last 6 months [%] † 61, 79 8 6 0.6 
Vaginal discharge in the last 6 months [%] † 61, 79 12 15 0.5 
† p-value calculated using Fischer's exact or*Mann-Whitney U-test; IQR: Interquartile range; #A cut-off of 1500 
cps/ml plasma was selected as this has been reported to be the lowest plasma level of HIV that was associated 
with heterosexual transmission of HIV (Quinn et al., 2000). 
 
3.3.2 Impact of partner HIV status on T-cell activation in blood 
The expression of activation markers CD38, HLA-DR, CCR5 and the nuclear proliferation 
marker Ki67 by T-cells in blood was measured to investigate the impact of partner status on 
activation of T-cells in HIV+ individuals. In specific combinations, these markers allowed 
assessment of the frequency of (1) highly activated T-cells (defined by dual expression of 
HLA-DR and CD38), (2) activated proliferating T-cells (defined by dual expression of Ki67 
and CD38); and (3) CCR5+ T-cells that represent the preferred target cells for HIV infection 
[activated CCR5+ cells (defined by dual expression of CCR5 and CD38) or proliferating 
CCR5+ cells (dual expression of CCR5 and Ki67)]. The overall level of activation (total 
activation) was defined as the cumulative expression of any permutation of the markers. 
Figure 3.1 shows representative plots of the gating strategy used to define each of these 
populations.
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Figure 3. 1 Representative plots showing the gating strategy used to define activated T-cell populations by flow cytometry. 
Peripheral blood mononuclear cells were stained with fluorochrome-labelled monoclonal antibodies to define CD3 (APC-H7), CD4 
(PerCPCy5.5), CD8 (QDot605), CCR5 (APC), CD38 (PE-CY7), HLA-DR (PE), Ki67 (FITC) and CD14/CD19/LIVE/DEAD 
Fixable Violet Dead Cell Stain (Pac Blue). Cell doublets/aggregates were removed by gating on singlets. Live CD3+ T-cell 
populations were differentiated into CD4+ and CD8+ T-cell subsets. Overall expression frequencies of activation markers as well as 
that of the permutations of expression that contributed to that frequency were evaluated. FMOs were set up to determine the 
positioning of the specific gates. 
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General activation status (total activation) was calculated for each T-cell population and was 
defined as the cumulative expression of any permutation of the markers (Figure 3.2). HIV+ 
individuals with HIV seroconcordant partners had higher frequencies of activated CD4+ and 
CD8+ T-cells than those in HIV serodiscordant relationships, significantly so for CD4+ T-
cells (p=0.01 for CD4+ and p=0.11 for CD8+ T-cells; Figure 3.2). 
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Figure 3. 2 Impact of partner HIV status on total activation of CD4+ and CD8+ T-cells in the blood from 
HIV+ individuals in HIV seroconcordant (red) versus serodiscordant (blue) relationships. Frequencies of 
immune activation markers on CD4+ and CD8+ T-cells derived from the blood of HIV+ individuals in 
serodiscordant and seroconcordant relationships were assessed for expression of CCR5, Ki67, HLA-DR, and 
CD38. The cumulative percentage of activated CD4+ and CD8+ T-cells in each group of individuals is depicted 
by box-and-whisker plots indicating the median (middle line), 25th (bottom line)and 75th percentiles (top line), 
and the range (whiskers) of the frequencies of T-cells expressing the respective activation markers. Mann-
Whitney U tests were applied to compare blood T-cell activation frequencies between seroconcordant and 
serodiscordant groups. 
 
CCR5, CD38, HLA-DR and Ki67 expression by CD4+ and CD8+ T-cells were compared 
individually or in biologically important combinations [HLA-DR/CD38 (representing highly 
activated T-cells), Ki67/CCR5 (representing proliferating T-cells which may be susceptible 
to HIV infection), CD38/CCR5 (representing susceptible, activated T-cells) and CD38/Ki67 
(representing activated, proliferating T-cells)]. HIV+ individuals in HIV seroconcordant 
relationship had significantly higher frequencies of CD4+ T-cells expressing the HIV co-
receptor CCR5 than those in serodiscordant relationships (p=0.03; Figure 3.3A). In contrast, 
expression of CD38, HLA-DR or Ki67 by CD4+ T-cells did not differ between groups. While 
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no causative relationship can be establish between seroconcordant individuals’ higher 
expression of CCR5 and their potentially higher susceptibility to HIV infection prior to 
seroconversion (since this is a cross sectional study and cause and effect can only be inferred 
in longitudinal studies where biological markers are measured pre- and post-infection), we 
can speculate that continuous exposure to HIV in a concordant couple situation may lead to 
increased immune activation (compared to sex with an uninfected partner in a discordant 
couple situation), and also potentially increase the likelihood of superinfection. 
Similarly, significantly higher frequencies of HIV+ individuals in HIV seroconcordant 
relationships expressed CCR5 on the surface of their CD8+ T-cells than their HIV 
serodiscordant counterparts (Figure 3.3B). In contrast, HIV seroconcordant individuals had 
lower frequencies of activated CD8+ T-cells than their serodiscordant counterparts as 
measured by the expression of either CD38 (p=0.03; Figure 3.3B) or HLA-DR (p=0.05; 
Figure 3.3B). This was surprising since total activation of CD8+ T-cells was similar in HIV+ 
individuals in seroconcordant and serodiscordant relationships (Figure 3.2). Elevated CCR5 
but lower CD38 and HLA-DR in seroconcordant versus serodiscordant individuals (Figure 
3.3) may account for the overall reduced difference between groups noted previously in 
Figure 3.2. 
In addition to significant differences in CCR5 expression by both T-cell subsets between 
groups, HIV+ seroconcordant individuals had the significantly higher dual-expression of 
CD38/CCR5 by both T-cell subsets compared to serodiscordant ones (p=0.03 for CD4+; 
Figure 3.3C and p=0.02 for CD8+; Figure 3.3D). 
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Figure 3. 3 Impact of partner HIV status on systemic T-cell activation (defined by expression of CD38, 
HLA-DR, CCR5, or Ki67) in HIV+ individuals in HIV seroconcordant (red) versus serodiscordant (blue) 
relationships. Frequency of specific activation marker expression (CCR5, Ki67, HLA-DR, CD38) on CD4+ 
(Panel A & C) and CD8+ (Panel B & D) T-cells derived from the blood of HIV+ individuals in HIV 
seroconcordant and serodiscordant relationships was assayed. The cumulative percentage of activated CD4+ and 
CD8+ T-cells in each group of individuals is depicted by box-and-whisker plots indicating the median (middle 
line), 25th (bottom line)and 75th percentiles (top line), and the range (whiskers) of the frequencies of T-cells 
expressing the respective activation markers. Mann-Whitney U tests were applied to compare blood T-cell 
activation frequencies between seroconcordant and serodiscordant groups. 
 
3.3.3 Impact of gender on T-cell activation in blood 
The levels of the individual markers for activation, proliferation and HIV co-receptor 
expression were investigated in men and women to determine if gender played a role in level 
of systemic activation. Generally, frequencies of all markers were similar in men and women 
for both CD4+ and CD8+ T-cells except for CD4+CD38+ which was significantly elevated in 
women compared to men (p=0.009; Figure 3.4). 
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Figure 3. 4 Impact of gender on systemic T-cell activation (defined by expression of CD38, HLA-DR, 
CCR5, or Ki67) in HIV+ women (purple) versus men (green). Frequency of specific activation marker 
expression (CCR5, Ki67, HLA-DR, CD38) on CD4+ (Panel A) and CD8+ (Panel B) T-cells derived from the 
blood of HIV+ women and men was assayed. The cumulative percentage of activated CD4+ and CD8+ T-cells in 
each group of individuals is depicted by box-and-whisker plots indicating the median (middle line), 25th (bottom 
line)and 75th percentiles (top line), and the range (whiskers) of the frequencies of T-cells expressing the 
respective activation markers. Mann-Whitney U tests were applied to compare blood T-cell activation 
frequencies between men and women. 
 
3.3.4 Relationship between HIV plasma load and systemic T-cell activation 
Because significantly more HIV+ individuals with seroconcordant positive partners had HIV 
plasma loads >1500 copies/ml than those with serodiscordant negative partners (Table 3.1), 
the impact of differences in plasma viremia on T-cell activation in HIV+ individuals was 
investigated (Figure 3.5). The cut-off of > or <1500 cps/ml was used in this Chapter because 
of the published finding by Quinn et al. (2000) that showed, from 415 serodiscordant 
heterosexual couples in rural Uganda, that no HIV transmission occurred within couples 
where the HIV+ partner had HIV viral loads <1500 cps/ml. Total activation by both CD4+ 
and CD8+ T-cells was significantly higher in HIV+ individuals with plasma viral loads of 
>1500 cps/ml than those with<1500 cps/ml (p=0.01 for CD8+ and p=0.04 for CD4+ T-cells). 
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Figure 3. 5 Comparison of total activation of CD4+ and CD8+ T-cells in the blood of HIV-infected 
individuals with plasma viral loads of >1500 cps/ml (orange) or <1500 cps/ml (purple). Frequencies of 
immune activation markers on CD4+ and CD8+ T-cells derived from the blood of HIV+ individuals with HIV 
plasma viremia <1500 cps/ml and >1500 cps/ml were assessed for expression of CCR5, Ki67, HLA-DR, CD38, 
and combinations of these markers. The cumulative percentage of activated CD4+ and CD8+ T-cells in each 
group of individuals is depicted by box-and-whisker plots indicating the median (middle line), 25th (bottom 
line)and 75th percentiles (top line), and the range (whiskers) of the frequencies of T-cells expressing the 
respective activation markers. Mann-Whitney U tests were applied to compare blood T-cell activation 
frequencies between the two groups. 
 
At the level of individual and defined combinations of activation marker expression, HIV+ 
individuals with plasma viral loads >1500 cps/ml had significantly higher frequencies of 
CD4+ T-cells expressing CCR5 than those with viral loads <1500 cps/ml (p=0.007; Figure 
3.6A). In contrast, expression of CD38, HLA-DR and Ki67 by CD4+ T-cells did not similarly 
track with plasma viral loads. CD8+ T-cells from those with viral loads >1500 copies/ml did 
not express elevated levels of CCR5 compared to those individuals with viral loads <1500 
copies/ml (Figure 3.6B), although significantly greater frequencies of CD8+ T-cells from 
these individuals did express CD38 and CD38 in combination with HLA-DR (p=0.01 for 
both; Figure 3.6B and D) compared to those with lower viral loads. 
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Figure 3. 6 Impact of plasma viral loads on the frequency of activation and proliferation marker 
expression by CD4+ and CD8+ T-cells in the blood. Frequencies of activation and proliferation marker 
expression (A-B: CCR5, Ki67, HLA-DR, CD38; and C-D: combinations of these) on CD4+ and CD8+ T-cells 
derived from the blood of HIV+ individuals with plasma viral loads <1500 cps/ml (purple) and >1500 cps/ml 
(orange). The cumulative percentage of activated CD4+ and CD8+ T-cells in each group of individuals is 
depicted by box-and-whisker plots indicating the median (middle line), 25th (bottom line)and 75th percentiles 
(top line), and the range (whiskers) of the frequencies of T-cells expressing the respective activation markers. 
Mann-Whitney U tests were applied to compare blood T-cell activation frequencies between the two groups. 
 
To further investigate whether plasma viral load was related to systemic T-cell activation in 
these HIV+ individuals, a univariate quantile regression model was used to test the 
relationship between plasma HIV load and frequency for each activation marker, alone or in 
combination (Figure 3.7). Overall, HLA-DR expression by CD4+ T-cells was generally 
positively associated with plasma viral loads either alone (in both seroconcordant and 
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serodiscordant) or in association with CD38 (seroconcordant; β-coefficient 1.74, p=0.02), 
irrespective of partner status, with every 1% increase in HLA-DR/CD38 expression by CD4+ 
T-cells predicting a similar 1.74% increase in plasma viral load. In contrast to CD4+ T-cells, 
expression of activation markers by CD8+ T-cells did not significantly positively predict 
changes in plasma viral loads (Figure 3.7B, D and F). 
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Figure 3. 7 Relationship between T-cell activation in blood and plasma HIV load. The association between 
plasma HIV load and blood CD4+ (left panels) or CD8+ (right panels) T-cells expressing immune activation 
markers CCR5, CD38, HLA-DR, Ki67, or their combination was assessed in all HIV+ individuals (A,B), in 
HIV+ seroconcordant individuals (C,D), and in HIV+ individuals whose partners were negative (serodiscordant; 
n=8; E,F) by univariate quantile regression analyses. Regression β-coefficients depicted in red circles represent 
significant associations (p-values ≤0.05) before adjusting for multiple comparisons. Bars represent standard 
error. All p-values were adjusted for multiple comparisons using the false discovery rate step-down approach 
(Columb and Sagadai, 2006). * denotes associations that stayed significant after adjusting for multiple 
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comparisons. β-coefficients are interpreted as the amount by which plasma viral load (HIV RNA copies/ml) 
increases with every percent increase in activation marker frequency. 
 
3.3.4 Impact of clinical status (CD4+ T-cell frequencies) on T-cell activation  
To determine the relationship between CD4+ T-cell frequencies (as an indicator of absolute 
CD4+ T-cell counts) and T-cell activation, a univariate quantile regression model was used 
with CD4 percentages as the independent variable (Figure 3.8). In both CD4+ and CD8+ T-
cells subsets, irrespective of partner HIV status, expression of HLA-DR (either alone or in 
combination with CD38) was consistently predictive of lower CD4+ T-cell frequencies in 
blood, after adjusting for multiple comparisons and HIV plasma load. Unlike plasma viral 
loads, this finding suggests that T-cell activation (defined as HLA-DR/CD38) broadly 
predicted lower CD4+ T-cell frequencies in blood, and further suggested that partner status 
did not impact on this relationship. This may partially explain why the 0.5 log10 difference 
between plasma viral loads in HIV+ individuals in seroconcordant and serodiscordant 
relationships did not predict more severe subsequent CD4 decline. 
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Figure 3. 8 Relationship between T-cell activation and CD4+ T-cell frequencies in blood of HIV+ 
individuals. The association between blood CD4 frequencies and CD4+ (left panels) or CD8+ (right panels) T-
cells expressing immune activation markers CCR5, CD38, HLA-DR, Ki67, or their combination was assessed in 
HIV+ seroconcordant (C,D), HIV+ serodiscordant (E,F), and their combination (A,B) by univariate quantile 
regression analyses. Regression β-coefficients depicted in red circles represent significant associations (p-values 
≤0.05). Bars represent standard error. All p-values were adjusted for multiple comparisons using the false 
discovery rate step-down approach (Columb and Sagadai, 2006). * denotes associations that stayed significant 
after adjusting for multiple comparisons. β-coefficients are interpreted as the amount by which plasma viral load 
(HIV RNA copies/ml) increases with every percent increase in activation marker frequency. 
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3.3.5 Cytokine concentrations in blood from HIV+ individuals 
The concentrations of IL-β, IL-6, IL-12p70, TNF-α, IL-10, IL-2, IFN-γ, IL-7 and GM-CSF 
were measured in plasma from HIV+ individuals in either serodiscordant or seroconcordant 
relationships (Table 3.2). Concentrations of cytokines were generally elevated in 
seroconcordant individuals compared to serodiscordant individuals, significantly so for IL-1β 
(p=0.04), TNF-α (p=0.03), IFN-γ (p=0.05) and IL-10 (p=0.02). None of the differences 
stayed significant after adjustment for multiple comparisons. 
Table 3. 2 Impact of couple HIV status on systemic cytokine levels in HIV+ individuals 
 
Function	   Cytokine	   	  	  	  	  	  	  	  	  	  	  Median	  cytokine	  conc	  (IQR;	  pg/ml)	  
	   	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  HIV	  Positive	   P-­‐value*	  
	  	   	  	   Concordant	   Discordant	   	  	  
Inflammatory	   IL-­‐β	   0.72	  (0.075-­‐2.85)	   0.38	  (0.04-­‐1.47)	   0.04	  
	  	   IL-­‐6	   5.26	  (2.83-­‐11.10)	   4.48	  (2.57-­‐8.62)	   0.2	  
	  
IL-­‐12p70	   0.005	  (0.005-­‐0.42)	   0.005	  (0.005-­‐0.005)	   0.5	  
	  	   TNF-­‐α	   9.45	  (5.61-­‐15.94)	   7.64	  (4.94-­‐13.07)	   0.03	  
Regulatory	   IL-­‐10	   12.60	  (7.75-­‐23.44)	   10.53	  (6.47-­‐15.74)	   0.02	  
Adaptive	   IL-­‐2	   0.11	  (0.005-­‐0.70)	   0.14	  (0.005-­‐0.87)	   0.6	  
	  	   IFN-­‐γ	   1.39	  (0.27-­‐6.33)	   1.09	  (0.14-­‐2.80)	   0.05	  
Hematopoietic	   IL-­‐7	   1.58	  (0.61-­‐3.09)	   1.45	  (0.72-­‐3.25)	   0.9	  
	  	   GM-­‐CSF	   0.19	  (0.005-­‐0.64)	   0.30	  (0.005-­‐0.86)	   0.1	  
 
*Mann-Whitney U tests were applied to compare cytokine concentrations between the seroconcordant and 
serodiscordant groups. 
 
3.3.6 Relationship between plasma cytokines and markers of HIV disease progression 
The relationship between cytokine concentrations in plasma and markers of HIV disease 
progression (plasma viral load and frequencies of CD4+ T-cells in blood) was investigated 
using quantile regression analysis (with viral load or CD4 frequencies as the predictor 
variables). In HIV+ individuals in seroconcordant relationships, TNF-α was positively 
associated with plasma viral load, after adjustments for multiple comparisons (β-coefficient 
3.79; or a 3.79% increase in viral load for every 1% increase in TNF-α concentrations; Figure 
3.9A). In contrast to the positive effect of TNF-α on plasma viral loads, a significant negative 
relationship was observed between IL-2 concentrations and viral load in this group, after 
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adjustment for multiple comparisons (β-coefficient of -0.31; or a decrease of 0.31% in plasma 
viral load for every 1% increase in plasma IL-2 concentrations). In HIV+ individuals in 
serodiscordant relationships, TNF-α and IL-2 were not similarly associated with changes in 
plasma viral load (Figure 3.9B), although plasma concentrations of TNF-α were significantly 
lower in this group than in seroconcordant HIV+ individuals (Table 3.2). Concentrations of 
IL-12p70 in plasma negatively predicted plasma viral loads in serodiscordant HIV+ 
individuals, although this was not significant after adjusting for multiple comparisons. In 
contrast to their relationship with plasma viral loads, none of the cytokines measured 
correlated with the frequency of CD4+ T-cells in blood in any of the groups evaluated in this 
study (data not shown). 
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Figure 3. 9 Relationship between plasma cytokine concentrations and viral loads. The association between 
blood HIV load and levels of different cytokines in plasma was assessed in HIV+ seroconcordant (A) and HIV+ 
serodiscordant (B) by univariate quantile regression analyses. Regression β-coefficients depicted in red circles 
represent significant associations (p-values ≤0.05). Bars represent standard error. All p-values were adjusted for 
multiple comparisons using the false discovery rate step-down approach (Columb and Sagadai, 2006). * denotes 
associations that stayed significant after adjusting for multiple comparisons. β-coefficients are interpreted as the 
amount by which plasma viral load (HIV RNA copies/ml) increases with every percentage increase in activation 
marker frequency. 
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3.3.7 Modeling the impact of systemic immune activation on plasma HIV loads and CD4 
counts 
In the light of the various independent associations observed in this study between systemic 
immune activation or inflammation and plasma HIV loads, multivariate linear regression was 
used to determine whether there was a combined effect of these two markers in shaping HIV 
viremia while adjusting for blood CD4%. The linear regression model included log 
transformed plasma HIV load as the independent variable and the predictor variables 
included known to influence plasma viremia: (1) T-cell activation (both CD4+ and CD8+), (2) 
plasma cytokines level and (3) CD4+ T-cell frequency. 
In this model (Table 3.3), plasma HIV load was positively associated with CD4+ T-cell 
activation (defined by the co-expression of HLA-DR and CD38), with a 1.45% increase in 
plasma HIV load for every 1% increase in the frequency of CD4+HLA-DR+CD38+ in blood. 
Similarly, plasma HIV load was significantly positively associated with plasma TNF-α 
concentrations, with a 2.5% increase in plasma HIV load for every 1% increase in plasma 
TNF-α concentrations. Both these associations were shown to be independent of blood 
CD4%. 
Table 3. 3 Contributing factors to plasma HIV level 
 
‡β-coefficients for multiple linear regression analyses represent the change in mean log of plasma 
HIV copies/ml with every unit increase of the predictor variable, adjusting for all other parameters. In 
this model, for example, a β-coefficient of 2.50 for TNF-α represents a 2.5% increase in the mean log 
of plasma HIV copies/ml with every 1% increase in log transformed plasma level of TNF-α. 
 † CI95% = 95% Confidence Interval.  
*P-values ≤0.05 were considered significant. 
 
In Chapter 2, using a selected group of individuals for whom CD4 counts and plasma HIV 
loads were available for two consecutive time points, 35% of the variability in CD4 depletion 
in blood was attributable to changes in HIV plasma loads. To establish what other factors 
may be predicting the remaining 65% of CD4 decline that remained unaccounted for, a 
multivariate linear regression model was developed to elucidate the effect of systemic 
Predictor	  variables β-­‐coefficient‡ CI95%† P-­‐value*
CD4+HLA-­‐DR+CD38+	  (log	  transformed	  %) 1.45 0.21	  -­‐	  2.69 0.023
TNF-­‐α	  (log	  transformed	  pg/ml) 2.50 1.06	  -­‐	  3.95 0.001
CD4%	  (log	  transformed	  %) 0.49 -­‐0.77	  -­‐	  1.76 0.43
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immune activation and inflammation on blood CD4 decline. All data included in the model 
were log transformed and the selection of the predictor variables for the model was based on 
the strength of their univariate association with CD4% (Sections 3.3.4 and 3.3.6).  
In this model (Table 3.4), CD4 frequencies were negatively associated with CD4 and CD8 T-
cell activation (defined by the expression of HLA-DR on both subsets), with a 1.09% and 
0.56% decrease in CD4% for a respective 1% increase in CD4+HLA-DR+ and CD8+HLA-
DR+ respectively. These associations remained significant after adjustment for plasma HIV 
loads. In the overall model, systemic immune activation, as defined by the frequency of 
CD4+HLA-DR+ and CD8+HLA-DR+, after adjusting for plasma HIV load accounted for 51% 
of the changes in CD4%, an improvement of 16% on the univariate model which only 
included plasma viremia as predictor variable. 
Table 3. 4 Contributing factors to blood CD4% 
 
‡β-coefficients for multiple linear regression analyses represent the change in mean log of blood 
CD4% with every unit increase of the predictor variable, adjusting for all other parameters. In this 
model, for example, a β-coefficient of -1.09 for CD4+HLA-DR+ represents a 1.09% decrease in the 
mean log of CD4% with every 1% increase in log transformed blood frequency of CD4+HLA-DR+. 
 † CI95% = 95% Confidence Interval.  
*P-values ≤0.05 were considered significant. 
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3.4 Discussion 
It has been established that HIV infection is characterized by chronic systemic immune 
activation, and that this hallmark of HIV infection can lead to accelerated T-cell apoptosis 
(Grossman et al., 2002), which in turn contributes to further CD4 decline (Sousa et al., 2002), 
and is strongly predictive of the rate of HIV disease progression (Hazenberg et al., 2003). 
Persistent immune activation is primarily manifested by an increase turnover of T-cells and 
high levels of CD4+ and CD8+ T-cell apoptosis. In addition, immune activation is also 
defined by hyperactivation of T-cells, as measured most commonly by expression of CD38 
and HLA-DR. While CD4+ T-cells are the primary targets for HIV infection and resultant 
death, it is important to also evaluate the activation status of CD8+ T-cells which are 
chronically activated by their function as cytotoxic cells against HIV-infected targets. Recent 
studies have also shown that biomarkers associated with inflammation like IL-6, D-dimer and 
changes in CRP predict mortality in HIV+ individuals (Kuller et al., 2008; Ledwaba et al., 
2012).  
Significantly higher plasma HIV loads were found in HIV+ individuals with seroconcordant 
partners compared to individuals in serodiscordant relationships in Chapter 2. The underlying 
mechanism accounting for this difference in viremia or the impact of viral load differences on 
rate of disease progression between HIV+ seroconcordant and serodiscordant individuals 
remained unclear. This Chapter investigated the influence of systemic immune activation and 
inflammation in this cohort on the rate of HIV disease progression. Measurement of total 
activation (defined by the cumulative expression of the four markers) in this cohort of 
chronically HIV+ individuals showed that both CD4+ and CD8+ T-cells were similarly 
activated, and that CD4+ T-cells (but not CD8+ T-cells) from HIV+ seroconcordant 
individuals were more activated than CD4+ T-cells from serodiscordant individuals. The 
differences seen in total activation between HIV+ seroconcordant and serodiscordant 
participants was mainly attributed to CCR5 expression. The higher expression of this HIV co-
receptor on T-cells of HIV seroconcordant individuals than serodiscordant individuals 
provides a plausible explanation or underlying mechanism that could account for the 
significant differences in plasma viremia in HIV seroconcordant versus serodiscordant 
individuals. The level of expression of CCR5 has previously been shown to be an important 
correlate of HIV infectability of target cells (Wu et al., 1997). 
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Binding of HIV to CCR5 on CD4+ T-cells is known to activate CD4+ T-cells, by an HIV 
Env-mediated signalling pathway, promoting the (1) expression of CD38 and HLA-DR; and 
(2) release of soluble factors including cytokines (Holm and Gabuzda, 2005). These released 
factors may in turn activate bystander CD8+ T-cells. T-cell activation is a precursor to clonal 
expansion, which during a normal immune response would end in death of a large number of 
T-cells through apoptosis after the infection was cleared. This dynamics of activation, clonal 
expansion and apoptosis differ for CD8+ and CD4+ T-cells (Catalfamo et al., 2008, 2011). 
The dynamics of immune activation is principally governed by the inflammatory response to 
HIV infection and the homeostatic response to CD4 T-cell depletion (Catalfamo et al., 2008). 
The greater proportion of activated CD8+ T-cells compared to activated CD4+ T-cells in 
either of the HIV seroconcordant or serodiscordant groups could be explained by the greater 
longevity of the expanded CD8+ T-cell pool upon activation to give rise to a stable resting 
pool of memory cells, whereas activated CD4 cells would also be infected with HIV and 
therefore die more quickly than their activated CD8 counterparts (Homann et al., 2001; 
Foulds et al., 2002). 
Expression of HLA-DR alone (without CD38) by CD8+ T-cells has been suggested in several 
studies to be a surrogate marker for long-term non-progression and survival (Giorgi et al., 
1994, 1999; Karim et al., 2013). These studies have suggested that CD8+HLA-DR+ T-cells 
have enhanced cytotoxic capacity and ability of rapid expansion to control HIV infection and 
counter HIV infected cells in tissue reservoirs than cells expressing other marker 
combinations. Despite observed significant differences in plasma viral loads between HIV+ 
seroconcordant and serodiscordant individuals, this Chapter showed that higher frequencies 
of CD8+ T-cells from HIV serodiscordant individuals were activated (defined by CD38+ 
expression) compared to seroconcordant individuals. Other studies have reported that a 
higher frequency of CD38 expression by CD8+ T-cells was associated with faster systemic 
CD4+ T-cell depletion and worse prognosis in terms of AIDS defining events (Tuaillon et al., 
2009; Karim et al., 2013). While the HIV+ serodiscordant individuals in this study had 
signatures of elevated immune activation, they did not experience worse disease outcome 
when compared to their seroconcordant counterparts using CD4 decline as a marker and also 
sustained lower viral loads over time than their seroconcordant counterparts. Although CD38 
expression as a marker of immune activation is a useful marker to predict HIV disease 
course, the value of this marker alone in this current study was undermined by the important 
differences between CCR5 expression by the HIV-target cells. CD4+CD38+CCR5+ T-cells 
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represent the perfect target cells for HIV to infect because of their expression of the HIV co-
receptor and their activated state implies rapid HIV turnover.  
When HIV+ individuals in this Chapter were categorized according to their HIV plasma load, 
those individuals with >1500 cps/ml HIV load had higher frequencies of both total CD4+ and 
CD8+ T-cell activation than individuals with <1500 cps/ml. CCR5 expression in particular 
was significantly higher in participants with >1500 cps/ml HIV load than those with <1500 
copies/ml, which could account for the difference in viral loads (higher propensity of CD4+ 
T-cells to generate more virus). HIV+ individuals with a higher plasma HIV load (>1500 
cps/ml) had significantly higher frequencies of activation markers on their CD8+ T-cells 
(CD8+CD38+ and CD8+HLA-DR+CD38+). This is in line with previous studies reporting a 
positive correlation between activation marker expression on CD8+ T-cells and plasma HIV 
loads (Bouscarat et al., 1996; Eggena et al., 2005; Resino et al., 2004). Regression analyses 
repeatedly revealed the association of HLA-DR expression on T-cells (with or without the 
co-expression of CD38) with plasma HIV load. 
Systemic CD4+ T-cell frequencies (indicating CD4+ T-cell counts) were negatively associated 
with HLA-DR expression on both CD4+ and CD8+ T-cells (both with or without co-
expression of CD38), irrespective of partner HIV status. In terms of predictive capacity, 
previous studies have shown that a higher level of systemic activation predicts a faster 
decrease of CD4+ T-cells (Hunt et al., 2003; Wilson et al., 2004; Deeks and Walker, 2004). 
Analyses presented in this Chapter on the other hand suggest that activation marker 
expression by CD4+ T-cells and the inflammatory cytokine TNF-α were better predictors of 
HIV plasma load than CD4 frequencies. A possible explanation for this could be that T-cell 
decline is restricted to CD4+ T-cells only, whereas HIV-induced immune activation involves 
both CD4+ and CD8+ T-cells. Total CD8+ T-cell numbers have been reported to typically 
remain elevated until late in infection and this can be partly attributed to direct cytopathic 
effects of HIV, as the subset of productively infected CD4+ T-cells is too low to account for 
all of the CD4+ T-cell loss (Chun et al., 1997; Clark et al., 1999). A study in mice showed 
that following clearance of viral infection, the number of antigen-specific CD4+ memory T-
cells declined readily whereas the number of CD8+ memory and effector T-cells remained 
elevated for life (Homann et al., 2001). From this finding, we can postulate different rates of 
CD4+ and CD8+ T-cell expansion in the event of viral infection. Taken together, these data 
are suggestive of considerably different lifespan of expanded CD4+ and CD8+ T-cells in the 
course of HIV infection and the accompanying condition of chronic immune activation. In 
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turn, this could provide the key to the different kinetics and death rates of memory and 
effector T-cells, whether CD4+ or CD8+. 
The higher concentrations of IL-1β, IFN-γ, and TNF- in plasma in HIV+ seroconcordant 
individuals compared to serodiscordant individuals is associated with higher plasma viral 
loads detected in seroconcordant versus serodiscordant individuals. Moreover, as we expect 
an inflammatory response to be counterbalanced by a more or less equal and opposing 
response, it is not surprising to observe concurrently higher level of regulatory cytokine IL-10 
in seroconcordant individuals compared to serodiscordant ones. Soluble markers of 
inflammation and coagulation such as IL-6, sCD14 and D-dimer have been shown to be 
useful biomarkers for systemic inflammation and its adverse effects in the context of HIV 
infection recently (Nixon and Landay, 2010; Kamat et al., 2012; Taiwo et al., 2013). These 
studies indicate that systemic inflammation could be playing a pivotal role in the setting of 
immune activation and represents a critical component of HIV disease pathogenesis as 
supported by the opposite trend seen in the associations of the different cytokines and plasma 
HIV load in seroconcordant and serodiscordant individuals. 
Multivariate regression modelling revealed that CD4+HLA-DR+CD38+ T-cell frequency and 
TNF-α level in systemic circulation were significant determinants of plasma HIV load. As for 
predictors of CD4%, the overall model, which included CD4+HLA-DR+ and CD8+HLA-DR+ 
frequencies, after adjusting for plasma viral load, accounted for 51% of the variation in blood 
CD4%, an improvement of 16% on the previous model which only included plasma viral 
load as predictor. This confirms that biological markers of systemic immune activation could 
prove helpful in the determination of when to start therapy, when used in conjuncture with 
CD4 count and HIV plasma load. 
The finding that the majority (68%) of the serodiscordant couples in our study had the female 
partner as the HIV+ one is in line with recent studies in South Africa, which report a gradual 
feminization of the index partner in HIV serodiscordant couples from a 29% in 2003 (Lurie et 
al., 2003) to 67% in 2012 (de Bruyn et al., 2012). Similarly, recent statistics available for 
female HIV+ serodiscordancy in the sub-Saharan region indicate that 77% of the index 
partners in HIV serodiscordant couples are female (Guthrie et al., 2009). Factors that could 
be responsible for women being predominantly the HIV+ partner in serodiscordant couples 
are intergenerational sex (younger females having sex with older males), where unequal 
power dynamics leads to lower power of the females negotiating for condom use. Moreover, 
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the relatively high median age of the participants enrolled in our study coupled with a greater 
risk of heterosexual HIV acquisition in women and the lower risk of male heterosexual HIV 
acquisition as opposed to male-to-female transmission (Leynaert et al., 1998; Varghese et al., 
2002) could be a determinant in the maintenance of the ‘serodiscordant’ status of the couple. 
Although biological factors are likely also to contribute to the disproportionate number of 
females in this study, it is also likely that this reflects unintended enrolment or recruitment 
bias when the study was conducted. 
One of the most important findings from this chapter was the different pattern of expression 
of the chemokine receptor CCR5, used as coreceptor for HIV entry into CD4+ T-cells, 
between HIV+ discordant versus concordant individuals (Moore et al., 1997). The elevated 
expression of this co-receptor on CD4+ T-cells of seroconcordant compared to serodiscordant 
individuals has important implication for HIV pathogenesis and lymphocyte recirculation. 
The significantly elevated frequencies of CCR5 expressing CD4+ T cells in seroconcordant 
individuals implies distinct susceptibility of T-cell subsets in these individuals to viral entry. 
This in turn may translate into a greater viral turnover, and as observed in this Chapter, HIV 
viral load is positively associated with inflammation. The initiation and long term persistence 
of inflammation in blood during HIV infection leads to the manifestation of a multiplicity of 
morbidities such as cardiovascular diseases (Friis-Moller et al., 2003; Palella and Phair, 
2011; Duprez et al., 2012), fibrosis of the lymphatic tissues (Schacker et al., 2002) and 
thymosuppressive effects (Linton and Dorshkind, 2004). Other than CCR5 expression, HIV 
susceptibility could be promoted by factors which enhance the number of potential target 
cells. In this Chapter, CCR5+ T-cells from seroconcordant individuals were found to be more 
activated than CCR5+ T-cells from serodiscordant individuals. This is an important finding 
because HIV has been shown to preferentially replicate in activated CD4+ T-cells (Zhang et 
al., 1999). 
Regulation of CCR5 expression is dynamic and it has been previously shown that several 
factors can mediate the induction of CCR5. For example, IFN-α was demonstrated to increase 
CCR5 expression on CD4 T-cells in thymic organ culture and neutralisation of IFN-α in R5 
HIV-infected SCID-hu mice using monoclonal antibodies inhibited both CCR5 upregulation 
and infection of the T-cell progenitors (Stoddart et al., 2010). Interleukin-2 has also been 
shown to upregulate CCR5 expression on macrophages in vitro (Weissman et al., 2000). 
While it is clear that an association exists between the level of CCR5 expression and HIV 
load in blood and other anatomical compartments, with greater levels of CCR5 expression 
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being associated with higher HIV RNA levels (Stewart et al., 1997; de Roda Husman et al., 
1999; Reynes et al., 2000), the causal relationship between these two biological markers is 
best confirmed in longitudinal studies. Finally, host genetic predisposition with regard to 
CCR5 expression level warrants further attention in the elucidation of the cyclic nature of its 
relationship with HIV burden. 
Chemokines and their respective receptors have been postulated to direct migration of 
specific immune cells to sites of inflammation (Springer, 1994; Mackay, 1996), and virtually 
all T-cell chemotractants studied to date selectively attract memory/activated T-cells (Schall 
et al., 1993; Qin et al., 1996, 1998). CCR5 has been characterised as a receptor responding 
functionally to a group of CC-chemokines which includes MIP-1β (Samson et al., 1996; 
Blanpain et al., 1999). In the previous Chapter, a significantly greater frequency of MIP-1β 
was observed when intracellular cytokine staining assays were performed, in both CD4+ and 
CD8+ T-cell subsets of seroconcordant individuals when compared to serodiscordant 
individuals. The expression of chemokine receptor CCR5, and potentially its ligands MIP-1β, 
are widely regarded as central to the pathogenesis of HIV infection as their regulation is 
thought to influence leukocyte migration, as well as HIV infection. 
In conclusion, this Chapter suggests that continuous immune hyperactivation in the event of 
chronic HIV infection may lead to continuous activation and differentiation of T-cells in a 
cycle involving systemic immune activation, inflammation and constant replication of HIV. 
This could be accelerating the depletion of the naïve T-cell pool, and this could be 
exacerbated by the limited regenerative capacity in replacing lost naïve T-cells in adults 
(Haase, 1999; Hazenberg et al., 2000). The findings above suggest that a number of these 
factors could be independently used in the assessment of ‘immune profile’ of individuals with 
asymptomatic HIV infection. As suggested by previous studies (Ahuja et al., 2008; Brass et 
al., 2008), assessment of an ‘immune score’ combined with other factors such as co-
morbidities, age and genetic profile, could help in the design of individualized therapeutic 
interventions prior to clinical manifestations of HIV immunodeficiency. 
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4.1 Introduction 
With heterosexual transmission of HIV accounting for the majority of new infection 
worldwide (Gouws et al., 2006), the female genital tract plays an important role in HIV 
acquisition and transmission. Recent statistics suggest that women may be at a greater risk for 
infection than men, with 30%-40% of the yearly global infection being estimated to occur 
across mucosal surfaces of the female genital tract via exposure to HIV-containing semen 
(Hladik and Hope, 2009). While plasma levels of HIV remain a strong predictor of 
transmission rates, studies have shown that the local mucosal factors like genital 
inflammation and concurrent STIs are also important independent determinants of HIV 
shedding at the genital tract and thus predict greater susceptibility to infection via the genital 
mucosa (LeGoff et al., 2007; Johnson et al., 2008; Blish et al., 2012; Mitchell et al., 2011, 
2013). Immune activation in the female genital tract, measured at the cellular level and as 
soluble innate mediators, in response to HIV infection has previously been reported by others 
from our group (Jaspan et al., 2011). Although such responses generally are a vital part of the 
protective response following infection, this response may also contribute to HIV 
susceptibility and/or pathogenesis through a steady supply of susceptible target cells to the 
virus (Lawn et al., 2001). 
In this Chapter, the impact of partner’s HIV status and interplay between inflammation and 
local HIV shedding in the genital tract was investigated. The concentrations of eotaxin, 
fractalkine, IL-8, IP-10, MCP-1, MIP-1α, MIP-1β, IL-1α, IL-β, IL-6, IL-12p40, IL-10, G-
CSF and IL-15 were compared in genital secretions from HIV+ women in seroconcordant 
and serodiscordant relationships and their relative impact compared to plasma viral loads on 
HIV shedding into genital secretions was evaluated. 
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4.2 Materials and Methods 
4.2.1 Description of study participants 
A total of 132 HIV+ women were included for this part of the study, of which 78/132 were in 
seroconcordant relationships and 54/132were in serodiscordant relationships. Section 2.2.1 
provides a relevant description of the full cohort. Women who were menstruating at the study 
visit, who were post-menopausal or had undergone a hysterectomy were excluded from the 
study. The samples used in this Chapter were collected at months 6, 18 and 30 after 
enrollment. 
 
4.2.2 Cytobrush collection and processing 
Cervical mononuclear cells (CMCs) were collected using a Digene cervical sampler (Digene 
Corporation, Gaithersburg, MD, USA) as described by Nkwanyana et al. (2009). The cervical 
sampler was inserted into the endocervical os under speculum examination and rotated 360o, 
sampling from the transformation zone. Cytobrushes were immediately transferred into 
transport tubes containing 3ml of cold transport medium – R10 [RPMI1640 (Life 
Technologies Corporation, Carlsbad, CA, USA) medium supplemented with 5mM glutamine, 
100 units/ml penicillin, 100 µg streptomycin, 10 mg/ml fungin and 10% fetal calf serum 
(FCS)((Life Technologies Corporation, Carlsbad, CA, USA)] and immediately transferred to 
a 4oC Nalgene Benchtop cooler (Sigma-Aldrich, MO, USA) for transport to the laboratory. 
Cervical samples that were visibly contaminated with blood were excluded from further 
study. Cytobrushes were processed within 4 hours of collection. 
Each cytobrush was flushed 30 times with R10 in the collection tube using a sterile Pasteur 
pipette. The cell suspension was then transferred to a 15ml Sterilin tube and centrifuged at 
1200 rpm (250g) for 10 minutes. The supernatant containing soluble factors from the cervical 
cytobrush and associated cervical mucus was aliquoted into three equal fractions and stored 
in cryovials at -80ºC for future assessment of cervical cytokine levels and HIV shedding. 
Pelleted cells were used for studies outside of this dissertation (Gumbi et al., 2011, Jaspan et 
al., 2011).  
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4.2.3 PBMCs collection and processing 
Blood (16ml) was collected from all study participants using standard venipuncture into 
sterile ACD anti-coagulated vacutainer tubes (BD Biosciences, Plymouth, UK). Blood was 
processed within 4 hours of collection; PBMCs were isolated using Ficoll-Hypaque (Sigma-
Aldrich, St Louis, MO, USA) density gradient centrifugation as described in Chapter 2 
(Section 2.2.2). 
 
4.2.4 Measurement of cytokine concentrations in cervical supernatant 
The concentrations of Eotaxin, Fractalkine, IL-8, IP-10, MCP-1, MIP-1α, MIP-1β, IL-1α, IL-
β, IL-6, IL-12p40, IL-10, G-CSF and IL-15 in cervical supernatants were measured using 
Human Cytokine LINCOplex Premixed kits (LINCO Research, MO, USA). The sensitivity of 
the kits ranged between 0.19 and 27.7 pg/ml for the cytokines measured. Data was collected 
using a Bio-Plex Suspension Array Reader (Bio-Rad Laboratories Inc) and a 5 PL regression 
formula was used to calculate cytokine concentrations from the standard curves. Data was 
analysed using BIO-plex manager software (version 4; Bio-Rad Laboratories Inc). Cytokine 
concentrations that were below the detection limit of the assay were reported as the mid-point 
between the lowest concentration measured for each cytokine and zero. 
 
4.2.5 Determination of HIV viral load in blood plasma and cervical supernatant 
HIV viral load in blood plasma and cervical supernatant was assayed using the 
NuclisensEasyq HIV Version 1.2 by the NHLS Diagnostic Virology Laboratory (Groote 
Schuur Hospital, Cape Town, South Africa). The detection limit of the assay was 50 HIV 
RNA copies/ml. 
 
4.2.6 Statistical analysis 
Shapiro-Wilk test for normality was performed to determine the distribution of variables 
within the dataset. Comparison of unpaired non-parametric data was done using the Mann-
Whitney U test. Statistical inferences on binary sets of data were performed using the 
Fisher’s exact test and odds ratios calculated. Non-parametric assessments of variation 
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between groups was carried out through the Kruskal-Wallis Analysis of Variance (ANOVA), 
with Dunn’s post-test being applied to test for the effect of multiple comparisons. Spearman 
Rank tests were used for correlations. The associations between cervical viral load and 
cervical cytokine concentration were examined using a zero-inflated negative binomial 
regression to take into account the considerable number of zero viral loads that skewed data 
for individual measurement. This analysis models the probability of no HIV shedding into the 
genital tract (zero response) and the mean of the HIV load in those shedding virus (non-zero 
responses) simultaneously, using a logistic model for binary response (zero and non-zero) 
and a negative binomial regression model for the continuous component of the response (HIV 
level). Statistical analyses were performed using GraphPad Prism version 5.00 for Windows 
(GraphPad Software, San Diego, CA, USA) and STATA 11 (College Station, TX, USA). All 
tests were two-tailed and p-values of ≤0.05 were considered significant. 
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4.3 Results 
4.3.1 Characteristics of HIV+ women in this study 
One hundred and thirty two HIV+ women were included to study the impact of partner HIV 
status on HIV-specific responses in the female genital tract, inflammation and HIV shedding 
in genital secretions. Of these 132 participants, 59% (78/132) were in a HIV seroconcordant 
relationship and 41% (54/132) were in a HIV serodiscordant relationship. No difference in 
age, cohabitation and duration of sexual activity was observed between groups. All the 
women included in this study were naïve to anti-retroviral therapy. While women from both 
groups reported a similar median number of sex acts in the last month (Table 4.1), HIV+ 
women with seroconcordant partners reported lower frequency of condom usage (60%) 
compared to HIV+ women with serodiscordant partners (74%; p=0.05). No differences were 
found in the incidence of vaginal discharge and genital ulceration in the last 6 months when 
comparing seroconcordant women to their serodiscordant counterparts, although considerably 
more women with seroconcordant partners (78%) were shedding HIV in their genital 
secretions than women with serodiscordant partners (41%; p=0.005). HIV+ seroconcordant 
women had significantly higher plasma viral loads than serodiscordant women (66000 cps/ml 
compared to 25000 cps/ml, respectively, p=0.01). 
Table 4. 1 Clinical and socio-behavioural characteristics of participants included in this study 
  
Characteristics n Concordant n Discordant P-value 
n 
 
78 
 
54 
 Age [yr; median (IQR)] * 78 31 (25-35) 54 32 (27-38) 1.0 
Living together with partner [%] † 76 72 53 65 0.2 
Sexual exposure [median years of sex (IQR)] * 77 16 (10-21) 53 16 (10-22) 0.9 
Sex acts in the last month [median (IQR)] * 76 4 (2-8) 52 4 (3-10) 0.4 
Condom usage [%] † 73 60 49 74 0.05 
Genital ulceration in the last 6 months [%] † 78 11 53 9 0.8 
Vaginal discharge in the last 6 months [%] † 78 25 53 23 1.0 
Plasma HIV RNA level [cps/ml] * 36 66000 19 25000 0.01 
Genital HIV shedding [%] † 36 78 22 41 0.005 
      † p-value calculated using Fischer's exact test 
     * p-value calculated using Mann-Whitney U-test 
     IQR: Interquartile range 
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4.3.2 Impact of partner HIV status on HIV shedding in genital secretions 
Of the 58 HIV+ women included in this part of the study for whom measurement of genital 
tract HIV loads were performed, 37/58 (64%) were shedding HIV in their genital secretions. 
A significant positive correlation was observed between plasma and cervical HIV load 
(Figure 4.1), with 89% of HIV+ women with HIV in their genital secretions having plasma 
viral loads >1500 copies/ml. HIV+ seroconcordant women were found to be shedding 1.6 
Log10 more HIV in their genital secretions than serodiscordant women (corresponding to a 
difference of 1450 cps/ml; p=0.001; Figure 4.2).  
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Figure 4. 1 Relationship between viral loads in plasma and genital secretions of HIV+ women. Each data 
point represents an individual woman’s plasma and cervical viral load. Spearman Rank test was used to test the 
association between HIV load in plasma and cervix, and a p-value<0.05 was considered significant. 
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Figure 4. 2 Comparison between HIV viral loads in genital secretions from HIV+ women with HIV 
seroconcordant or serodiscordant partners. Each data point represents an individual women’s cervical viral 
load. The red line indicates the median viral load and associated IQR for each group. Mann-Whitney U test was 
used to compare the cervical viral load between HIV seroconcordant and HIV serodiscordant women, and p-
values of <0.05 were considered significant. 
 
4.3.3 Impact of partner HIV status on genital tract cytokines 
The concentrations of IL-1α, IL-β, IL-6, IL-8, IL-12p40, IL-10, Eotaxin, Fractalkine, IP-10, 
MCP-1, MIP-1α, MIP-1β, IL-15, and G-CSF were measured in genital tract secretions from 
HIV+ women with serodiscordant or seroconcordant partners (Table 4.2). Overall, no 
significant differences were found between HIV+ women with seroconcordant versus 
serodiscordant partners, although IP-10, IL-6 and G-CSF concentrations tended to be higher 
in HIV+ seroconcordant compared to serodiscordant women (Table 4.2). 
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Table 4. 2 Impact of couple HIV status on cervical cytokine levels in HIV 
positive women 
 
      Median cytokine conc (IQR; pg/ml) 
 Cytokine HIV Positive P-value* 
 
Concordant Discordant 
 Eotaxin 15.5 (3.5-21.22) 12.75 (5.17-25.52) 0.9 
Fractalkine 77.41 (29.66-144.8) 56.44 (10.97-149.8) 0.5 
IL-8 153.6 (56.67-344.5) 123.3 (61.67-424.3) 0.8 
IP-10 441.1 (172.7-1002) 336.8 (100.2-867.7) 0.3 
MCP-1 42.83 (16.41-122.6) 43.26 (15.97-96.65) 0.7 
MIP-1α 13.64 (1.36-38.16) 15 (1.36-40.28) 0.6 
MIP-1β 29.26 (10.10-43.71) 30.24 (3.71-54.74) 0.8 
IL-1α 34.96 (15.52-99.38) 39.92 (17.62-122.1) 0.8 
IL-1β 4.07 (0.69-7.14) 3.21 (1.1-12.8) 0.3 
IL-6 18.39 (4.9-55.6) 11.46 (4.63-33.18) 0.07 
IL-12p40 34.51 (5.64-67.33) 29.93 (3.55-80.7) 0.8 
IL-10 2.6 (1.26-5.65) 2.91 (1.05-6.29) 1 
G-CSF 759.8 (200.7-1847) 403.4 (117.5-1522) 0.1 
IL-15 2.07 (1.24-4.1) 1.78 (0.88-4.55) 0.9 
 
*Mann-Whitney U tests were applied to compare cytokine concentrations between the seroconcordant and 
serodiscordant groups. 
 
4.3.4 Relationship between genital tract cytokine concentrations and HIV shedding 
The relationship between cytokine concentrations and the concentration of HIV in genital 
secretions was investigated using linear regression analysis (Figure 4.3). Genital tract 
concentrations of IL-1α and IL-1β of HIV+ women (irrespective of partner’s HIV status) 
were positively associated with genital HIV load, after adjusting for plasma viral loads (IL-
1α: β-coefficient 0.68 for seroconcordant and 0.50 for serodiscordant women; IL-1β: β-
coefficient 0.50 for seroconcordant and 0.52 for serodiscordant women). A β-coefficient of 
0.68 for IL-1α is equivalent to a 0.68% increase in genital tract viral load for every 1% 
increase in IL-1α concentration. Additionally, levels of IL-8 (β-coefficient 0.67) and IL-10 
(β-coefficient 0.51) were positively associated with genital tract HIV load in HIV+ 
serodiscordant women, independently of plasma HIV load. 
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Figure 4. 3 Relationship between genital tract cytokine concentrations and mucosal viral loads. The 
association between genital tract HIV loads and levels of different cytokines was assessed in HIV+ 
seroconcordant or HIV+ serodiscordant by linear regression analyses. Left panel shows the level of association 
before adjusting for plasma HIV load while right panel shows the level of association after adjusting for plasma 
HIV load. Regression β-coefficients depicted in red circles represent significant associations (p-values ≤0.05). 
Bars represent standard error. All p-values were adjusted for multiple comparisons using the false discovery rate 
step-down approach (Columb and Sagadai, 2006). β-coefficients are interpreted as the amount by which cervical 
viral load (HIV RNA copies/ml) increases with every percentage increase in cytokine concentration. 
To further demonstrate whether HIV shedding in the female genital tract was associated with 
genital inflammation, an alternative analysis comparing concentrations of cytokines in 
women who were found to be shedding virus in their genital secretions with those who were 
not was performed (Figure 4.4). HIV+ women shedding HIV at their genital secretions had 
higher concentrations of the majority of cytokines measured [including IL-8 (p=0.008), IP-10 
(0.002), IL-1α (p=0.007), IL-1β (p=0.004), IL-6 (P=0.005), MCP-1 (p=0.03), MIP-1β 
(p=0.01), IL-10 (p=0.01) and G-CSF (0.002)]. 
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Figure 4. 4 Concentrations of cytokines in genital fluid collected from HIV+ women shedding HIV 
(orange) versus those not shedding HIV (pink) in their genital secretions. The concentration of cytokines in 
each group of women is depicted by box-and-whisker plots indicating the median (middle line), 25th (bottom 
line) and 75th percentiles (top line), and the range (whiskers) of the measured concentration of each cytokine. 
Mann-Whitney U tests were applied to compare cervical cytokine concentration between seroconcordant and 
serodiscordant women and p<0.05 were considered significant. (___) LOD: Limit Of Detection (for each 
individual cytokine). 
 
 
4.3.5 Relationship between clinical status and cytokine concentrations in the genital tract 
The relationship between clinical status (as indicated by plasma HIV loads) and cytokine 
concentrations in genital secretions was investigated using linear regression analysis (Figure 
4.5). Overall, plasma HIV load was not associated with changes in genital cytokine 
concentrations. 
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Figure 4. 5 Relationship between plasma viral loads and genital cytokine concentrations. The association 
between plasma HIV load and levels of different cytokines in the cervix was assessed in HIV+ seroconcordant 
(A; n=36) or HIV+ serodiscordant (B; n=19) by linear regression analyses. Bars represent standard error and 
p<0.05 were considered significant. 
 
4.3.6 Predictors of HIV shedding in the female genital tract 
Since plasma HIV load and markers of genital tract inflammation (including IL-1α, IL-1β, 
IL-8 and IL-10) both predicted having detectable HIV in genital secretions in the women 
included in this study, the relative predictive value of each of these factors was compared in a 
zero-inflated negative binomial regression model. In HIV+ women who were shedding virus 
in their genital secretions, the linear model (the mean of the HIV load in those shedding virus 
[non-zero responses]) did not identify any one factor that predicted the magnitude of genital 
tract shedding (Table 3.3). In the inflated model (models the probability of no HIV shedding 
into the genital tract [zero response]), IL-1β and plasma HIV load predicted shedding HIV at 
the cervix. For IL-1β, an OR of 1.40 indicated a 40% increased odds of shedding HIV in 
genital secretions with every 1% increase in the concentration of IL-1β in the genital tract. 
This data suggests a positive relationship between genital inflammation and HIV genital 
shedding, with IL-1β concentrations independently predicting HIV shedding in that 
compartment (after adjusting for plasma viral load). It is important to note, however, that 
none of the biological parameters measured in this study predicted HIV genital shedding as 
strongly as plasma viral load. 
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Table 4. 3 Modeling predictors of genital tract HIV shedding 
  
Linear Model Incidence-rate Ratio1 95% CI2 P-value 
IL-1β (log pg/ml) 1.0 0.98-1.01 0.6 
IL-8 (log pg/ml) 1.0 1.00-1.00 0.9 
Plasma HIV load (log cps/ml) 2.1 0.76-1.14 0.5 
Inflated Model Odds Ratio3 95% CI4 P-value 
IL-1β (log pg/ml) 1.4 1.01-1.93 0.04 
IL-8 (log pg/ml) 1.08 0.96-1.21 0.2 
Plasma HIV load (log cps/ml) 5.75 1.61-20.5 0.007 
 
1Incidence-rate Ratio for the linear part of the zero-inflated negative binomial regression model represents the 
ratio of the mean genital tract viral load associated with one unit increase in the parameter in women who were 
shedding HIV into the genital tract (ie. Non-zero values for cervical viral load). 2Confidence Intervals. 3Odds 
Ratio for the inflated or logistic part of the zero-inflated negative binomial regression model represents the odds 
of a genital HIV RNA level of zero i.e. the odds of not shedding HIV in the genital tract. 4Logistic part of the 
model adjusted for plasma viral load. 
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4.4 Discussion 
The micro-environment in the female genital tract plays a significant role for both acquisition 
and transmission of HIV during heterosexual contact. A number of studies have shown that 
plasma viral loads are the best predictors of both the amount of HIV being shed in genital 
secretions (Iversen et al., 1997; Hart et al., 1999; Shepard et al., 2000; Kovacs et al., 2001; 
Vettore et al., 2006; Taton et al., 2011) and risk for HIV transmission to new partners (Quinn 
et al., 2000; Attia et al., 2009). Results from this Chapter confirm that plasma viral load is the 
strongest predictor of genital tract shedding of HIV in HIV+ women. Furthermore, HIV+ 
seroconcordant women, who had significantly higher plasma viral loads than HIV+ 
serodiscordant women, were also shedding more HIV in their genital secretions than 
serodiscordant women (with a median difference between groups of 1450 copies/ml of 
diluted secretion). This is the first report to my knowledge that HIV+ women with 
seroconcordant partners have higher genital tract viral loads than HIV+ women in 
serodiscordant relationships. Given the strong positive association between plasma viral loads 
and genital tract HIV loads, the finding that HIV+ seroconcordant women sustain higher 
plasma and genital HIV loads compared to serodiscordant women could indicate either that 
passive transudate from blood to genital tract, or active recruitment or homing of HIV-
infected target cells to the genital mucosa under a chemokine gradient were driving HIV 
shedding. Local factors in the genital compartment, like inflammation, are likely to be 
important in determining the extent of HIV-infected target cell homing to the mucosa, 
possibly independently of plasma viral loads, thereby increasing local shedding of HIV 
(Nkwanyana et al., 2009). 
While systemic inflammatory cytokines were found to be significantly elevated in HIV 
seroconcordant compared to serodiscordant individuals (Chapter 3), no such difference was 
found in the genital inflammatory profile of seroconcordant and serodiscordant women in this 
Chapter. The finding that the difference in plasma viral load was 10-fold greater than the 
difference observed in genital secretions might explain why differences between groups in 
systemic inflammatory profiles were significant compared to inflammation in the genital 
tract. Alternatively, while plasma viral load and systemic inflammation were possibly directly 
related in Chapter 3, it is likely that little genital tract inflammation was directly linked to 
HIV replication at the mucosa as a result of competing and stronger drivers of local 
inflammation such as other STIs or BV. 
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Pro-inflammatory (TNF-α, IL-1β, IL-6) and chemotactic cytokines (IL-8) are known to 
enhance HIV replication (Al-Harthi et al., 1997) and attract neutrophils to sites of 
inflammation (Dinarello et al., 2000). Increased concentrations of these cytokines within the 
female genital tract are likely to represent a hostile activated milieu for women, putting them 
at risk of infection by HIV. This finding of an association between genital tract cytokine 
concentrations and viral loads within the genital tract is similar to previous studies during 
chronic HIV infection (Lawn et al., 2001; McGowan et al., 2004). In this Chapter, a clear 
association was found between genital tract concentrations of two classical markers of 
inflammation, IL-1α and IL-1β, and genital tract HIV loads, independently of couple status 
and plasma viral load. In addition, IL-8 and IL-10 were also associated with genital HIV 
burden in serodiscordant women. HIV infection has previously been associated with an 
increase in IL-10 production by several cell subsets, but it remains unclear whether it has a 
role in HIV disease progression or protection (Ostrowski et al., 2001; Biancotto et al., 2007; 
Nilsson et al., 2007; Brockman et al., 2009). The observation of a lower genital HIV load in 
serodiscordant women compared to seroconcordant women, coupled with the association 
found between genital HIV burden and genital IL-10 concentrations, suggest that IL-10 in 
genital secretions may function synergistically with other immunoregulatory factors to 
balance the pro-inflammatory environment in this compartment, and thereby indirectly 
impact on HIV shedding in genital secretions. Further studies are however needed to 
determine causality. 
Independently of plasma viral load, findings from this Chapter suggest that certain genital 
tract cytokines were associated with higher HIV genital loads, with certain cytokines that 
were elevated in women shedding HIV (such as MIP-1β and IL-8) serving both pro-
inflammatory and chemotactic functions. Upregulation of these cytokines could in turn lead 
to the recruitment and activation of more T-cells, which in turn would more likely result in 
increased production of cytokines with different functions in the genital tract (Abbas and 
Lichtman, 2007). Previous studies have shown that pro-inflammatory cytokines can stimulate 
production of growth factors as well as other secreted factors important in tissue repair, 
lymphangionesis and angiogenesis as well as inducing IL-10 to counterbalance the 
inflammatory process (Rafii et al., 2003; Cursiefen et al., 2004; Tammela et al., 2005). 
Results in this study similarly show that upregulation of genital tract pro-inflammatory 
cytokines in women shedding HIV at their cervix was accompanied by increased 
concentrations of the hematopoietic cytokine G-CSF. Although this cytokine has generally 
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been associated with hematopoietic functions, secondary pro-inflammatory functions have 
also been associated with G-CSF, such as differentiation of granulocytes from stem cell 
progenitors, stimulating pro-inflammatory cytokine production by leukocytes, and 
chemotaxis of other immune cells (Gomez-Cambronero et al., 2003; Wira et al., 2005). 
Plasma viral loads were shown to be completely independent of genital cytokine 
concentrations, confirming that systemic factors are unlikely to play a major role in the 
modulation genital inflammation. While chronic inflammation is an accepted hallmark of 
HIV pathogenesis, few prior studies have measured the inflammatory milieu systemically and 
in the genital tract in relation to plasma HIV load. A previous study from our group found a 
positive correlation between the frequency of activated T-cells in blood and from the lower 
genital tract of HIV-infected women, and that genital T-cell activation predicted HIV 
shedding (Jaspan et al., 2012). 
Several reports have shown that STIs predict both genital inflammation and HIV genital 
shedding (Rotchford et al., 1999; LeGoff et al., 2007; Kaul et al., 2008; Shin and Kaul, 2008; 
Rebbapragada and Kaul, 2008; Kaul et al., 2011). No laboratory based screening for STIs 
was conducted in this study, although signs and symptoms were recorded (genital ulcerative 
disease and vaginal discharge by clinical exam). Few women in this study did have clinical 
evidence of an STI (ulceration or discharge), and those women with symptoms of an STI 
were equally distributed between seroconcordant and serodiscordant women. While 
inflammation can persist long after STI symptom resolution (such as subclinical HSV 
infection or reactivation), the strong association of several inflammatory markers and HIV 
shedding in this study validate the multivariate model that identified IL-1β and HIV plasma 
load as determinants modulating genital HIV burden. 
In conclusion, this Chapter showed that genital tract inflammation was significantly 
associated with increased genital HIV shedding, a finding that was independent of plasma 
HIV loads or partner status. Elevated genital HIV shedding in HIV seroconcordant women 
compared to serodiscordant women together with the finding that genital tract inflammation 
further elevated shedding (irrespective of partner status) may suggest an increased risk for re-
infection (or super-infection) of HIV seroconcordant partners or primary infection of HIV 
negative serodiscordant partners in women with genital tract inflammation. This also 
highlights one of the limitations of using plasma viral loads to predict HIV transmission risk. 
Although recent studies have reported that treating STIs would reduce HIV transmission risk 
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(Nagot et al., 2007; Delaney et al., 2009; Vanpouille et al., 2009), findings from this Chapter 
additionally suggest that treatment of genital tract inflammation, irrespective of its causes, 
may also help to reduce genital HIV shedding, which in turn may also curb HIV risk. 
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5.1 Introduction	  
Studies of HIV transmission risk and resistance to infection in defined cohorts of HIV 
exposed-uninfected individuals has provided important insight into the mechanisms 
underlying resistance to HIV infection. Remaining seronegative in the face of HIV exposure 
has been documented in commercial sex workers (Jennes et al., 2004), serodiscordant 
couples (Bernard et al., 1998; Lo Caputo et al., 2003; Suy et al., 2007), injection drug users 
(Makedonas et al., 2002), infants born to HIV infected mothers (Hygino et al., 2008), 
occupational exposures in healthcare workers (Clerici et al., 1994) and men having sex with 
men (Hladik et al., 2003). In spite of considerable efforts to unravel the mechanisms of 
protection from HIV infection in these HIV exposed individuals, these remain largely 
undefined although they are likely to be multifactorial. 
Numerous host factors have been associated with protection against HIV infection at the 
mucosa in these individuals; including co-receptor susceptibility (Paxton et al., 1998), 
components of the innate and adaptive immune response (Furci et al., 2002; Wichukchinda et 
al., 2007); as well as several secreted cytokines including RANTES, SLP-1, MIP-1α and 
MIP-1β (Iqbal et al., 2005; Hirbod et al., 2008). In addition, elevated frequencies of HIV-
specific IFN-γ and IL-2 secreting T-cells have been recognized in different cohorts of 
exposed-uninfected individuals (Kebba et al., 2004; Pallikkuth et al., 2007). 
Recent studies have suggested that, in addition to protective innate and adaptive responses at 
the mucosa, lower levels of immune activation and “immunological quiescence” are strongly 
associated with resistance to HIV infection in these individuals (Koning et al., 2005; Bégaud 
et al., 2006; Jennes et al., 2006). While it has been suggested by Card et al. (2008) that 
decrease in immune activation in resistance to HIV infection is associated with an elevated 
frequency of regulatory T-cells (Treg), an exact mechanism for the long term maintenance of 
the low level of immune activation has yet to be identified. 
Multiple and sometimes conflicting immunological influences in the systemic and mucosal 
compartments have been proposed to confer protection against HIV infection in HIV 
exposed-uninfected individuals. The purpose of this Chapter was to investigate the interaction 
between systemic inflammation (measured by soluble cytokine concentrations) and systemic 
immune activation and explore their respective roles in resistance to HIV infection. 
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5.2 Materials and Methods 
5.2.1 Cohort description 
A total of 215 HIV negative (HIV-) individuals were included for this part of the study, of 
which 103/215 were in HIV- seroconcordant relationships and 113/215 were in 
serodiscordant relationships. In addition, a total of 144 HIV+ seroconcordant individuals 
were included as a comparison group. Chapter 2 (Section 2.2.1) provides a full description of 
these individuals. These participants were followed longitudinally, with immune activation 
and inflammatory cytokine production in blood and cervix being measured at 6, 18 and 30 
months in the study. All aspects of the study were approved by the Research Ethics 
Committee of the University of Cape Town (UCT REC# 258/2006) and informed written 
consent was obtained from all individuals before initiation of the study. 
 
5.2.2 PBMCs collection and processing 
Blood (16ml) was collected from all study participants using standard venipuncture into 
sterile ACD anti-coagulated vacutainer tubes (BD Biosciences, Plymouth, UK). Blood was 
processed within 4 hours of collection; PBMCs were isolated using Ficoll-Hypaque (Sigma-
Aldrich, St Louis, MO, USA) density gradient centrifugation as described in Chapter 2 
(Section 2.2.2). 
 
5.2.3 Cryopreservation of PBMCs 
All PBMCs used in this study were cryo-preserved and subsequently stored in liquid nitrogen 
as described in Chapter 3 (Section 3.2.3). 
 
5.2.4 Thawing of cryo-preserved PBMCs 
Frozen PBMCs were thawed rapidly in a 37ºC water bath as described in Chapter 3 (Section 
3.2.4). 
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5.2.5 Counting of PBMCs using the automated Guava cell counter 
Thawed PBMCs were diluted 20-fold in Guava Viacount reagent and counted using a Guava 
Automated cell counter as previously described in Chapter 2 (Section 2.2.3). 
 
5.2.6 Staining for markers of T-cell activation by flow cytometry 
PBMCs were stained in BD Falcon Round-Bottom tubes (BD Biosciences, San Jose, CA, 
USA) and 1 million PBMCs were used per staining reaction per participant as described in 
Chapter 3 (Section 3.2.6). 
 
5.2.7 Measurement of cytokine concentrations in blood plasma 
The concentrations of IL-1β, IL-6, IL-12p70, TNF-α, IL-10, IL-2, IFN-γ, IL-7 and GM-CSF 
were measured in blood plasma from all individuals using High Sensitivity Human Cytokine 
LINCOplex Premixed kits (LINCO Research, MO, USA). A description of the assay is 
according to the method described in Chapter 3 (Section 3.2.7). 
 
5.2.8 Statistical analysis 
Shapiro-Wilk test for normality was performed to determine the distribution of variables 
within the dataset. Comparison of unpaired non-parametric data was done using the Mann-
Whitney U test. Statistical inferences on binary sets of data were performed using the 
Fisher’s exact test and odds ratios calculated. Non-parametric assessments of variation 
between groups was carried out through the Kruskal-Wallis Analysis of Variance (ANOVA), 
with Dunn’s post-test being applied to test for the effect of multiple comparisons. Quantile 
regression analyses were used to estimate the median value of the independent (response) 
variable for given levels of the dependent (predictor) variables. Adjustment for multiple 
comparisons was performed using a false discovery rate step-down approach. Statistical 
analyses were performed using GraphPad Prism version 5.00 for Windows (GraphPad 
Software, San Diego, CA, USA) and STATA 11 (College Station, TX, USA). All tests were 
two-tailed and p-values of ≤ 0. 05 were considered significant. 
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5.3 Results 
5.3.1 Characteristics of HIV- unexposed and HIV- exposed individuals 
Two hundred and fifteen HIV negative (HIV-) individuals, which included individuals who 
were from 52 unexposed couples and 112 HIV serodiscordant couples, were included to 
investigate the role of sexual partner HIV status on systemic immune activation and 
inflammation, as potential correlates of HIV risk (Table 5.1). Of 215 HIV- individuals, 
103/215 (48%) had similarly HIV- partners, and 112/215 (52%) had HIV+ partners. The 
HIV- exposed participants were the partners of the HIV+ serodiscordant participants included 
in Chapter 3. While the majority of HIV+ serodiscordant individuals included in Chapter 3 
were women, HIV- exposed individuals were predominantly male in this Chapter (73%). 
HIV- unexposed individuals were 4 years younger than HIV- exposed individuals (Table 5.1, 
p=0.01). This reflects the fact that HIV- exposed individuals were more likely to be men 
(73%) in this study and the Sub-Saharan African custom that men are on average older than 
women in many heterosexual couples (Eyawo et al., 2010). Possibly also reflecting the age 
and gender distribution difference between HIV- exposed and unexposed individuals, it was 
not surprising to see that individuals in HIV unexposed relationship reported having had a 
longer sexual exposure than their exposed counterparts (Table 5.1). 
HIV- exposed and unexposed individuals reported several other differences in sexual 
behavior; with HIV- unexposed individuals reporting higher frequencies of sex acts in the last 
month and lower frequencies of condom usage than the exposed ones. As discussed in 
Chapter 3 (Section 3.3.1), self reported condom use may be overreported in the HIV- exposed 
individuals compared to unexposed individuals because the exposed individuals perceive that 
this is the more socially desirable response to the question. Aside from these sexual behavior 
differences, CD4 percentages, proportion of individuals cohabiting, or having either 
ulceration or discharge were similar in esposed and unexposed individuals (Table 5.1). All 
men included in this study were circumcised. The HIV+ seroconcordant individuals studied 
in Chapter 3 were included as a control in this present Chapter. 
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Table 5. 1 Clinical and socio-behavioural characteristics of participants included in this study 
 
†p-value calculated using Fischer's exact test 
*p-value calculated using Mann-Whitney U-test comparing HIV- unexposed (seroconcordant) 
individuals to HIV- exposed (serodiscordant) individuals 
IQR: Interquartile range 
 
5.3.2 Impact of partner HIV status on T-cell activation in blood of HIV- individuals 
The expression of activation markers CCR5, CD38 and HLA-DR and the nuclear 
proliferation marker Ki67 by T-cells in blood was measured in HIV- unexposed and exposed 
individuals in to investigate the impact of partner status on activation of T-cells in HIV- 
individuals. These markers allowed assessment of the frequency of (1) highly activated T-
cells (defined by dual expression of HLA-DR and CD38), (2) activated proliferating T-cells 
(defined by dual expression of Ki67 and CD38); and (3) CCR5+ T-cells that represent the 
preferred target cells for HIV infection [activated CCR5+ cells (defined by dual expression of 
CCR5 and CD38) or proliferating CCR5+ cells (dual expression of CCR5 and Ki67)]. The 
overall level of activation (total activation) was defined as the cumulative expression of any 
permutation of the markers. 
The global activation status of CD4+ T-cells from HIV- exposed and unexposed individuals 
was similar (p=0.51; Figure 5.1) and were significantly lower than global activation status of 
CD4+ T cells from HIV+ individuals (p<0.001 for both HIV- exposed and unexposed 
individuals). In contrast, HIV+ seroconcordant individuals had an overwhelmingly higher 
activation status for their CD8+ T-cell subset than HIV- exposed individuals (p<0.001; Figure 
5.1). Interestingly, HIV- unexposed individuals had similar levels of total activation in their 
CD8+ T-cell subset as in HIV+ seroconcordant controls, both of which were significantly 
higher than frequencies observed in HIV- exposed individuals (Figure 5.1). 
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Figure 5. 1 Impact of partner HIV status on total activation of CD4+ and CD8+ T-cells in the blood from 
HIV- individuals (yellow for HIV- unexposed (seroconcordant) and green for HIV- exposed 
(serodiscordant)) compared to HIV+ individuals (red). Frequencies of immune activation markers on CD4+ 
and CD8+ T-cells derived from the blood of HIV- exposed and unexposed individuals were assessed for 
expression of CCR5, Ki67, HLA-DR, and CD38. Similar measurements assessed for HIV+ seroconcordant 
individuals (Chapter 3, Section 3.3.2) were included as comparisons. The cumulative percentage of activated 
CD4+ and CD8+ T-cells in each group of individuals is depicted by box-and-whisker plots indicating the median 
(middle line), 25th (bottom line)and 75th percentiles (top line), and the range (whiskers) of the frequencies of T-
cells expressing the respective activation markers. Non-parametric assessments of variation between groups was 
carried out through the Kruskal-Wallis Analysis of Variance (ANOVA), with Dunn’s post-test being applied to 
test for the effect of multiple comparisons. 
 
CCR5, CD38, HLA-DR and Ki67 expression by CD4+ and CD8+ T-cells were compared 
individually or in biologically important combinations [HLA-DR/CD38 (representing highly 
activated T-cells), Ki67+CCR5+ (representing proliferating T-cells which may be susceptible 
to HIV infection), CD38+CCR5+ (representing susceptible, activated T-cells) and 
CD38+Ki67+ (representing activated, proliferating T-cells)]. HIV- exposed individuals had 
significantly lower frequencies of CD4+ T-cells expressing the HIV co-receptor CCR5, alone 
or in combination with Ki67 or CD38, than HIV- unexposed individuals (p=0.05 for CCR5 
alone, p<0.05 for CCR5/Ki67 and p<0.05 for CCR5/CD38; Figure 5.2A and C). These data 
suggest that CD4+ T-cells from HIV- exposed individuals were possibly less susceptible 
(more quiescent) to HIV infection compared to those in HIV- unexposed, on account of 
having lower frequencies of activated and proliferating CCR5+ cells to facilitate infection. 
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Similarly, HIV- exposed individuals had significantly lower frequencies of CCR5, alone or in 
combination with Ki67 and CD38, on the surface of their CD8+ T-cells than their HIV- 
unexposed counterparts (p=0.05 for CCR5 alone, p<0.01 for CCR5/Ki67, p<0.01 for 
CCR5/CD38; Figure 5.2B and D). In addition, HIV- exposed individuals also had lower 
frequencies of their CD8+ T-cells expressing HLA-DR than HIV- unexposed participants 
(p<0.01; Figure 5.2B). 
 
Figure 5. 2 Impact of partner HIV status on specific T-cell activation (defined by expression of CD38, 
HLA-DR, CCR5, or Ki67) in HIV- unexposed individuals (seroconcordant) (yellow) versus HIV- exposed 
(serodiscordant) (green) relationships. Frequency of specific activation marker expression (Ki67, HLA-DR, 
CD38) on CD4+ (panels A and C) and CD8+ (panels B and D) T-cells derived from the blood of HIV- exposed 
and unexposed was assayed. Similar measurements assessed for HIV+ seroconcordant individuals (Chapter 3, 
Section 3.3.2) were included in this comparison as positive controls. The cumulative percentage of activated 
CD4+ and CD8+ T-cells in each group of individuals is depicted by box-and-whisker plots indicating the median 
(middle line), 25th (bottom line)and 75th percentiles (top line), and the range (whiskers) of the frequencies of T-
cells expressing the respective activation markers. Non-parametric assessments of variation between groups was 
carried out through the Kruskal-Wallis Analysis of Variance (ANOVA), with Dunn’s post-test being applied to 
test for the effect of multiple comparisons. 
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In addition to absolute frequencies of CCR5+ CD4+ and CD8+ T cells being lower in HIV- 
exposed participants compared to the unexposed individuals, a further analysis of the mean 
fluorescence intensity (MFI) of CCR5 on CD4+ and CD8+ T-cells showed that CCR5 MFIs 
were lower in HIV- exposed compared to unexposed individuals, significantly so for CD4+ T 
cells (p=0.04 for CD4+ and p=0.07 for CD8+ T cell subsets, Figure 5.3). This finding 
suggests that HIV- exposed individuals had significantly fewer CD4+ T cells expressing 
significantly lower amounts of CCR5 than unexposed individual. This important finding may 
explain why they remain HIV negative despite being in a stable, long term relationship with 
an HIV+ partner who is not taking HAART. 
 
Figure 5. 3 Impact of partner HIV status on expression of CCR5 on CD4+ and CD8+ T-cells (mean 
fluorescence intensity). The cumulative MFI in each group of individuals is depicted by box-and-whisker plots 
indicating the median (middle line), 25th (bottom line) and 75th percentiles (top line), and the range (whiskers) of 
the frequencies of T-cells expressing the respective activation markers. Non-parametric assessments of variation 
between groups was carried out through the Kruskal-Wallis Analysis of Variance (ANOVA), with Dunn’s post-
test being applied to test for the effect of multiple comparisons. 
 
5.3.3 Impact of gender on T-cell activation in blood 
As more men than women were included in the HIV- exposed group, the levels of the 
individual markers for activation, proliferation and HIV co-receptor expression were 
investigated in men and women to determine if gender played a role in level of systemic 
activation. Generally, frequencies of all markers were similar in men and women, in either 
unexposed (concordant) (Top Panel) or exposed (discordant) (Bottom Panel) and for both 
CD4+ and CD8+ T-cells (Figure 5.4). While the CD4+HLA-DR+ subset of men in both 
unexposed and exposed relationship seemed to be higher than their respective female 
counterpart, this difference was not statistically significant. Similarly, no significant 
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differences were found when comparing the different combinations of activation markers 
when comparing men to women (data not shown). 
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Figure 5. 4 Impact of gender on systemic T-cell activation (defined by expression of CD38, HLA-DR, 
CCR5, or Ki67) in HIV- women (purple) versus men (green). Frequency of specific activation marker 
expression (CCR5, Ki67, HLA-DR, CD38) on CD4+ (Panel A, C) and CD8+ (Panel B, D) T-cells derived from 
the blood of HIV- women and men in unexposed (seroconcordant) (Top Panel) and exposed (serodiscordant) 
(Bottom Panel) was assayed. The cumulative percentage of activated CD4+ and CD8+ T-cells in each group of 
individuals is depicted by box-and-whisker plots indicating the median (middle line), 25th (bottom line)and 75th 
percentiles (top line), and the range (whiskers) of the frequencies of T-cells expressing the respective activation 
markers. Mann-Whitney U tests were applied to compare blood T-cell activation frequencies between men and 
women. 
 
5.3.4 Impact of sexual partner HIV status on systemic inflammation in HIV- individuals 
The concentrations of TNF-α, IL-β, IL-6, IL-10, IL-7, GM-CSF IL-12p70, IL-2 and IFN-γ 
were measured in plasma from HIV- unexposed and exposed individuals and compared to 
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concentrations measured in plasma from HIV+ individuals (Table 5.2). Plasma 
concentrations of IL-2 (p=0.02), IFN-γ (p=0.05) and GM-CSF (p=0.006) were significantly 
lower in HIV- exposed compared to unexposed individuals, with the difference between 
groups in GM-CSF concentrations remaining significant after adjustment for multiple 
comparisons. Compared to HIV+ individuals in seroconcordant relationships, HIV- exposed 
individuals had significantly lower plasma concentrations of IL-6 and TNF-a but significantly 
higher concentrations of GM-CSF. No significant differences were observed when comparing 
the level of circulating cytokines in men versus women in either exposed or unexposed 
relationships. 
 
Table 5. 2 Impact of HIV status and couple HIV status on systemic cytokine levels 
Function Cytokine            Median cytokine conc (IQR; pg/ml) 
  HIV Negative P-value◊ HIV Positive P-valueΔ 
    Unexposed Exposed   Concordant   
Inflammatory IL-β 0.45 (0.07-1.43) 0.35 (0.04-1.25) 0.5 0.72 (0.075-2.85) 0.07 
 IL-6 4.66 (2.36-7.87) 3.90 (1.75-7.50) 0.2 5.26 (2.83-11.10) <0.0001‡ 
 IL-12p70 0.005 (0.005-0.83) 0.005 (0.005-0.58) 0.8 0.005 (0.005-0.42) 0.03 
  TNF-α 6.00 (3.94-8.14) 5.85 (4.02-7.78) 0.7 9.45 (5.61-15.94) 0.04 
Anti-
inflammatory IL-10 10.43 (5.60-22.26) 9.08 (5.88-17.95) 0.7 12.60 (7.75-23.44) 0.08 
Adaptive IL-2 0.28 (0.005-1.03) 0.0075 (0.005-0.69) 0.02 0.11 (0.005-0.70) 0.2 
  IFN-γ 0.94 (0.14-2.91) 0.64 (0.02-1.93) 0.05 1.39 (0.27-6.33) 0.6 
Hematopoietic IL-7 1.86 (0.68-3.49) 1.51 (0.69-3.46) 0.7 1.58 (0.61-3.09) 0.3 
  GM-CSF 0.64 (0.20-1.46) 0.32 (0.12-0.82) 0.006‡ 0.19 (0.005-0.64) <0.0001‡ 
 
Mann-Whitney U tests were applied to compare cytokine concentrations between the HIV- unexposed and HIV- 
exposed groups, and the HIV- unexposed and HIV+ seroconcordant groups. ‡ denotes p-value that remained 
significant after adjustment for multiple comparisons using the false discovery rate step-down approach 
(Columb and Sagadai, 2006). ◊denotes p-value for comparisons between HIV- unexposed and HIV- exposed 
individuals. Δdenotes p-value for comparisons between HIV- unexposed and HIV+ seroconcordant individuals. 
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5.4 Discussion 
Studies in HIV exposed-uninfected individuals provide a unique opportunity to determine 
correlates of protection associated with natural resistance to HIV infection. Serodiscordant 
couples, where an HIV uninfected individual is in stable relationship with HIV-infected 
partner, represent one of the best models in humans to study these correlates of protection. 
Central to productive HIV infection of cells is the binding of HIV both CD4 receptor as well 
as binding to the co-receptor CCR5. This Chapter showed that HIV- exposed individuals 
have a more quiescent immune profile compared to unexposed participants. The finding in 
this Chapter that significantly lower frequencies of CD4+ and CD8+ T cells from HIV- 
exposed individuals expressed CCR5 and had lower per cell amounts of CCR5 is therefore of 
great significance. The importance of this finding was further accentuated by the fact that 
these exposed individuals had a significantly smaller pool of activated susceptible T cells 
(CD38+CCR5+) and less of these susceptible cells were proliferating (Ki67+CCR5+) when 
compared to HIV- unexposed controls.  
A recent study by Pandrea et al. (2007) showed that lower frequencies of CD4+CCR5+ T cells 
in the natural SIV hosts was associated with decreased level of SIV replication, and also a 
decreased homing of activated CD4+ T-cells to inflamed tissues. In this same study, they 
demonstrated that natural hosts for SIV infection (such as Sooty Mangabeys and African 
Green Monkeys, which also do not exhibit hallmark symptoms of SIV disease progression 
like macaques) have markedly reduced numbers of CD4+CCR5+ T cells in systemic blood 
and several lymphoid compartments like the bone marrow and lymph nodes. Previous studies 
in HIV exposed seronegative female sex workers in Kenya and Ethiopia also found that 
expression levels of CCR5 were reduced compared to unexposed control subjects (Fowke et 
al., 1998; Messele et al., 2001). These early studies did not take into account sexual partner 
HIV status so the extent of HIV exposure in exposed seronegative women as well as the 
extent of no exposure in unexposed controls was based on epidemiological and behavioural 
risk criteria. An early study from Paxton et al. (1998) linked the decreased infectibility of 
CD4+ T-cells from exposed-uninfected sex workers to lowered expression of CCR5 and 
concurrent elevated production of β-chemokines (the cognate ligand for CCR5). In addition, 
in vitro studies have revealed that CCR5 levels, their expression patterns, and β-chemokine 
production correlated with infectibility of PBMCs by HIV (Wu et al., 1997; Blaak et al., 
2000). While resistance to HIV infection has been attributed in some cohorts to 
116 
 
homozygosity for the mutant alleles of the CCR5 receptor (CCR5Δ32; Huang et al., 1996), 
this mutant allele is present at high frequencies (~10%) in Caucasian populations (Samson et 
al., 1996; Novembre et al., 2005) but at extremely low frequencies (0.1%) in black African 
populations (Williamson et al., 2000).  
Previous studies in persistently HIV exposed-uninfected individuals from Kenya, the Central 
African Republic, the Ivory Coast and the Netherlands have suggested that lower levels of T 
cell activation account for some of the in protection from HIV infection (Card et al., 2008; 
Bégaud et al., 2006; Jennes et al., 2006; Koning et al., 2005). The study from Kenya focused 
on persistently HIV-uninfected commercial sex workers and evaluated the expression of three 
classical markers of cellular immune activation, namely HLA-DR, CD38 and CD69 on both 
CD4+ and CD8+ T-cells. The study from the Ivory Coast also focused on HIV exposed 
seronegative sex workers and measured activation on CD4+ and CD8+ T cells by CD69 
expression (Jennes et al., 2006). The study from the Netherlands focused on highly exposed 
but seronegative MSM and reported that protection was associated with lower CD38, HLA-
DR and CD70 expression by CD4+ T cells (Koning et al., 2005). Although several studies 
have suggested that HIV-exposed seronegative individuals have lower activation status than 
other low risk individuals, there have been other studies reporting elevated frequencies of 
activated CD8+CD38+ T-cells in HIV exposed seronegative sex workers when compared to 
low-risk blood donors (Jennes et al., 2003). Findings from this Chapter [from stable, 
heterosexual black South African couples in which one partner is HIV- and the other is either 
HIV+ (serodiscordant) or HIV- (seroconcordant)] similarly suggest that activation of T cells 
was globally reduced in HIV- exposed individuals compared to those in unexposed 
relationships. While classic markers of activation were identified in other studies to be 
associated with this immune quiescence, this study showed that reduced activation by T cells 
was largely attributed to lower frequencies and lower relative expression of the HIV co-
receptor CCR5 by both HIV target cells CD4 as well as CD8 T cells. 
A study from Clerici et al. (2000) concluded that levels of systemic immune activation in 
individuals from Africa was influenced by environment rather than genetics when they 
compared individuals from Africa (HIV- individuals from Ugandan, living in Africa) to 
individuals from Europe (HIV- individuals of Italian decent and individuals of Ugandan 
decent living in Italy). Moreover, they observed that surface expression of CCR5 was 
enriched in African residents compared to Italian residents. They suggested that 
environmental factors, such as parasites, hygiene practices and nutrition are likely 
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contributing to differences in immune activation depending on geographic location. Recent 
studies by Cohen et al. (2010) confirmed that the findings by Clerici et al. (2000) were also 
prevalent in the genital tract of healthy young women from Sub-Saharan Africa. They 
reported an increased activated mucosal T-cell level in the genital tract of STI/HIV free 
Kenyan women, with a specifically elevated level of CD4+CD69+, CD4+CD69+CCR5+ and 
CD8+CD69+ T-cell subsets when compared to women from San Francisco. They proposed 
that this elevated level of genital immune activation could partly account for the higher HIV 
incidence in young women from Sub-Saharan Africa. 
HIV- exposed individuals in this study had lower concentrations of the classical Th1 
cytokines IFN-γ and IL-2 in blood plasma than HIV- unexposed controls. Other studies have 
similarly reported a significant reduction of IL-2 and IFN-γ expression in both CD4+ and 
CD8+ of highly exposed persistently seronegative individuals when compared to negative 
controls (Alimonti et al., 2005; Nicastri et al., 1999). These downregulated Th1 cytokines 
found in HIV- seronegative individuals might reflect less activated cells (anergic), which 
indirectly result in protection from HIV acquisition. The decreased concentrations of both 
IFN-γ and IL-2 could be involved in very low levels of activation of T cells. Moreover, a 
lowered expression of IFN-γ could affect the capability of macrophages to present antigens, 
thus resulting in a reduction of the cell-to-cell spread of infection (Gowda et al., 1989). The 
finding in this Chapter that frequencies of HLA-DR expressing cells and concentrations of 
IFN-γ and IL-2 were significantly reduced in HIV- exposed compared to unexposed 
individuals are important, considering that IFN-γ as well as IL-2 are known to modulate 
HLA-DR expression. Reduced levels of these two cytokines may be directly involved in the 
downregulation of HLA-DR (Paxton et al., 1996). In addition to regulating HLA-DR 
expression, IL-2 is involved in upregulation of CC chemokine receptors and chemotaxis of T 
cells, both functions necessary for recruitment of antigen-activated T-cells to sites of immune 
and inflammatory responses (Loetscher et al., 1996). 
GM-CSF in particular was significantly lower in plasma of HIV- exposed compared to 
unexposed individuals. Since GM-CSF promotes activation, maturation and differentiation of 
several immune cells (Kedzierska et al., 1998; Shi et al., 2006), this difference could impact 
on susceptibility to HIV infection. At high concentrations, GM-CSF might result in a rapid 
increase in numbers of leukocytes available in blood, which could then infiltrate and increase 
the frequency of HIV target cells in lymphoid tissues. 
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In conclusion, findings in this Chapter suggest a generalized lower level of systemic immune 
activation and inflammation in HIV- exposed individuals, who could potentially be exposed 
to HIV during sex with their HIV-infected partners, when compared to HIV- unexposed 
individuals. Moreover, a lower availability of susceptible cells for infection by the virus 
could partially explain why these individuals remain HIV- despite HIV exposure. Jaspan et 
al. (2011) showed that levels of activation in blood significantly and broadly predicted 
similar activation at the genital tract in women. It could be hypothesized from the findings in 
this Chapter that the reduction of susceptible target cells in blood would also result in the 
lower availability of these cells (targets for HIV infection) at the cervix. Elucidating the 
biological characteristics underlying protection against HIV can provide valuable insight on 
the protective mechanisms that may be harnessed for the development of new treatments and 
anti-HIV strategies. 
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6.1 Introduction 
A number of studies worldwide have described a phenomenon of ‘resistance’ to HIV 
infection in women who remain HIV negative despite repeated exposure to the virus (Clerici 
et al., 1994; Makedonas et al., 2002; Hladik et al., 2003; Jennes et al., 2004; Suy et al., 2007; 
Hygino et al., 2008). The variability in risk for HIV infection has been associated with a 
multitude of factors, including viral, host genetic, immunological and sociobehavioural 
variables (Paxton et al., 1998; Wichukchinda et al., 2007; Hirbod et al., 2008). Chapter 5 
focused on systemic differences in levels of immune activation between HIV- individuals in 
HIV exposed and unexposed relationships, in which multiple markers of systemic activation 
(including CCR5, CD38, and HLA-DR expression by HIV target cells) were identified as 
being lower in exposed versus unexposed individuals. Studies of mucosal samples from HIV-
exposed uninfected individuals offer an important opportunity to investigate biological events 
predicting HIV risk as well as those that predict protection. 
Although several studies have described unique compartment specific drivers of 
inflammatory cytokines in blood and at the genital mucosa, relatively few have directly 
compared the relatedness or overlap between inflammatory or immune responses in the 
genital compartment and blood. Gumbi et al. (2008) reported that HIV-specific CD8+ T-cell 
IFN-γ responses in the female genital tract were of higher magnitude compared to responses 
in matching blood of HIV-infected women. Other studies have shown no association between 
level of inflammation in the female genital tract and in blood (Hedges et al., 2006; Lajoie et 
al., 2008; Blish et al., 2012; Roberts et al., 2012). 
The purpose of this Chapter is to investigate the impact of sexual partner HIV status on 
female genital mucosal inflammatory cytokine markers, as predictors of risk for HIV 
infection. Furthermore, this Chapter describes the relatedness between important 
inflammatory markers in blood and in the female genital compartment. 
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6.2 Materials and Methods 
6.2.1 Description of study participants 
A total of 85 HIV- women were included for this part of the study, of which 69/85 were in 
HIV- unexposed relationships with HIV- stable male partners and 16/85 were in exposed 
relationships. Chapter 2 (Section 2.2.1) provides a full description of these individuals. These 
women were followed longitudinally, with inflammatory cytokine production in blood and 
cervix being measured at 6, 18 and 30 months in the study. For comparison, 78 HIV+ women 
in HIV+ concordant relationships were included.  All HIV+ women were naïve to HAART. 
 
6.2.2 PBMCs collection and processing 
Blood (16ml) was collected from all women using standard venipuncture into sterile ACD 
anti-coagulated vacutainer tubes (BD Biosciences, Plymouth, UK).Blood was processed 
within 4 hours of collection; PBMCs were isolated using Ficoll-Hypaque (Sigma-Aldrich, St 
Louis, MO, USA) density gradient centrifugation as described in Chapter 2 (Section 2.2.2). 
 
6.2.3 Genital supernatant collection and processing 
Cervical mononuclear cells (CMCs) were collected using a Digene cervical sampler (Digene 
Corporation, Gaithersburg, MD, USA) as described in Chapter 4 (Section 4.2.2). The cervical 
supernatant collected after the centrifugation of the cervical specimen was aliquoted and kept 
at -80°C and thawed over ice, overnight prior to any assay. 
 
6.2.4 Measurement of cytokine in blood and genital secretions 
The concentrations of 9 cytokines (IL-1β, IL-6, IL-10, IL-12p70, TNF-α, IL-2, IFN-γ, IL-7 
and GM-CSF) were measured in blood plasma using High Sensitivity Human Cytokine 
LINCOplex Premixed kits (LINCO Research, MO, USA). A description of the assay is 
available in Chapter 3 (Section 3.2.7). 
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The concentrations of 14 cytokines (IL-β, IL-6, IL-10, IL-8, IP-10, MCP-1, MIP-1α, MIP-
1β, IL-1α, IL-12p40, G-CSF, Eotaxin, Fractalkine, and IL-15) were measured in cervical 
supernatants using Human Cytokine LINCOplex Premixed kits (LINCO Research, MO, 
USA). A description of the assay is available in Chapter 4 (Section 4.2.5).  Cytokines listed in 
bold were those measured in both compartments although it should be noted that the 
sensitivity of the kits used to measure these were different depending on the sample analyzed. 
 
6.2.5 Statistical analysis 
Shapiro-Wilk test for normality was performed to determine the distribution of variables 
within the dataset. Comparison of unpaired non-parametric data was done using the Mann-
Whitney U test. Statistical inferences on binary sets of data were performed using the 
Fisher’s exact test and odds ratios calculated. Non-parametric assessments of variation 
between groups was carried out through the Kruskal-Wallis Analysis of Variance (ANOVA), 
with Dunn’s post-test being applied to test for the effect of multiple comparisons. Non-
parametric association between groups was carried out through the Spearman rank test. 
Statistical analyses were performed using GraphPad Prism version 5.00 for Windows 
(GraphPad Software, San Diego, CA, USA) and STATA 11 (College Station, TX, USA). All 
tests were two-tailed and p-values of ≤0.05 were considered significant. 
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6.3 Results 
Eighty five HIV- women were included in this part of the study to investigate the impact of 
partner HIV status on the comparative level of genital inflammation in HIV- unexposed 
women (69/85) and HIV- exposed women (16/85). In addition, 78 HIV+ women in HIV 
seroconcordant relationships were included for comparison. While HIV- women shared 
similar sociodemographic and reported a similar frequency of genital disease irrespective of 
partner status, HIV- exposed women reported a significantly higher condom usage than 
unexposed ones (70% versus 39%; p=0.002). 
Table 6. 1 Clinical and socio-behavioural characteristics of women included in this study 
 
Characteristics	   n	   Unexposed	   n	   Exposed	   P-­‐value	  
n	   	   69	   	   16	   	  
Age	  [yr;	  median	  (IQR)]	  *	   69	   33	  (27-­‐41)	   16	   35(29-­‐40)	   0.5	  
Living	  together	  with	  partner	  [%]	  †	   67	   71	   15	   66	   0.4	  
Sexual	  exposure	  [median	  years	  of	  sex	  (IQR)]	  *	   66	   18 (12-23) 15	   19 (10-24) 0.9	  
Sex	  acts	  in	  the	  last	  month	  [median	  (IQR)]	  *	   65	   4 (2-8) 14	   4 (3-9) 0.4	  
Condom	  usage	  [%]	  †	   68	   39	   16	   70	   0.002	  
Genital	  ulceration	  in	  the	  last	  6	  months	  [%]	  †	   69	   5	   16	   5	   0.8	  
Vaginal	  discharge	  in	  the	  last	  6	  months	  [%]	  †	   69	   6	   16	   7	   0.6	  
 
†p-value calculated using Fischer's exact test 
*p-value calculated using Mann-Whitney U-test 
IQR: Interquartile range 
 
 
6.3.1 Cytokine concentrations in genital secretions  
The concentrations of 14 cytokines (IL-β, IL-6, IL-10, IL-8 IL-1α, IL-12p40, IP-10, MCP-1, 
MIP-1α, MIP-1β, IL-15, Eotaxin, Fractalkine, and G-CSF) were measured in genital 
secretions from HIV- women in either exposed or unexposed relationships (Table 6.2). 
Concentrations of IL-1α were significantly higher in HIV- exposed women when compared 
to HIV- unexposed women (p=0.001; Table 6.2). Overall, the level of most cytokines (except 
for G–CSF and IL-1β) were elevated in the exposed women when compared to unexposed 
ones (p=0.02; Figure 6.1). Genital cytokine concentrations available from 78 HIV+ 
seroconcordant women were included for comparison. HIV+ seroconcordant women 
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generally had higher cytokine concentrations in their genital compartments than either HIV- 
exposed or unexposed women, and this was significant for IL-1α, IL-6, IL-8, G-CSF and IP-
10 (Table 6.2). It was interesting to note that HIV- exposed women had profiles closer to 
HIV+ concordant women than HIV- unexposed women, suggesting a signature of 
inflammation-associated HIV risk was detectable in these women despite them not being HIV 
infected. 
 
Table 6. 2 Impact of HIV status and couple HIV status on cervical cytokine levels 
            
  Median cytokine conc (IQR; pg/ml)  
Cytokine HIV Negative P-value◊ HIV Positive P-valueΔ 
  Unexposed Exposed   Concordant   
Eotaxin 12.91 (4.36-19.02) 16.37 (10.49-20.43) 0.3 15.5 (3.5-21.22) 0.4 
Fractalkine 70.63 (30.26-129.4) 76.27 (39.72-224.3) 0.3 77.41 (29.66-144.8) 0.7 
IL-8 75.36 (28.48-219.8) 149.3 (40.91-303.9) 0.5 153.6 (56.67-344.5) 0.01‡ 
IP-10 61.44 (22.77-159.1) 102.5 (21.63-208.5) 0.7 441.1 (172.7-1002) p<0.0001‡ 
MCP-1 29 (8.89-102.8) 37.82 (23.7-71.58) 0.6 42.83 (16.41-122.6) 0.1 
MIP-1α 5.62 (1.36-28.50) 20.71 (1.36-43.47) 0.1 13.64 (1.36-38.16) 0.2 
MIP-1β 20.25 (1.96-40.39) 28.93 (8-66.93) 0.1 29.26 (10.10-43.71) 0.06 
IL-1α 14.53 (4.53-32.95) 45.31 (23-128.5) 0.001‡ 34.96 (15.52-99.38) p<0.0001‡ 
IL-1β 3.11 (0.26-7.87) 2.61 (0.5-8.62) 0.9 4.07 (0.69-7.14) 0.4 
IL-6 9.42 (2.13-21.62) 9.9 (3.43-31.36) 0.7 18.39 (4.9-55.6) 0.008‡ 
IL-12p40 25.82 (0.26-61.92) 36.09 (6.07-60.13) 0.6 34.51 (5.64-67.33) 0.4 
IL-10 2.35 (0.77-6.15) 5.37 (0.56-10.26) 0.3 2.6 (1.26-5.65) 0.5 
G-CSF 388.6 (51.53-952.8) 349.3 (122.6-857.7) 1 759.8 (200.7-1847) 0.01‡ 
IL-15 2.22 (1.06-3.81) 2.63 (0.75-5.39) 0.8 2.07 (1.24-4.1) 0.9 
 
IQR: Interquartile range 
Mann-Whitney U tests were applied to compare cytokine concentrations between the HIV- unexposed and HIV- 
exposed groups, and the HIV- unexposed and HIV+ seroconcordant groups. ‡ denotes p-value that remained 
significant after adjustment for multiple comparisons using the false discovery rate step-down approach 
(Columb and Sagadai, 2006). ◊denotes p-value for comparisons between HIV- unexposed and HIV- exposed 
individuals.Δdenotes p-value for comparisons between HIV- unexposed and HIV+ seroconcordant individuals. 
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Figure 6. 1 Comparison of genital cytokine levels in HIV+ seroconcordant, HIV- unexposed 
(seroconcordant) and exposed (serodiscordant) individuals. The median value of each of the 14 cytokines 
measured in genital secretions was compared between groups using Wilcoxon signed rank test. 
 
6.3.2 Compartmental relatedness between cytokines 
To evaluate the relatedness between compartments in inflammatory markers, the association 
between concentrations of IL-1β, IL-6 and IL-10 (the cytokines which were measured in both 
compartments) was investigated in HIV- (Figure 6.2A) and HIV+ women (Figure 6.2B). 
Irrespective of HIV or partner status, no association was observed between matching plasma 
and genital tract concentrations of IL-1β, IL-6 and IL-10, suggesting that these cytokines are 
likely to be independently produced in the female genital tract compared to blood. 
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Figure 6. 2 Relationship between cervical level of IL-1β, IL-6 and IL-10 and their matching blood plasma 
level of HIV- (A) and HIV+ (B) women. Matching levels of IL-1β (A), IL-6 (B) and IL-10 (C) in the cervical 
compartment and blood plasma were investigated using simple linear regression. p<0.05 were considered 
significant. 
 
Figure 6.3 depicts the compartmentalization of cytokines by paired sample ratios of their 
cervical to blood plasma concentration. Ratios >1 or <1 indicate enrichment of a cytokine in 
cervix and blood plasma, respectively. This analysis suggests that the genital tract is 
dominated by a more inflammatory profile (irrespective of HIV status), whereas blood is 
characterized by a more anti-inflammatory/regulatory profile. 
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Figure 6. 3 Comparison of the genital:blood plasma cytokine ratios from HIV- (blue) and HIV+ women 
(red). Mean and standard error of cytokine concentration ratios in cervical and blood plasma are shown for 
HIV- and HIV+ women. 
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6.4 Discussion 
Sexual transmission remains the predominant mechanism for HIV acquisition and the 
efficiency of transmission reflects the biology of this specific mucosal compartment 
(Broliden, 2010). The presence, activation status and phenotype of immune cells and 
receptors at the genital tract therefore represent an influential combination of factors 
influencing the outcome on exposure to HIV. The female genital tract provides a highly 
alterable environment with constant physiological changes in the form of induced 
inflammation, hormonal cycle and seminal deposition. 
While no significant differences were found in the blood plasma inflammatory profile of 
HIV- unexposed and exposed individuals, inflammatory markers were generally higher at the 
cervix of exposed women compared to unexposed one, with IL-1α concentrations being 
significantly different between the two groups. While inflammation in the female genital tract 
could lead to recruitment of HIV target cells and other immune cells to this compartment, the 
elevated inflammatory profile measured in HIV- women in HIV exposed relationships could 
represent signature of exposure to HIV rather than elevated risk. This interpretation is 
supported by the finding in Chapter 5 that HIV- exposed individuals had significantly lower 
frequencies of activated and proliferating CD4+ HIV target cells compared to unexposed 
individuals, and the previous observation from our group that the extent of immune activation 
in blood significantly and broadly predicted similar T cell activation in the genital tract of 
women (Jaspan et al., 2011). 
It was interesting to observe that the inflammatory profile in genital secretions from HIV- 
exposed women were more similar to HIV+ individuals than HIV- unexposed women, which 
could be reflective of HIV exposure rather than HIV risk. In contrast to the overall higher 
genital inflammatory cytokines in HIV- exposed compared to unexposed, Chege et al. (2012) 
reported contrastingly blunted pro-inflammatory cytokine responses, measured by mRNA 
expression rather than protein, in both the genital tract and blood of HIV-exposed 
seronegative female sex workers in Kenya. In addition to relative immune quiescence, 
however, HIV-exposed uninfected status has also been linked with HIV-specific T-cells with 
a pro-inflammatory function profile (Piacentini et al., 2008). It could be argued that cellular 
immune quiescence in the female genital mucosa establishes a reduction in the pool of 
susceptible target cells for HIV to infect after initial sexual exposure, decreasing HIV 
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acquisition risk, and such repeated exposure to the virus may in turn generate the mucosal 
HIV-specific responses that have been observed. Whether these responses contribute to 
protection on exposure has not been established, but their low frequency suggests that they 
may contribute to protection, while at the same time maintaining a low enough density of 
activated and susceptible target cells at the genital mucosa. 
Few studies have investigated the relatedness between innate immune responses in blood and 
at the genital mucosa, and results from this Chapter suggest that the female genital tract and 
blood are immunologically separate compartments, with cytokine responses being likely 
driven by local stimuli within the mucosa compared to blood. In support of this finding, 
Hedges et al. (2006) previously reported that serum concentration of IL-1β, IL-6 and IL-8 
were not influenced by any changes in genital levels of these cytokines, which they suggested 
were associated rather with change in vaginal flora. A study to compare expression of 
immunoregulatory cytokines in the cervicovaginal lavages with matching serum of 
commercial sex workers (HIV+ and HIV-) and HIV- low risk individuals in Benin similarly 
suggested differences in immunoregulatory cytokine expression patterns between the two 
compartments (Lajoie et al., 2008). Lisco et al. (2012) showed that semen and blood are 
distinct immunological compartments in which concentrations of cytokines are profoundly 
different. Blish et al. (2012) similarly found no association between genital and systemic 
cytokine concentrations. Strategies to decrease HIV transmission should take into account 
local genital tract inflammation, as this is not reflected in plasma measurements.  
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CONCLUSION 
In spite of the considerable scientific advancements in understanding the interactions between 
HIV, the individual and the community, the biological correlates of protection against HIV 
infection remain elusive. The observation that a select group of individuals appear to resist 
HIV infection has led to a host of epidemiological studies aimed at defining protective 
biological and behavioural attributes that confer protection against infection of these 
individuals. Data gathered from studying such cohorts of individuals could inform on the 
design of appropriate strategies that would mimic the effective responses of these resistant 
individuals. In this dissertation, HIV serodiscordance among black stable heterosexual 
couples in Sub-Saharan Africa was investigated to determine potential correlates of 
protection against HIV infection. 
Chapter 2 focused on HIV+ individuals who were either in HIV serodiscordant or 
seroconcordant relationships. It explored the potential virological and immunological risks 
associated with being an HIV+ individual in a relationship with a stable partner who is either 
HIV seroconcordant or serodiscordant, using objective biomarkers of HIV disease 
progression (including plasma HIV load and absolute blood CD4 counts). The most 
compelling finding from this Chapter was that HIV+ individuals in HIV seroconcordant 
relationships with similarly HIV+ stable sexual partners had 0.5 log10 higher plasma HIV 
loads than HIV+ individuals in HIV serodiscordant relationships (with HIV- partners). Even 
though HIV loads in plasma were negatively associated with absolute CD4 counts overall in 
this cohort, this 0.5 log10 higher viral load in HIV+ seroconcordant compared to 
serodiscordant individuals did not predict a worse clinical outcome in seroconcordant 
individuals (as indicated by lower absolute CD4 counts at future visits over a 2 year period of 
follow-up). Although this appears counterintuitive, there are several published studies in 
discordant couples similarly reporting differences in viral loads depending on partner status 
although some studies report differences in CD4 counts over time while others do not 
(Malamba et al., 2005; Chatterjee Rogers et al., 2005; Kumarasamy et al., 2010). In this 
study, it is possible that the difference in plasma viral loads between seroconcordant and 
serodiscordant individuals (0.5 Log = 14700 copies RNA/ml), although being significantly 
different between groups, was not high enough in magnitude to result in a worse clinical 
outcome as measured by blood CD4 count.  
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In HIV+ individuals, plasma RNA load is generally accepted as a good predictor of the rate 
of loss of CD4 cells at a population level (Lima et al., 2009). However, there remains a wide 
variability in the rate of CD4 depletion among infected individuals (Grabar et al., 2000; 
Florence et al., 2003; Jevtovic et al., 2005; Badri et al., 2008). In Chapter 2, it was shown 
that initial CD4 count at baseline was a strong predictor of the magnitude of the eventual loss 
of CD4 cells over the following 12 months, accounting for 77% of CD4 depletion in blood 
from baseline to month 12. While a change in plasma HIV load was predictive of a change in 
blood CD4 count over the same period, it accounted for only 35% of the variability in CD4 
counts. While this association was stronger than that reported by Rodriguez et al. (2006), it 
remains of paramount importance to define other factors influencing CD4 counts, using more 
in depth techniques in treatment decisions and for understanding HIV pathogenesis. Since 
CD4 cell counts and viral loads can vary widely among individuals, due to a wide range of 
genetic and biological factors, the inclusion of any of these factors that could account for any 
additional variation, over and above that explained by the model could prove determinant in 
the improvement of the timing of therapy initiation. 
While the molecular basis for the difference in HIV plasma load between seroconcordant and 
serodiscordant individuals remains unclear, viral load setpoint represents an accepted 
predictor of clinical disease course during HIV infection.  This therefore suggests that HIV+ 
seroconcordant individuals in this study may be at greater risk of a more rapid disease 
progression (Lavreys et al., 2006; Saathoff et al., 2010). It is likely that HIV seroconcordant 
couples are infected with viruses with similar phenotype or characteristics, which may result 
in higher viral load setpoints. Future studies from this cohort will aim to use 454 sequencing 
to identify whether seroconcordant individuals are sharing viruses with their partners and 
whether there is any evidence for dual-, co- and superinfection. This will determine if any 
continuous viral movement between partners exists and will allow us to determine which of 
the partners was the likely donor versus recipient. Moreover, to investigate whether HLA 
matched or mismatched coupled display differences in frequencies/rates of superinfection and 
immunopathogenesis, future studies will evaluate HLA types of couples. Data suggest that 
HLA incompatibility between sexual partners confers protection against HIV transmission 
(Jennes et al., 2013). 
From the host perspective, a number of immune cell subsets are also key in HIV 
pathogenesis, in particular HIV-specific effector cells endowed with effective antiviral 
functions. The role of cytotoxic CD4+ T-cells in the control of HIV has been supported by 
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recent findings reported by Zheung et al. (2009), where the ability of Nef-specific CD4+ T-
cells to suppress HIV replication in HIV-infected CD4+ T-cells and macrophages was 
demonstrated. Intracellular cytokine staining assays following Gag-specific stimulation in 
Chapter 2 revealed a higher magnitude of IFN-γ and MIP-1β production by CD4 T-cells from 
HIV+ seroconcordant individuals when compared to serodiscordant individuals. This, 
however, was not associated with better control of HIV as has previously been reported in 
HIV+ individuals by Soghoian et al. (2012). CD8+ T-cells have the capacity to kill infected 
cells through the ability to produce and secrete an array of cytokines with antiviral properties, 
such as IFN-γ, TNF-α, MIP-1α and β, RANTES, perforin and granzyme. Chapter 2 assessed 
Gag-specific CD8+ T-cell functional properties and revealed higher frequencies of IFN-γ and 
MIP-1β production by HIV+ individuals in seroconcordant relationships compared to those in 
serodiscordant relationships. Moreover, a significant positive association was found between 
HIV-specific IFN-γ responses by CD8+ T-cell and HIV plasma loads, confirming that 
frequencies of CD8+ T cell responses were tracking antigenic load (Ogg et al., 1998; Betts et 
al., 2001; Edwards et al., 2002). 
The direct depletion of CD4+ T-cells by HIV infection was shown to only partially account 
for the decrease of the CD4+ T-cell pool in systemic circulation in Chapter 2, and a range of 
bystander mechanisms have been postulated as contributors to CD4+ T-cell death (Grossman 
and Paul, 2000; Sousa et al., 2002; Holm and Gabuzda, 2005). Recent views consider 
HIV/AIDS as a dynamic and progressive disease stemming from a mixture of hyperimmune 
activation and chronic inflammation. The broader comprehension gathered in the field of 
HIV immunology over the past 3 decades, made possible by technological advancement such 
as multiparametric flow cytometry analysis, offers the opportunity of monitoring a 
constellation of cellular immune markers relevant for immune activation, inflammation, 
control of replication or the exhaustion and modification of the immune functions. Following 
productive HIV infection, the host’s immune system on the one hand plays a predominant 
role in keeping this persistent virus in check, while on the other hand, this long-term control 
is accompanied by chronic hyper activation and inflammation, such that a progressive 
exhaustion of the host immune competence ensues and this leads to the onset of non-AIDS 
defining co-morbidities. Chapter 3 focused primarily on the monitoring of cellular activation 
and soluble inflammatory markers in the blood of HIV+ participants. 
Assessment of systemic immune activation levels has become a routine indicator in the 
immunomonitoring of HIV+ patients, as these levels are significantly associated and 
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predictive of HIV disease progression, even in viral suppressed participants on therapy (Hunt 
et al., 2003; Vrisekoop et al., 2008; d’Ettorre et al., 2011). In Chapter 3, the expression of 
receptors CD38, HLA-DR and Ki67 on T-cells, which generally reflect the activity of the 
immune system against viral antigens, were assimilated to the degree of systemic immune 
activation. In addition to these receptors, the expression of the coreceptor CCR5 was also 
assessed. While the total activation status of CD4+ and CD8+ T-cells in systemic circulation 
of HIV+ seroconcordant individuals were higher than that of HIV+ serodiscordant 
individuals, it came as a surprise that serodiscordant individuals displayed a significantly 
higher level of CD8+ T-cell activation as measured by the individual expression of CD38 and 
HLA-DR. This could be explained by the fact that CD8+ T-cell activation occurs at a lower 
viral threshold because of their cytotoxic potential, but progressively, it is expected that 
hyperactivation will lead to CD8 cell exhaustion and anergy (Karim et al., 2012). One of the 
limitations of this study is the lack of an accurate timescale for when the participants became 
infected with HIV. If the seroconcordant participants had been infected for a longer period 
compared to the serodiscordant ones, they may have reached this stage of exhaustion and 
anergy for their CD8+ T-cell subset.  
CD38 expression remains a well documented marker of early T-cell activation and is 
moreover associated with increased cytokine production and increased T-cell differentiation 
(Ausiello et al., 1996; Orendi et al., 1998; Savarino et al., 2000). While most studies assessed 
immune activation through the measurement of frequency of T-cell expressing CD38, the 
prognostic value of T-cell activation is improved when assessed by the coexpression of CD38 
with HLA-DR (Benito et al., 2004), suggestive of a hyperactivated profile. Findings from 
Chapter 3 following the comparison of the systemic activation profile of participants with 
low (<1500 cps/ml) and higher (>1500 cps/ml) HIV viremia revealed that individuals with 
higher plasma HIV load had significantly higher level of CD8+ T-cells expressing CD38 
individually or dually with HLA-DR. The further association observed between CD38 and 
HLA-DR coexpression on T-cells and plasma HIV load and blood CD4% lend support to 
earlier observation that T-cells dually activated with CD38 and HLA-DR are significantly 
predictive of a worse disease outcome as observed in separate studies (Kovac et al., 2010; 
Karim et al., 2012). 
In agreement with other reports, cross sectional cytokine data from Chapter 3 showed that a 
key driving force in the establishment of a continued HIV cycling, and probably progression 
to worse HIV disease outcomes, is the ongoing and aberrant systemic inflammation. The 
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constant priming of the immune system for action results in the ongoing release of pro-
inflammatory cytokines, such as TNF-α and IL-1β. Consistent with earlier observations of 
higher HIV viremia in seroconcordant individuals compared to serodiscordant ones, 
seroconcordant participants manifested a significantly higher plasma concentration of 
proinflammatory cytokines leading to the setting up of a vicious cycle involving HIV 
replication, systemic immune activation and chronic plasma inflammation, whereby the 
increase in any one of these three factors would be analogous to ‘adding fuel to the fire’. The 
lack of difference seen when comparing absolute blood CD4 count in seroconcordant and 
serodiscordant individuals could be partly attributed to a greater ability of the seroconcordant 
individuals to switch into anti-inflammatory mode, as supported by a higher circulating level 
of IL-10, potentially resulting in a slower erosion of immune protection. Multivariate analysis 
revealed that the dual expression of CD38 and HLA-DR on CD4+ T-cells and circulating 
level of TNF-α were the best predictors of HIV plasma viral load. 
As understanding of the attributes of the immunological response to HIV infection grows and 
the role of chronic systemic inflammation shows more relevance, it is necessary that this 
acquired knowledge becomes integrated in the clinical management of the infection. Chapters 
2 and 3 highlighted the fact that decisions concerning the implementation of therapy can no 
more be purely based on HIV viremia and absolute blood CD4 count. It is imperative that the 
current systemic immune activation and inflammation profile be taken into consideration 
when treatment programs are set up. There can be significant clinical benefits in the inclusion 
of affordable and accessible laboratory markers of immune activation and inflammation in 
the treatment or monitoring of patients with chronic HIV infection. 
The central finding of this dissertation centres on the CCR5 coreceptor expression on T-cells 
of participants with different HIV and couple status, and its implication in disease 
progression in HIV+ participants and HIV transmission risk in HIV- participants. CCR5 is 
the major coreceptor for infection by macrophage tropic strains of HIV-1 and therefore has a 
vital role in the transmission and pathogenesis linked to the virus (Deng et al., 1996; Dragic 
et al., 1996). Memory CCR5+CD4+ activated T-cells represent the preferred targets for HIV 
and it has been confirmed that up to 80% of the GALT CD4+ T-cells, consisting mainly of 
CCR5+ activated cells, can be depleted within the first month of primary HIV infection 
(Brenchley et al., 2004). The most compelling piece of evidence outlining the importance of 
CCR5 in HIV infection has been demonstrated by a 32 bp deletion in the CCR5 ORF, the 
CCR5Δ32 mutation, which translates to a phenotype of reduced CCR5 surface expression in 
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individuals heterozygous for the gene, and conferring full resistance to HIV in individuals 
homozygous for the gene, as they fail to express CCR5 on cell surfaces (Liu et al., 1996; Wu 
et al., 1997). 
Using data from Chapter 3 showing a significantly higher level of expression of CCR5 on the 
T-cells (both CD4+ and CD8+) of seroconcordant participants compared to serodiscordant 
participants, it can be proposed that plasma HIV load difference observed between the two 
groups could be partly attributable to this differential expression of CCR5. Increased CCR5 
density was determined to correlate with high HIV viral load in a study by Reynes et al. 
(2000). Moreover, the observation that seroconcordant individuals have a higher frequency of 
CD4+CD38+CCR5+ T-cells in their systemic circulation lends support to the argument that  
these individuals manifest a higher HIV viremia compared to serodiscordant individuals on 
account of a greater HIV infection and replicative capabilities. This is further confirmed by 
the fact that the CD4+CCR5+ subset in circulation is even greater in individuals with a higher 
plasma HIV load (>1500 cps/ml) when compared to those with lower viral burden (<1500 
cps/ml). The expression of chemokine receptor CCR5, and potentially its ligands MIP-1β, are 
widely regarded as central to the pathogenesis of HIV infection as their regulation is thought 
to influence leukocyte migration, as well as HIV infection. CCR5 density has been identified 
as being one of the determinants of the efficiency of CCR5 in the chemotactic response to its 
ligands (Desmetz et al., 2006). In Chapter 2, a significantly greater frequency of MIP-1β was 
observed when intracellular cytokine staining assays were performed, in both CD4+ and 
CD8+ T-cell subsets of seroconcordant individuals when compared to serodiscordant 
individuals. Finally, from an immunopathological perspective, elevated CCR5 density, as 
measured by mean number of molecules/cell in HIV+ patients has been linked to faster 
disease progression (Reynes et al., 2001; Gervaix et al., 2002) as well as poorer response to 
therapy (Ketas et al., 2007; Heredia et al., 2008). 
Individuals in various cohorts globally have been documented to have what appears to be 
some form of resistance to HIV infection in spite of several exposures (Clerici et al., 1994; 
Bernard et al., 1998; Makedonas et al., 2002; Lo Caputo et al., 2003; Hladik et al., 2003; 
Jennes et al., 2004; Suy et al., 2007; Hygino et al., 2008). This variability in susceptibility to 
infection by HIV and its immunopathogenic consequences has been widely investigated and 
was found to correlate with a plethora of immunological, genetic, viral and sociobehavioural 
factors. Nevertheless, the exact mechanisms of protection in these individuals are yet to be 
elucidated. In order to evaluate the immunological factors that may contribute to the relative 
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resistance in the exposed uninfected HIV- partners in HIV serodiscordant couples, the 
‘immune quiescence’ hypothesis described in previous studies (Card et al., 2009; McLaren et 
al., 2010; Chege et al., 2012) was investigated. Immune quiescence refers to the low baseline 
level of immune activation and inflammation. Vatakis et al. (2010) showed that quiescent T-
cells can be infected but viral replication would be rendered inefficient, as HIV preferentially 
infects activated T-cells offering all the necessary host factors for efficient HIV infection 
(McLaren et al., 2010). 
In line with findings from previous studies documenting an increased HIV susceptibility with 
increased activation (Shapira-Nahor et al., 1998; Naranbhai et al., 2012) and decreased 
susceptibility with lower activation (Card et al., 2009, 2012; Songok et al., 2012), it was 
reasonable to hypothesise that the exposed seronegative individuals included in Chapter 5 
would have a lower level of immune activation on account of their lower susceptibility to 
HIV infection. When compared to HIV- controls in HIV unexposed relationship, HIV- 
exposed individuals manifested a phenotype of reduced systemic activation. Firstly, HIV- 
exposed participants expressed a lower frequency of CD8+HLA-DR+ T-cells, consistent with 
previous findings of reduced systemic activation described in a HESN MSM cohort (Koning 
et al., 2005 - reduced expression of HLA-DR, CD38, CD70 and Ki67) and serodiscordant 
couple cohorts (Camara et al., 2010 - reduced expression of CD38; Begaud et al., 2006 - 
reduced expression of HLA-DR). As observed with HIV+ serodiscordant individuals in 
Chapter 3, HIV- exposed individuals expressed significantly lower frequencies of CCR5 
coreceptors on both CD4+ and CD8+ T-cells when compared to HIV- unexposed controls. 
Moreover, the CCR5+ T-cells in HIV- exposed individuals had a reduced proliferative 
capacity (Ki67+CCR5+) and lower activation status (CD38+CCR5+) when compared to HIV- 
unexposed controls. Keeping in mind that HIV preferentially replicates in activated T-cells, 
these findings altogether translates to an immune quiescent state where protection against 
HIV infection is conferred through the limitation of target cell availability. 
There exist several lines of evidence showing a relation between the lowered frequency of 
CD4+CCR5+ T-cells and decreased level of replication/infection by firstly, SIV in non-human 
primate models (Pandrea et al., 2007) and secondly, HIV in exposed but uninfected FSW 
(Fowke et al., 1998; Messele et al., 2001). In addition to a lowered expression of CCR5 on 
CD4+ T-cells in the FSW enrolled in their study, Paxton et al., 1998 also reported on a 
concurrently elevated level of β-chemokines, the cognate ligand for CCR5. In vitro studies by 
Platt and collaborators (1998) have revealed the existence of a specific range for CCR5 
136 
 
density threshold on cells required for efficient replication of R5 viruses. Moreover, the 
density of CCR5 molecules on CD4+ T-cells has been shown to correlate positively with 
replication of R5 HIV-1 (Lin et al., 2002; Heredia et al., 2007). The present study confirmed 
CCR5 as a critical and central factor in HIV infection. It is however known that this 
coreceptor has interpopulation, racial and gender variability in its expression. Picton et al., 
(2012) in two separate studies, firstly documented the differential expression patterns of 
CCR5 in two racially distinct South African populations, showing notably that the CCR5 
expression, both in term of density (number of receptors per cell) and frequency was higher 
within all cell subsets measured in African individuals compared to Caucassian individuals. 
They also evaluated the influence of CCR5 haplotypes on CCR5 expression in healthy HIV 
uninfected individuals, highlighting the protective effect of the HHC haplotype in South 
African Caucassians and the HHA haplotype in South African Africans, both linked to a 
lowered density of CCR5 expression on leukocytes. The individuals who were homozygous 
for the CCR5Δ32 mutation conferring resistance to HIV infection were excluded from their 
analysis. The influence of this mutation is not thought to be a major confounder within the 
cohort described in this dissertation. While population studies have revealed that the mutation 
is present at a frequency of 10% in Europe (Samson et al., 1996; Novembre et al., 2005), it is 
however very rare in Africans (Williamson et al., 2000). 
Soluble inflammatory factors in plasma were compared in HIV- unexposed and exposed 
participants, and together with the differential expression pattern of CCR5 on T-cell surfaces 
of these two groups of individual is the observation that HIV- exposed individuals have a 
lower concentration of IL-2 in systemic circulation. There are previous reports of IL-2 
upregulating the CCR5 expression on T-cell surfaces (Zou et al., 1999; Weissman et al., 
2000; Yang et al., 2001). The reduced level of systemic IL-2 and IFN-γ concentrations in 
HIV- exposed individuals compared to their unexposed counterparts is generally suggestive 
of a lowered systemic activation status and hence lowered HIV susceptibility. GM-CSF was 
another cytokine that was significantly reduced in the systemic circulation of HIV- exposed 
individuals, and again, as this hematopoietic factor promotes activation, maturation and 
differentiation of several immune cells (Kedzierskae et al., 1998; Shi et al., 2006), this 
difference could impact on the susceptibility to HIV infection by increasing the frequency of 
HIV target cells available in blood that could infiltrate and increase risk of HIV acquisition in 
lymphoid tissues. 
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The majority of HIV transmission worldwide occurs at the genital mucosa and therefore 
knowledge of mucosal immunology is essential in HIV susceptibility studies. As such, it is of 
primary importance to design strategies that can confer protection to the human mucosal port 
of entry to HIV. Study of the female genital compartment in this dissertation was aimed at 
improving our understanding of genital mucosal immunology and its potential linked to the 
systemic immune system. HIV+ and HIV- women in exposed and unexposed relationship 
were respectively compared to their counterpart.  It has been established in previous studies 
that there exists a positive association between HIV plasma load and genital HIV load 
((Iversen et al., 1997; Hart et al., 1999; Shepard et al., 2000; Kovacs et al., 2001; Vettore et 
al., 2006; Taton et al., 2011). A similar observation was made in this study and in line with 
the significantly higher plasma HIV burden observed in seroconcordant women compared to 
serodiscordant women in Chapter 2, seroconcordant women were shown to shed more virus 
at the genital tract when compared to serodiscordant ones. This represents a greater risk of 
transmission to their partners. To determine if this difference in genital viral load observed 
between the two groups was indicative of passive transudate from blood to the genital tract, 
or the active recruitment and homing of HIV-infected target cells to the genital mucosa under 
a chemokine gradient, the concentration of local inflammatory and regulatory factors were 
measured in genital secretion. While systemic inflammatory cytokines were found to be 
significantly elevated in HIV seroconcordant compared to serodiscordant ones, no such 
difference was found at the genital mucosal level. The lack of difference in genital 
inflammatory profile between seroconcordant and serodiscordant women could be down to 
the 10-fold greater difference observed in plasma HIV load (14 700 cps/ml) compared to 
genital HIV load (1450 cps/ml) between seroconcordant and serodiscordant individuals. 
The association between specific genital cytokine levels and genital HIV load was confirmed 
when stratifying women by genital HIV load. Women who were shedding HIV at their cervix 
had significantly higher level of inflammatory, chemotactic and regulatory cytokines 
compared to women who were not shedding. After adjusting for plasma viral load, genital 
concentrations of IL-1α and IL-1β remained strong predictors of genital HIV shedding. IL-10 
and IL-8 also remained significant after adjustment for plasma HIV load confirming that both 
and inflammatory and chemotactic gradients are in play to determine genital shedding. 
Sexually transmitted infections may also have an impact on genital mucosal immunity and 
have been associated with an elevated risk of HIV transmission through physical disruption 
or the modulation of immune factors associated with HIV acquisition (Rotchford et al., 1999; 
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LeGoff et al., 2007; Kaul et al., 2008; Shin and Kaul, 2008; Rebbapragada and Kaul, 2008; 
Kaul et al., 2011). One of the shortcomings in this study was that no laboratory based 
screening for STIs was conducted, although signs and symptoms (genital ulceration and 
vaginal discharge) were documented through clinical exam. Syndromic management 
guidelines for the treatment of STIs and other reproductive tract infections has been 
introduced by the WHO in the early 1990s to circumvent problems that may be experienced 
with limited laboratory facilities, high cost of laboratory tests and coordination of patients 
receipt of test results (Johnson et al., 2011). Few women in this study did have clinical 
evidence of an STI (ulceration or discharge), and those women with symptoms of an STI 
were equally distributed between seroconcordant and serodiscordant women. 
Comparison of the inflammatory profile of the genital compartment of women in HIV- 
exposed and unexposed relationship revealed that the inflammatory markers in exposed 
women were generally but not significantly higher than the HIV- unexposed women. IL-1α 
was the only significantly elevated cytokine and this could potentially represent a signature of 
HIV exposure rather than elevated risk of HIV acquisition. This interpretation is supported by 
the finding in Chapter 5 that HIV- exposed individuals had significantly lower frequencies of 
activated and proliferating CD4+ HIV target cells compared to unexposed individuals, and 
the previous observation from our group that the extent of immune activation in blood 
significantly and broadly predicted similar T cell activation in the genital tract of women 
(Jaspan et al., 2011). Finally, Chapter 6 confirmed that there exist clear differences in terms 
of immune parameters when comparing the female genital tract and blood. When matching 
levels of IL-1β, IL-6 and IL-10 in genital secretion and blood plasma were measured, no 
significant association between the genital compartment and systemic circulation was 
observed. Cytokine responses within the genital compartment could be locally driven by local 
stimuli rather than transudation of immune factors from blood. Several studies have 
confirmed that the female genital tract and blood are immunologically separate compartments 
(Hedges et al. 2006; Lajoie et al., 2008; Blish et al., 2012).  
Most studies conducted in exposed seronegative individuals have looked at heterogeneous 
populations, given the difficulties to recruit such individuals and have moreover used cross-
sectional designs. As such, the interpretation of results in term of the protective role of 
immune responses on resistance to HIV infection remains difficult. While it was confirmed 
that the difference observed in plasma HIV load between seroconcordant and serodiscordant 
individuals was maintained over 3 consecutive time points, it will be interesting to see if the 
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difference seen in inflammation and immune activation profile are sustained over time. 
Another area of potential research is the genotyping of HLA genes. These play a role in 
activating the immune system to respond to foreign substances. There is an increasing body 
of evidence emerging with regard to the role of HLA in HIV transmission. The differences in 
correlates of protection among HIV-exposed uninfected individuals have been the focus of 
several investigations and the MHC has emerged as a vital factor determining susceptibility 
or resistance to infection. Concordance and discordance in HLA class I alleles between HIV 
transmission pairs has been shown to impact on the likelihood of HIV transmission with the 
sharing of HLA-B allele resulting in a two-fold greater risk of HIV transmission (Dorak et 
al., 2004). Possession of other specific HLA alleles has also been implicated with a reduced 
risk of HIV seroconversion, such as A2/6802 (MacDonald et al., 2000). As for the role of 
specific HLA alleles in the immunopathogenesis of HIV infected individuals, studies have 
suggested a protective effect for HLA-B27 and HLA-B57, whereby these individuals tend to 
progress more slowly than usual to AIDS (Migueles et al., 2000; Carrington and O’Brien, 
2003). HLA typing will be performed for a subset of the participants included in this 
dissertation in a future study to see if this factor plays any role in protection to HIV infection 
or disease progression. Moreover, deep-sequencing will be carried for the HIV+ 
seroconcordant couples included in this study to establish if there exists any intra-couple 
transmission of different viral variants. 
In conclusion, the studies described in this dissertation provides valuable insight into the 
understanding of HIV susceptibility and disease progression profile through the 
characterisation of different immune parameters in HIV positive and negative seroconcordant 
and serodiscordant couples. Firstly, it was noted that HIV+ seroconcordant individuals had a 
significantly higher plasma HIV load compared to the their serodiscordant counterparts and 
that this difference however did not translate into a worse disease outcome in seroconcordant 
participants, as measured by absolute blood CD4 count. While it was observed that the level 
of viral replication only partially predicted the rate of CD4 decline, this could be explained by 
a process wherein the level of HIV replication either determines or reflects the existing level 
of T-cell activation, and as such only indirectly impact on the CD4 T-cell count. Therefore, 
the observations that CD4+ T-cells are infected by HIV and depleted during the course of 
infection may merely be an unfortunate coincidence (Roederer, 1998), while the actual basis 
for the HIV associated CD4 decline may be that these cells are more depleted than CD8+ T-
cells to the chronic damage induced by immune activation. The different associations 
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observed between systemic and genital markers of immune activation and inflammation and 
HIV viral load, both systemically and genitally, leads us to suggest that currently, the 
standard guideline used to monitor HIV infection, namely clinical assessment, flow 
cytometric determination of absolute blood CD4 count and molecular assays to quantify 
plasma HIV burden lacks sensitivity in determining disease stage, progression and therapy 
initiation and responses. We suggest the inclusion of these extra parameters in conjunction 
with current laboratory measures, to provide a more ‘tailor-made’ therapeutic assistance to 
infected patients. This will however represent a huge challenge on the account of the already 
high burden of HIV/AIDS in certain regions, such as Sub-Saharan Africa. Finally, CCR5 
expression on HIV target cells represents a potential avenue for the development of an anti-
HIV strategy to reduce the number of successful viral transmissions in the event of an 
exposure to HIV. 
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